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Neurodegenerative disorders (NDDs) have become a major global health burden.  
Despite persistent advances in understanding the neurodegeneration process, 
pathogenesis has not been fully clarified and no cures are yet available.  As a therapeutic 
approach for NDDs, RNA interference (RNAi) can be a potent mode of treatment 
because it can specifically downregulate target genes that are directly or indirectly 
associated with the onset and progression of neurodegeneration.  For example, Keap1, a 
negative regulator of the antioxidant responsive element (ARE) can be targeted for gene 
downregulation in order to enhance the endogenous antioxidant capacity and protect 
brain cells against extensive oxidative stress, a pathological hallmark observed in many 
NDDs.  However, small interfering RNAs (siRNAs) bear limiting factors, including 
instability in the bloodstream and limited capacity to cross the blood-brain barrier (BBB) 
mainly due to their bulky size and negatively charged backbone.  Thus, there is need for 
an adequate carrier that can protectively load and deliver bioactive siRNAs to brain cells.  
In this dissertation we detail the evaluation of a peptide-based siRNA carrier for 
neurotargeted siRNA delivery and the assessment of Keap1 RNAi therapeutic potential in 
brain cells.  First, we have designed a myristoylated cell-penetrating peptide equipped 
with a transferrin receptor targeting sequence (myr-TP-Tf) and examined its 
physicochemical properties and biological functions.  The myr-TP-Tf was shown to 




of the target gene.  Myr-TP-Tf also transported the siRNAs across a brain endothelial cell 
monolayer in a transwell system.  Second, we have assessed the therapeutic potential of 
Keap1 RNAi against beta amyloid (Aβ) peptide-induced oxidative stress in a human 
glioma cell culture.  It was found that the Keap1 siRNA-peptide complex-pretreated 
group had better tolerance to the cytotoxicity from the Aβ and displayed lower levels of 
oxidative stress and autophagic activity compared to the control groups, demonstrating 
the neuroprotective effect of Keap1 RNAi.  Third, we examined the brain-targeting and 
functional target gene silencing abilities of the siRNA-peptide carrier complex in vivo.  
Although the direct local injection exerted a greater performance, the systemic 
administration also delivered a measurable amount of siRNA to the brain, which led to a 
significant knockdown of the target gene.  In summary, results demonstrate that this 
peptide-based siRNA carrier system can be a promising strategy for neurotargeted siRNA 
delivery both in vitro and in vivo. 
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1.1 General introduction 
Neurodegenerative disorders (NDDs) have become a rapidly growing health issue, 
with approximately 12 million Americans suffering today from Alzheimer’s disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease 
(HD) (1).  The number of patients is increasing with the continuously growing population 
of age 65 and older.  In 2012, approximately $9.1 billion was estimated as the health care 
cost for dementia caregiving in the US and the economic burden is expected to increase 
substantially (2). 
Despite the global demand for clinically viable therapeutics, as yet, there are no 
cures or effective treatments for NDDs.  It is because the neurodegeneration process has 
not been fully clarified, and partly because the blood-brain barrier (BBB) poses a major 
obstacle for drug delivery to the brain (3).  The endothelial cells lining the microvessels 
in the brain form a highly selective barrier prohibiting the passages for the molecules that 
are hydrophilic or larger than 400 Da.  In addition, the tight junction proteins between the 
endothelial cells block the paracellular transport.  Even for the drugs that can exploit the 
transcellular pathway, the drug efflux pumps may transport those substances out of cells 
back into the capillaries (4).  Therefore, the strategies to overcome the BBB should be 






In the case of AD, the most common type of dementia, there are currently two 
types of medications approved for patients: cholinesterase inhibitors and memantine (5).  
However, these drugs can only alleviate the cognitive symptoms and cannot 
fundamentally prevent the further progression of the neurodegeneration.  According to 
the amyloid hypothesis, the amyloid plaque, the insoluble beta amyloid (Aβ) peptide 
aggregates, have been considered a major culprit to initiate the AD pathology (6).  
Therefore, clinical trials have been conducted to evaluate the amyloid plaques-targeting 
drugs such as solanezumab and bapineuzumab, but both immunotherapy agents failed to 
prove the efficacy in AD patients.  Another antibody-based drug, crenezumab is now 
focusing on the early-stage of AD because drugs are prone to fail for the advanced stages 
of AD due to the irreversibly progressed prevailing neuronal damages (7).  Another class 
of drugs is the BACE1 (beta-site APP cleaving enzyme 1) inhibitors, which block the 
beta secretase enzyme activity, thereby preventing the accumulation of the Aβ peptides.  
The recent clinical trials have reported promising results showing the decreased level of 
Aβ peptide in the cerebrospinal fluid (CSF) of mild-to-moderate AD patients (8).    
Along with the clinical therapeutics mentioned above, the RNA interference 
(RNAi) approach can be a promising mode of NDD treatment because this technology 
allows the highly specific degradation of the target mRNAs that are directly or indirectly 
associated with the onset and the progression of the neurodegeneration.  In AD treatment, 
for instance, the BACE1 gene can be targeted for the gene silencing in order to reduce the 
beta amyloid production and amyloid plaque accumulation (9).  The amyloid precursor 





the Aβ peptides (10).  Aside from the amyloid plaque, phosphorylated tau proteins are a 
characteristic pathological hallmark of the AD.  As the cyclin-dependent kinase 5 
(CDK5) has a major role in the tau phosphorylation, the RNAi can be applied against the 
CDK5 to interfere with the tau phosphorylation (11).  In many NDDs, not only the 
abnormal protein aggregates, but also extensive oxidative stress is considered one of the 
key pathological factors contributing to the disease progression.  In this context, the Nrf2 
(NF-E2-related factor 2)-ARE(antioxidant responsive element) pathway can attract 
attention because the Nrf2 is known to activate the ARE, leading to the upregulation of 
detoxifying and antioxidant genes which attenuate the oxidative stress (12-16).  However, 
the basal activity of the Nrf2 is normally restricted by the Keap1 protein through 
cytoplasmic sequestration and the ubiquitin-mediated degradation pathway (17,18).  
Therefore, the RNAi approach to the Keap1 gene will rescue the Nrf2 activity and 
thereby boost the endogenous antioxidant capacity providing the cytoprotection to the 
brain cells against the oxidative stress.   
However, the siRNA delivery to the brain has been a challenging task not only 
because of the defensive vasculature of the BBB, but also because of the susceptibility of 
naked siRNA to the serum nucleases (19).  Therefore, there is a need for the development 
of siRNA delivery vehicles that can stably encapsulate and protect siRNAs, and deliver 
them to the brain parenchyma across the BBB.  A range of various siRNA delivery 
modes have been studied including chemically modified siRNA (20,21), polymeric 
nanoparticles (22,23),  liposomes or exosomes (24,25),  antibody-fusion molecules (26), 
and cholesterol-conjugated siRNA (27).  However, further investigations are still needed 





functional target gene knockdown, and sufficient brain-targeting ability.   
In this study, we have designed a myristoylated cell-penetrating peptide equipped 
with a transferrin receptor (TfR)-targeting peptide sequence as a siRNA delivery vehicle 
for brain-targeted delivery.  The peptide-based siRNA carrier can be produced by the 
solid-phase peptide synthesis in which a series of manipulations can be easily conducted 
in the automated machine.  Among various cell-penetrating peptides, the transportan 
sequence was chosen based on a recent finding in which the transportan sequence was 
shown to optimally load siRNAs, deliver them to the cells, and successfully release the 
bioactive siRNAs in the cytosol resulting in the target gene knockdown (28).  As a brain-
targeting moiety, we incorporated a TfR-targeting peptide sequence because it has been 
well identified that TfRs are abundantly expressed on both brain endothelium and 
neurons/astrocytes (29).  Moreover, the relatively short peptide sequence is expected to 
be less likely to affect the size and the structure of the siRNA-peptide complex.  The 
myristic acid at the N-terminus of the carrier will establish the hydrophobic core of the 
siRNA-peptide complex contributing to the stable complex formation and possibly 
enhance the interaction between the complex and the cellular membrane through the 
hydrophobic interaction (30).  We hypothesized that this myr-TP-Tf peptide will serve as 
a functional siRNA carrier for brain-targeted delivery.  
This dissertation is organized into a literature review of the current status of 
Alzheimer's disease treatments, RNAi therapeutic targets, and siRNA delivery strategies 
for NDDs.  Chapter 3 details the characterization and in vitro evaluation of the siRNA-
peptide complex.  Chapter 4 describes the therapeutic potential of the RNAi approach 





vivo validation studies on the brain targeting ability and the functional gene silencing 
capacity of the siRNA-peptide complex are delineated.  Finally, Chapter 6 will briefly 
summarize the study results and describe future work regarding the optimization of the 
carrier design and the further evaluation of the siRNA-peptide complex in NDD animal 
models.  
1.2 Specific aims 
The RNAi therapy can be a promising approach for NDDs because it can be used 
specifically to downregulate the genes associated with the pathogenesis.  To deliver 
therapeutic siRNAs to the brain across the BBB, however, there is a need for a siRNA 
carrier that can achieve the adequate siRNA encapsulation and protection, the effective 
brain targeting, and the functional cytosolic release of the bioactive siRNAs leading to 
the successful suppression of the target gene.  To this end, we first conceived a peptide-
based siRNA carrier which is comprised of an N-terminal myristic acid, a transportan 
cell-penetrating peptide, and a TfR-targeting short peptide sequence.  We hypothesized 
that a myristoylated cell-penetrating peptide equipped with a TfR-targeting sequence will 
accomplish the stable condensation and protection of siRNA and targeted delivery of 
siRNA to the brain cells across the brain endothelial barrier in vitro.  Next, we proposed 
the RNAi approach against the Keap1 gene using our peptide-based siRNA carrier as a 
potential NDD treatment.  The fact that many NDDs are associated with elevated 
oxidative stress is well investigated.  Because the Keap1 acts as a negative regulator of 
Nrf2, which is responsible for the basal expression of antioxidant genes, the 
downregulation of the Keap1 gene will lead to the augmentation of the endogenous 





assault.  We hypothesized that the Keap1 siRNA-peptide complex pretreatment to the 
brain cells will help maintain the cell viability and protect cells against the Aβ peptide-
induced oxidative stress compared to the control group.  Finally, an in vivo evaluation of 
the siRNA-peptide complex was planned to assess the brain targeting ability of the 
siRNA-peptide complex and the functional target gene knockdown in a living system.  
The following specific aims were designed to evaluate these hypotheses and to perform 
the validations.  The experimental design for each specific aim is shown in Figure 1.1. 
 Specific aim 1: Characterization and in vitro evaluation of a myristoylated cell-
penetrating peptide equipped with a TfR-targeting sequence (myr-TP-Tf) 
a) Physicochemical characterization of myr-TP-Tf 
b) Evaluation of the functional siRNA delivery and the target gene silencing 
in a    brain cell line and primary brain cells 
c) Examination of the siRNA transport across a brain endothelial cell 
monolayer  
 Specific aim 2: In vitro evaluation of the neuroprotective potential from the 
Keap1 siRNA-peptide complex pretreatment 
a) Examination of the antioxidant activation after the Keap1 siRNA-peptide 
complex treatment 
b) Assessment of the cell viability after the oxidative assault  
c) Evaluation of the cytoprotective effect against the Aβ peptide-induced 
oxidative stress  
 Specific aim 3: In vivo validation of the brain targeting ability and the target gene 





a) Evaluation of the brain-targeted siRNA delivery 
b) Examination of the functional downregulation of the target gene 
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CURRENT STATUS OF ALZHEIMER’S DISEASE TREATMENTS 
AND RNA INTERFERENCE STRATEGIES AS A PROMISING 
THERAPEUTIC OPTION: A LITERATURE REVIEW 
2.1 Abstract 
Alzheimer’s disease (AD), the most common form of neurodegenerative disorders 
(NDDs), has become a significant healthcare concern with the aging population growing 
worldwide.  Despite the expanded understanding of the neurodegenerative process, the 
AD pathogenesis has not been fully elucidated.  Furthermore, the restrictive brain 
vasculature has been a key hurdle for brain-targeted drug delivery, posing challenges to 
the development of AD treatments.  Here, we briefly overviewed the specialized 
characteristics of the blood-brain barrier (BBB) in relation to the CNS-targeted drug 
delivery and examined the current status of AD medicines.  In addition, we propose that 
the RNA interference (RNAi) approach can be a potent mode of NDD treatment via 
effective suppression of the NDD-associated gene expression.  The second part of this 
article is chiefly devoted to reviewing the potential therapeutic targets of AD and other 
types of NDDs to which RNAi technology can be applied and the strategies for the brain-
targeted siRNA delivery, particularly with a focus on the RNAi delivery systems and the 
routes of administration.  The limitations of the diverse approaches and alternatives are 






As the average lifespan has steadily extended, age-associated diseases have 
become one of the major public health problems.  Particularly, Alzheimer’s disease (AD) 
has ranked 6th among the leading causes of death in the US in 2013 (1).  However, 
current AD medicines provide only temporary symptomatic relief without substantial 
disease-modifying effects.  The AD drugs under laboratory and clinical investigations 
have also suffered limited pharmacological action largely because of the restrictive 
blood-brain barrier (BBB) (2).  To improve the transport of therapeutics into the brain 
parenchyma, we need to understand the structural and functional features of the BBB and 
devise proper drug delivery strategies to overcome this obstacle.  The relentless research 
effort over three decades has identified key pathological processes that are responsible for 
various neurodegenerative disorders (NDDs), yet much remains unclear.  The potential 
AD drugs which directly address those major disease-causing factors have been evaluated 
in clinical trials with occasional promising news, but no clinical success in finding AD 
cures has been reported until now.  At present, multiple clinical trials are still in progress 
with a hope to slow down or stop the AD progression.  Along with this effort, the RNA 
interference (RNAi) therapy as an experimental neurotherapeutics approach for AD and 
other types of NDDs is worth attempting.  The RNAi has emerged as a promising 
treatment modality for many human diseases owing to the posttranscriptional suppression 
of the specific target gene expression (3).  However, the RNAi approach encounters 
multifarious hurdles that need to be addressed for successful results in the living system.  
A wide variety of RNAi delivery vehicles tested in preclinical studies and alternative 





possibly to accelerate the RNAi therapy transition to clinical application for NDD 
treatment. 
2.3 Blood-brain barrier (BBB) as a major obstacle  
for drug delivery to the brain 
2.3.1 The restrictive properties of the BBB 
 The existence of the BBB was first observed by Paul Ehrlich who injected various 
water-soluble vital dyes to the animals and found that the majority of the organs were 
stained while the brain and spinal cord remained unstained.  He explained this 
phenomenon as the central nervous system lacks affinity for the vital dyes (4).  Later, 
Lewandowsky named this biological wall bluthirnschranke (BBB) for the first time (5).  
Today, it has been well known that the endothelial cells that compose brain 
microvascular capillaries have complex and distinct structures that form the basis of 
characteristic selective permeability of the BBB.  The BBB allows the passage of water, 
oxygen, and other important nutrients and hormones via various transport systems, as 
delineated in Figure 2.1.  For other types of molecules, however, the following 
characteristics of the BBB restrict the path to the brain compartment.  First of all, the 
endothelial cells are closely attached together by tight junction proteins that block 
paracellular passages of substances in the blood circulation.  These tight junction proteins 
include zonula occludins (ZO), claudins, junctional adhesion molecules (JAMs) and 
others (6).  The molecules with small size (< 500 Da) and sufficient lipophilicity may 
enter the transcellular pathway across the endothelial membrane (7).  However, the active 
efflux transporters (AET) such as P-glycoproteins (Pgp), multidrug resistance proteins 





substances back into the bloodstream posing a difficulty for the transcellular pathway as 
well (8,9).  In addition, the BBB functions as a biochemical barrier.  The enzymatic 
proteins (e.g., γ-glutamyl transpeptidase (γ-GTP), aromatic acid decarboxylase, and 
alkaline phosphatase) are widely expressed on plasma membranes of brain endothelial 
cells, pericytes and astrocyte foot processes, which directs the materials crossing the BBB 
to the metabolic degradation (10).  Therefore, AD treatments as well as other CNS 
therapeutics require strategies to overcome the major challenges by the BBB for 
successful brain-targeted drug delivery.  
2.3.2 Strategies to circumvent the BBB 
 Researchers have attempted diverse approaches to transport drugs across the BBB.  
One is to design small molecule drugs to have more lipid soluble structure.  Drugs with 
high partition coefficient values (LogP) are more likely to migrate across the cellular 
membrane because of the favorable lipophilicity (11).  However, this may also cause 
unscheduled interaction with hydrophobic proteins, which can lead to toxic effects (12).  
Therefore, the drug design should pass through an elaborate examination in regard to 
pharmacokinetic properties as well as physicochemical characteristics.  Instead of the 
systemic administration, CNS drugs can be directly injected to the brain parenchyma via 
intracerebral injection or intracerebroventricular injection (13).  Direct injection ensures 
BBB circumvention and substantive delivery of therapeutics to the specific brain region.  
On the contrary, the drugs may not be sufficiently diffused further into the brain tissues, 
limiting the therapeutic effect.  Considering patient convenience, safety, and cost, the 
craniotomy-based approach may not be a feasible option for certain conditions that need 





have temporary openings for drug passage.  The possible methods for this approach 
include: injection of hyperosmotic mannitol solution (14), application of high intensity 
focused ultrasound (HIFU) (15,16) and use of vasoactive compounds such as bradykinin, 
histamine, and leukotrienes (17,18).  However, the disruptive opening approach also 
allows the entry for all types of blood constituents that may increase the risk of getting 
toxic substances into the brain.  The growing field of pharmaceutical research has 
suggested various engineered drug delivery vehicles that are constructed for favorable 
pharmacokinetic behavior, protective drug loading, and improved brain accumulation, 
often by exploiting targeting moieties that bind to receptors or transporters on brain 
endothelium (19).  Although no unitary method completely satisfies the criteria for a 
general drug delivery approach for the brain yet, unceasing research efforts have been 
continually leading a step forward to breaching the BBB.   
2.4 Current status of AD treatments 
2.4.1 Clinical impact of AD 
 AD is the most common form of neurodegenerative disorders, affecting over 35 
million people worldwide now.  The number of AD patients is estimated to reach 115 
million by 2050 with an accelerating pace of population aging (20).  Along with the 
growing number of AD patients, the cost for healthcare has become a serious economic 
burden with approximately $148 billion of total annual health care spending for AD 
patients (21).  The neurodegeneration typically develops and worsens over many years, 
afflicting patients in their memory, judgment, communication, orientation, and ability to 
perform daily tasks depending on the severity of the cognitive impairment.  Moreover, 





not only the individual patients but also their immediate caregivers, usually their family, 
suffer from the high emotional burden.  However, the effort to develop a potent cure for 
AD has not been successful yet.  The currently prescribed drugs for AD patients merely 
provide temporary amelioration of symptoms without having significant disease 
modifying effects.  This unmet clinical need is one of the most urgent health problems on 
which researchers have steadily worked. 
2.4.2 Risk factors for AD incidence 
 Several known risk factors for AD incidence include aging, family history, 
genetic predisposition, cardiovascular disease risk factors (e.g., obesity, diabetes, and 
smoking), education, social and cognitive engagement, and traumatic brain injury (1).  
Among these, the largest risk factor is aging.  Lopez et al. found that the prevalence of 
mild cognitive impairment (MCI) increased with age, showing that 19% of people 75 
years or younger had MCI while it increased to 29% for those 85 years or older (22).  
Despite the fact that aging plays a significant role in AD incidence, it should be noted 
that AD is not a normal process of healthy aging.  Family history also poses a risk factor.  
A study reported that individuals having AD patients in their first degree relatives are at a 
greater risk to develop AD in life (23).  Regarding the genetic predisposition, the 
apolipoprotein E4 (ApoE4) variant may partly account for family history-related AD 
occurrence.  ApoE, a major class of apolipoprotein responsible for cholesterol transport, 
exists as one of three isoforms (E2, E3, E4) that are encoded by ε2, ε3, and ε4 allele (24).  
These variants possess different amino acid residues at positions 112 and 158 on their 
primary structures (25).  In particular, the arginine residue at position 112 of ApoE4 is 





which is known to mediate the production of NFT-like intracellular deposits resulting in 
neurotoxicity (26).  Individuals bearing either one or two ε4 alleles are more likely to 
develop late-onset familial AD with ~2.8-fold greater risk (27).  However, possessing one 
or two ε4 alleles does not necessarily translate to a definitive diagnosis of AD.  It appears 
that the AD onset is governed not only by the individual genetic profile but also by many 
other factors.  Lifestyle can also influence AD occurrence.  Studies have shown that  
midlife obesity is related to increased risk of AD development later in life (28,29).  Ott et 
al. also showed that smoking contributes to the incidence of AD and other types of 
dementia with a doubled risk compared to the AD incidence for nonsmokers (30).  The 
known risk factors and other factors that contribute to the pathogenesis of Alzheimer’s 
disease are delineated in Figure 2.2.  
2.4.3 Neuropathological features and clinical symptoms of AD 
From the neuropathological point of view, AD is typically represented by gradual 
neuronal demise and loss of synapses in the cerebral cortex, hippocampus, and other 
brain regions (31).  The progressive loss of neurons leads to severe brain shrinkage, (i.e., 
cerebral atrophy), in late-stage AD.  A magnetic resonance imaging (MRI)-based 
volumetric measurement study confirmed that the medial temporal lobe structures in AD 
patients were significantly diminished relative to the control group, which also indicates 
the neuronal loss along with the AD progression (32).  Brain tissues from patients with 
AD are commonly characterized with extracellular accumulation of amyloid plaques that 
are composed of beta amyloid peptides (Aβ), an aberrant proteolytically cleaved fragment 
produced from the amyloid precursor protein (APP).  Studies have shown that an array of 





axonal transport, cytotoxicity and neuronal death (33).  Another neuropathological 
feature is the intracellular neurofibrillary tangles (NFT), the major component of which is 
hyperphosphorylated tau protein, a type of microtubule-associated protein (MAP).  MAPs 
are known to contribute to the stability and assembly of the microtubule network, but 
enhanced phosphorylation of tau proteins disrupts the microtubule assembly, leading to 
impaired axoplasmic flow, synaptic loss, and ultimately, neuronal demise (34).  The Aβ 
plaque and NFT formation processes are illustrated in Figure 2.3.  
The representative AD symptoms include memory loss, reduced ability to learn 
new information, confusion with time and place, difficulty in understanding, judgment 
and communication, and changes in personality and emotions (1).  As the AD progresses, 
these symptoms worsen and patients become bedbound, requiring assistance from their 
caregivers in virtually all aspects of daily life.  Regarding the severity of the symptoms, 
there seems to be a connection between the symptomatic indication and the prevalence of 
neuropathological hallmarks to a certain extent.  For example,  Savva et al. conducted a 
study with postmortem brain tissues where they found that the neocortical cerebral 
atrophy showed a strong relationship between the age and dementia in both 75-year-old 
subjects and 95-year-old subjects (35).  However, the relationship between the 
neocortical neuritic plaques and dementia was reduced for the 95-year-old group 
compared to the 75-year group, indicating that certain neuropathological features may not 
translate directly to clinical manifestation.  Indeed, it has been well known that brain 
changes occur approximately one to two decades earlier than the emergence of the first 
AD signs (36).  Even though the accumulation of amyloid plaques and 





may not be sufficient to result in clinical symptoms of AD considering that the 
asymptomatic period spans multiple years.  The magnitudes of AD biomarkers, brain 
atrophy and cognitive impairment along the disease progression are shown in Figure 2.4.  
2.4.4 Molecular mechanisms of AD pathogenesis 
Throughout the last three decades, studies have considerably broadened our 
understanding about the molecular and cellular mechanisms associated with 
neurodegenerative disorders.  Nonetheless, the exact mechanism that directs AD 
development has not been fully clarified with the exception of familial cases of AD 
triggered by known genetic mutations such as those in APP, presenilin 1 (PS1), and 
presenilin 2 (PS2).  Regarding the cause for AD development, researchers have proposed 
three central hypotheses: cholinergic hypothesis, amyloid hypothesis, and tau hypothesis.  
Although the precise mechanism for the AD initiation and symptomatic deterioration 
remains vastly unknown, the amyloid hypothesis has gained much more scientific 
strength in the AD research field.  
According to the amyloid cascade hypothesis, the accumulation of amyloid 
plaques has a primary role for initiating AD pathology (37).  This hypothesis is largely 
bolstered by studies that have shown the link between the genetic mutations in APP, PS1, 
and PS2 genes and clinical manifestations of early onset familial AD (EOFAD) (38,39).  
These Aβ peptide production-related genetic alterations result in Aβ accumulation in the 
brain and eventually the loss of neurons and decline in cognitive abilities.  Aβ peptides, 
the key component of amyloid plaques are produced from the sequential cleavage of APP 
by two proteases: β-secretase and γ-secretase.  The β-secretase cleaves the extracellular 





releasing the Aβ peptide fragment (40).  The γ-secretase may cut varying sites on the 
APP transmembrane domain producing Aβ fragments with different numbers of amino 
acids (Aβ37, Aβ38, Aβ40, Aβ42, Aβ43) and distinct biophysical properties (33,41).  All 
of these species are found in both healthy individuals and AD patients, but to different 
extents.  In contrast to others, Aβ42 is the most fibrillogenic, thus, forming amyloid 
deposits that cause interruption of synaptic transmission, neuronal damage, and 
eventually AD development (42).  Despite evidences proving the neurotoxicity of Aβ 
peptide, the amyloid hypothesis has a controversial element in that the level of Aβ 
aggregates in brain tissues with AD does not necessarily correlate to the degree of 
cognitive symptoms.  Rather, the soluble, invisible form of Aβ was found to serve as a 
better predictor for the neurodegeneration (43).  This indicates that the symptomatic 
exacerbation may be a consequence of complex molecular and cellular processes 
involving other factors aside from Aβ plaques.   
The tau hypothesis states that the hyperphosphorylated tau protein is the critical 
pathological substrate for AD.  The hyperphosphorylated form of tau proteins form 
paired helical filaments (PHF) and straight filaments (SF), which are major components 
of the neurofibrillary tangles (44).  Studies have shown that there is a high correlation 
between the cognitive impairment and the level of NFTs in the affected brain region, as 
well as the hyperphosphorylated tau protein concentration in cerebrospinal fluids from 
AD patients (45,46).  In addition, multiple studies have demonstrated the reduction of tau 
proteins protect brain cells from the Aβ-mediated neurotoxicity in vivo as well as in vitro.  
This suggests the important role of tau for the Aβ-induced neurodegeneration (47-49).  





For example, a study reported that Aβ activates glycogen synthase kinase-3β (GSK-3β), 
which is responsible for producing phosphorylated tau protein, the neurotoxic form of tau.  
Moreover, a postmortem assessment revealed that Aβ accumulation significantly 
precedes tau formation, at least in the frontal cortex of AD patients (50).  Though the 
general consensus from the field is weighed more on the amyloid hypothesis, it is also 
evident that there is a close relationship between tau pathology and Aβ-mediated 
neurotoxicity.  
The cholinergic hypothesis states that the lack of acetylcholine, a type of 
neurotransmitter, leads to the neurodegenerative condition and cognitive decline.  This 
was supported from the finding that there is an association between the loss of 
cholinergic neurons in the cerebral cortex and the memory deficit of the AD patients (51).  
However, it is now apparent that the acetylcholine deficit has rather an indirect effect on 
the memory function (52).  In fact, cholinomimetic agents or cholinesterase inhibitors do 
not prevent AD progression, but provide limited cognitive benefits.   
Other cellular processes that are associated with neurodegeneration in brain 
tissues with AD include reactive oxygen species (ROS)-mediated oxidative stress, 
programmed cell death, glial cell activation,  protein misfolding and proteasomal 
malfunction which leads to abnormal protein aggregates (53).  Among these, oxidative 
stress has been highlighted as pivotal in all of these cellular events.  In addition, Aβ-
associated free radical formation was observed both in vitro and in vivo, implying the key 
role of oxidative stress in Aβ-mediated neurotoxicity in AD brain tissues (54).  Another 
study reported that metal-catalyzed oxidation facilitates the formation of Aβ deposits in 





cause for the neurodegeneration or just a consequence of the disease process, findings 
from numerous studies indicate that oxidative stress is at least closely interlinked with 
those cellular events leading to the neuronal damage and death, which rationalizes the 
attempts for antioxidant therapy to NDD patients.  
2.5 Current AD medicines 
The AD diagnosis requires physicians to perform a comprehensive medical 
assessment that includes patient’s medical history, mental status exam, physical exam, 
neurological exam, blood tests and brain imaging.  Depending on the severity of the 
cognitive symptoms, Dr. Barry Reisberg classified the disease state into seven stages: 
stage 1: no impairment; stage 2: very mild decline; stage 3: mild decline; stage 4: 
moderate decline; stage 5: moderately severe decline; stage 6: severe decline; and stage 7: 
very severe decline (56).  Currently, the medications prescribed for AD patients at varied 
stages are largely categorized into two classes: acetylcholinesterase inhibitors (AChEI) 
and N-methyl-D-aspartate (NMDA) receptor antagonists. 
AChEIs are chemical drugs that suppress the acetylcholinesterase activity, thereby 
preventing the degradation of acetylcholine and maintaining the postsynaptic cholinergic 
activity.  The medicines in this category are Tacrine (Cognex), Donepezil (Aricept), 
Rivastigmine (Exelon), and Galantamine (Razadyne).  Tacrine was discontinued due to 
its potential risk of causing liver enzyme elevation (57).  These AChEI drugs have shown 
a significant cognitive decline delaying effect in AD patients from multiple clinical 
studies (58,59).  However, it is generally accepted that AChEI drugs do not provide 
reliable disease modifying effects in AD treatment (60).   





drug, repress the effect of glutamate, a key excitatory neurotransmitter responsible for 
various cognitive functions (61).  It has been known that the overstimulation of glutamate 
receptors leads to the elevation of post synaptic calcium level causing excitotoxicity to 
neurons and eventually neurodegenerative conditions (62).  Clinical studies showed the 
treatment of memantine, a type of NMDA receptor antagonist, resulted in beneficial 
outcome in cognitive and behavioral symptoms of moderate-to-severe AD patients 
(63,64).  As opposed to these results, other clinical studies suggest that the efficacy of 
memantine for attenuating AD symptoms has a lack of evidence with no significant 
difference in clinical outcome between the placebo and the drug treatment group (65,66).  
These study results indicate that the propagation of the neurodegeneration process is not 
intervened merely by modulating the neurotransmitters, demanding further clarification 
for underlying mechanisms of neurodegeneration.  
2.6 AD medicines under laboratory and clinical investigations 
According to a recent report, the failure rate of AD drug development between 
2002 and 2012 was 99.6% (67).  This unacceptably high failure rate also discourages the 
pharmaceutical industry from investment in this high risk project, as is evidenced by 
relatively fewer drug candidates and clinical trials for AD treatment compared to the 
oncology drugs.  Despite this gloomy record, researchers have been continuously 
investigating various AD drugs that focus on Aβ plaques, tau pathology, neuropsychiatric 







Propelled by numerous studies that propose Aβ plaques as an initial disease 
triggering factor in AD pathogenesis, a number of clinical trials have tested anti-amyloid 
strategies in the form of immunotherapy.  The immunotherapies for AD are largely 
classified into two different modes: active vaccination and passive vaccination.  The 
active vaccination approach is to inject Aβ peptide-derived fragments into patients, 
thereby stimulating the production of anti-Aβ antibody.  Alternatively, the passive 
vaccination approach is to administer the ready-made antibodies against Aβ to the AD 
patients.  Both approaches were conceived to clear the Aβ plaques from the brain tissues 
via antibody-mediated phagocytic clearance mechanism (68).   In the active vaccination 
approach, there are three peptide vaccines under clinical investigations: ACC-001 
(Pfizer), CAD-106 (Novartis), and Affitope (AFFiRiS AG).  These peptides are 
composed of a carrier protein fused with the Aβ(1-6) fragment that acts as a B-cell 
epitope.  Following the phase I studies where the safety and tolerability of these drugs 
were confirmed, phase II studies with early or mild-to-moderate AD patient groups are 
now under evaluation.  Regarding the passive vaccination approach, humanized 
antibodies prepared from different parts of Aβ peptide have been investigated.  These 
include Bapineuzemab (Pfizer), Solanezumab (Eli Lilly and Company), Gantenerumab 
(Hoffmann-La Roche), and Crenezumab (Genentech).  Although there have been 
promising reports about anti-Aβ antibodies in reducing the Aβ level in brain tissues 
(69,70), no remarkable success from clinical studies has been announced yet.  In fact, 
Bapineuzumab failed to show significant disease-modifying effects on cognitive abilities 





antibody was also unsuccessful in proving its therapeutic effectiveness in cognitive 
functions of mild-to-moderate AD patients (72).  These recent failures imply that the 
attempts to clear the Aβ deposits may not be opportune enough to stop the disease 
progression.  In this context, pharmaceutical companies are now redirecting their focus 
on preventive medicines or early initiation of treatments.  As an example, Crenezumab, 
another Aβ-targeting antibody, is being investigated in individuals bearing PS1 mutation.  
This population does not display noticeable cognitive symptoms at the time of treatment.  
The study will examine whether early treatment using Crenezumab can prevent AD onset 
for people at high risk (73).     
2.6.2 BACE inhibitors 
Another approach to fight against Aβ plaques is to use the drugs that prevent the 
production of the Aβ peptide from APP protein upstream.  The β-secretase 1 encoded in 
the BACE1 gene was identified as an enzyme that cleaves the extracellular domain of the 
APP, releasing the neurotoxic Aβ fragments (74).  Therefore, it is conceivable that 
inhibiting BACE1 activity will prevent Aβ accumulation.  Indeed, Roberds et al. reported 
that the primary cortical culture from BACE1 knockout transgenic mice displayed a 
significantly lower level of Aβ peptide as well as β-secretase 1 activity below the limit of 
detection (75).  The therapeutic effect of a BACE1 inhibitor is also under clinical 
investigation.  A recent report from Merck showed a promising effect of MK-8931, a 
BACE inhibitor,  in reducing Aβ level in cerebrospinal fluid of AD patients (76).  The 
more upstream anti-Aβ approach provides anticipation for better therapeutic outcomes, 





2.6.3 Tau kinase inhibitors 
Along with amyloid plaques, the hyperphosphorylated tau protein has also been 
considered a prime disease trigger for AD (77).  To tackle the tauopathy, studies have 
tested the inhibition of protein kinases responsible for tau phosphorylation.  Noble et al. 
showed that lithium chloride successfully suppressed the activity of glycogen synthase 
kinase-3 (GSK-3), a tau protein kinase, and significantly reduced the insoluble tau 
aggregation (78).   Moreover, another study reported that lithium chloride treatment 
reduces Aβ accumulation in APP transgenic mice, suggesting that the inhibition of tau 
phosphorylation could be a promising strategy for effective treatment of AD (79).  The 
clinical investigation on Tideglusib/NP-12 (Noscira), a GSK-3 inhibitor, is ongoing with 
mild-to-moderate AD patients after a phase I study confirmed no relevant adverse issues 
involved with the treatment.  
2.6.4 Repositioning of the existing drugs 
Rather than starting over, researchers have suggested the idea of repositioning the 
existing drugs (80).   The medicines for other indications may have beneficial effects in 
slowing AD progression.  In this case, remarkable time and cost can be saved compared 
to the new drug development process and the validated pharmacotoxicological profiles of 
the existing drugs relieve safety concerns.  One example is the use of selective serotonin 
reuptake inhibitors (SSRI) that were originally prescribed for treatment of major 
depressive disorder.  According to one report, the activation of serotonin receptors 
facilitates α-secretase-mediated APP processing which produces nonamyloidogenic 
soluble Aβ fragments (81).  Therefore, SSRIs may help divert the neurotoxic Aβ form 





to be effective in reducing Aβ production in AD transgenic mice and healthy individuals, 
supporting the potential capacity of SSRIs for AD prevention (82).  
2.6.5 Further effort for AD drug development 
There have been a number of hopeful reports about the potential efficacy of AD 
treatments.  However, we still do not have a single effective cure that can prevent or even 
considerably delay progression of the disease.  It is imperative to expend persistent 
efforts to develop an effective drug for AD treatment.  In the meantime, more strategic 
plans should be contemplated to improve the therapeutic outcome in clinical studies.  
Recent failures of amyloid plaque targeting antibodies in clinical studies teach us that the 
therapeutics solely focused on the amyloid hypothesis may not be a sufficient solution to 
holding AD propagation.  Extensive laboratory research shows that Aβ deposits can be 
both a disease-causative agent and a consequence of AD progression.  To tackle the AD 
pathogenesis beyond Aβ, there should be more research using other approaches that 
eliminate hyperphosphorylated tau proteins or ameliorate the neuroinflammatory 
conditions in brain tissues, for example (83).   
The other lesson from recent failures is that treatment at later stages of the disease 
process come too late to attain desirable therapeutic benefits.  The AD brain undergoes 
distinct biochemical changes along with the course of disease progression, such that the 
treatment strategies should be tailored to the altered gene or protein expression profile 
(84).  The development of early diagnosis technology is also required, as it allows 
physicians to begin earlier treatment on patients at the presymptomic stage, which is 
more likely to produce better therapeutic outcomes.  Recently, Mapstone et al. reported a 





normal individuals within a 2-3 year timeframe with high and reliable accuracy (85).  
They identified 10 lipid metabolites that are depleted in plasma from individuals who are 
predestined to develop cognitive decline within 2-3 years.  A blood-based biomarker test 
is advantageous over the cerebrospinal fluid analysis, which involves an invasive lumbar 
puncture procedure.  Such diagnostic tools that detect the alteration of AD-relevant 
biomarkers, possibly at early stages, will greatly improve clinical results.  
2.7 RNAi therapy as a promising NDD treatment option  
and potential targets 
2.7.1 Brief overview of RNAi 
RNA interference (RNAi), one of the most notable discoveries in biology, has 
received attention in the biomedical research field due to the utility of specific 
modulation of disease-associated genes under pathological conditions (86).  The 
mechanism of RNAi is as shown in Figure 2.5.  Briefly, the pri-miRNAs transcribed from 
the genome are processed by an enzyme complex to generate pre-miRNAs, which are 
~60 to 70 nucleotide-long hairpin RNAs.  These pre-miRNAs are subsequently 
transported to the cytosol where they are cleaved by Dicer, an RNase type III enzyme, 
into small double-stranded RNA fragments, known as mature miRNA duplexes.  These 
are then bound to the RNA-induced silencing complex (RISC), which cuts out the 
passenger strand of miRNA and brings the guide strand to its complementary mRNA 
species.  The specific binding of miRNA to the target mRNA leads to the degradation of 
the mRNA, thereby silencing the expression of the corresponding gene (87).  The specific 
gene silencing mechanism of RNAi can be advantageous in manipulating particular 





molecule drugs, proteins, and antibody drugs, the identification and synthesis process of 
lead RNAi sequences can also be rapidly completed (88).  Davis et al. reported successful 
results from a clinical investigation where they observed the systemic administration of 
siRNA-loaded nanoparticles led to significant target gene knockdown in solid-tumor 
bearing patients (89).  This promising announcement stimulated the RNAi therapy 
development for various pathological conditions.  Regarding the NDD treatment, the 
RNAi approach may also be a promising mode of therapy tackling the genes associated 
with NDD pathology.  The potential RNAi targets for NDDs are listed in Table 2.2. 
2.7.2 RNAi targets for Alzheimer’s disease (AD) 
According to the amyloid cascade hypothesis, the key pathological incident in AD 
onset is the formation of insoluble Aβ aggregates.  As overviewed previously, the 
neurotoxic form of Aβ fragments is generated when amyloid precursor proteins (APP) are 
proteolytically cleaved by β-secretase 1 (BACE1) and γ-secretase.  To curtail the Aβ 
level in the brain tissues, an RNAi approach may be applied to APPs.  Although the exact 
physiological roles of APP are not fully understood, the increased expression of APP is 
known to elevate the risk of AD development indicating that mild knockdown of APP 
may provide clinical benefit in AD prevention (90,91).  Another conceivable target is the  
BACE1 gene, which encodes β-secretase, a major contributor for Aβ production.  A 
postmortem analysis of brain tissues with AD showed significantly elevated BACE-1 
activity, which was also correlated to Aβ production in AD brain (92).  Therefore, this 
suggests that the suppression of the BACE1 expression may prevent the overproduction 
and accumulation of toxic Aβ fragments reducing the likelihood of Aβ plaque buildup.   





also be considered for the application of RNAi therapy.  As the hyperphosphorylated 
form of tau is known as a predominant component of intracellular NFTs, clinical efforts 
have been made on the development of small molecule inhibitors of tau protein kinases 
such as mitogen-activated protein kinase 1 (MAPK1), cyclin-dependent kinase 5 
(CDK5), and glycogen synthase kinase 3 (GSK3) (93).  The RNAi technology targeting 
these genes would also repress the extent of tau phosphorylation, slowing the formation 
of intracellular tangles.  Indeed, the viral vector-aided RNAi against CDK5 gene resulted 
in reduction of tau phosphorylation in brain tissues of AD transgenic mice (94).   
In addition to these targets, the oxidative stress associated pathways can also be a 
target for RNAi therapy, as virtually all neurodegenerative disorders display extensive 
oxidative stress in affected brain regions (95).  One example is the Nrf2 (NF-E2-related 
factor 2)-ARE(antioxidant responsive element) pathway.  The Nrf2, which normally 
exists in the cytosol, translocates to nucleus in response to oxidative stress and binds to 
the ARE activating the expression of various detoxifying and antioxidant genes (96-99).  
However, the Nrf2 activity is suppressed by Kelch-like ECH associating protein 1 
(Keap1), which sequesters Nrf2 in the cytoplasm and eventually directs it to proteasomal 
degradation (100,101).  To enhance the endogenous antioxidant capacity against 
oxidative stress, the Keap1 gene can be a subject for the RNAi approach.  Keap1 
silencing was also shown to provide neuroprotection against MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine)-induced dopaminergic damage, which suggests that the 





2.7.3 RNAi targets for other types of NDDs 
Parkinson’s disease (PD) is the second most common NDD characterized by 
progressive death of dopamine-producing neurons in the substantia nigra, which results in 
movement-related symptoms (103).  The key neuropathological feature of PD is that 
neurons contain Lewy bodies that are formed from the enhanced aggregation of α-
synuclein proteins (104).  While the physiological role of α-synuclein remains elusive, 
the first RNAi trial against the α-synuclein gene showed promising neuroprotective 
effects against neurotoxin N-methyl-4-phenylpyridinium (MPP+) in vitro without 
affecting the cell viability.  This suggests that the RNAi approach targeting the α-
synuclein gene can be a possible mode of PD treatment (105). 
Huntington’s disease (HD) is a hereditary neurodegenerative disorder, symptoms 
of which include cognitive decline, disorientation, and other behavioral abnormalities 
(106).  It is caused by dominant mutations in the Huntington gene (HD) that contains 
trinucleotide CAG repeats in varying lengths.  The abnormally expanded CAG repeats 
produce polyglutamine (poly Q)-containing proteins, which form cytoplasmic poly Q 
aggregates leading to neurodegeneration (107).  As the Huntington gene is known to have 
essential functions for  brain development (108), RNAi therapy needs to be designed for 
allele-specific silencing of the mutant poly Q protein in order to maintain the normal 
copy of the HD gene.  
Amyotrophic lateral sclerosis (ALS) is another type of NDD, the representative 
symptom of which is muscle atrophy caused by progressive loss of motor neurons (109).  
One of the major disease triggering factors for ALS is the mutations in the superoxide 





organs as well as the nervous system (110).  Therefore, RNAi therapy targeting the 
mutant SOD1 genes may be advantageous to relieve deleterious effects from mutant gene 
products.  However, the RNAi construct should be carefully customized to specifically 
target individual mutation types considering that more than 100 point mutations have 
been identified so far in the SOD1 gene.   
Regarding the actual application of RNAi therapy for any target, a thorough 
consideration of the extent of gene silencing should be included because the essential 
biological functions, if any, of the target gene product can be substantially compromised 
by RNAi.  Therefore, refinement of the dose and the duration of the RNAi treatment are 
very important steps to accomplish the optimal therapeutic benefit without serious side 
effects.  One can also think of a combinatorial approach targeting multiple genes to 
maximize the therapeutic effect.  Strategically schemed combinatorial RNAi therapy may 
exert an additive or synergistic effect in attenuating neuropathological and clinical 
symptoms of NDDs. 
2.8 RNAi delivery strategies 
2.8.1 Limitations of RNAi for clinical application 
RNAi technology can be a powerful therapeutic intervention for various human 
diseases because of its highly specific target gene silencing mechanism.  The synthetic 
small interfering RNA (siRNA), which contains a target mRNA complementary sequence 
of 21-25 nucleotides in length, has been commonly applied for downregulation of 
pathology-associated genes.  However, siRNAs lack druggable properties described by 
Lipinski’s rule of five (111).  The negatively charged phosphate backbone of siRNAs 





daunting task for siRNAs to interact with cell membranes.  The relatively high molecular 
weight (~14 kD) and the bulky size also make them unfavorable for cellular uptake.  
Importantly, siRNAs are vulnerable to serum nucleases and reticuloendothelial system 
(RES)-mediated clearance, which poses another challenge in its application for living 
systems (88).  RNAi therapy, particularly for neurological diseases, is even more difficult 
largely because of the highly restrictive properties of the BBB.  As reviewed previously, 
the brain microvascular endothelial cells do not allow hydrophilic and large molecules to 
pass across them.  Understandably, it is apparent that there should be additional tactics 
that assist siRNA delivery to brain tissues.  Generally, strategies for brain-targeted siRNA 
delivery should be capable of the following key aspects: to protect siRNA in biological 
fluid, to bypass or get across the BBB, to deliver bioactive siRNA to the brain cells, and 
to produce reliable target gene silencing effect.  Additionally, the siRNA delivery 
strategies should not involve any serious adverse effects caused by non-specific uptake of 
other organs, immunogenicity of the delivery vehicles, and perturbation of normal 
cellular processes resulting from the RISC machinery saturation.  The examples of RNAi 
delivery methods that have been attempted in rodent models are listed in Tables 2.3 and 
2.4.  
2.8.2 RNAi delivery methods 
2.8.2.1 Viral delivery  
The RNAi can be achieved by short hairpin RNAs (shRNA), or artificial 
microRNAs (amiRNA) that are typically delivered in a viral vector form.  The target 
sequence-containing constructs are embedded in the viral vector of choice such as adeno-





RNAi effects in nondividing cells such as neurons because AAV vectors exist episomally.  
The AAV vectors are not integrated to the host genome where the insertional 
mutagenesis is unlikely to occur.  Alternatively, lentivirus-delivered transgene can be 
integrated into the host genome and it can be advantageous for sustained RNAi effect in 
dividing cells.  However, the genomic integration may also cause the activation of 
oncogenes or inactivation of tumor suppressor genes (112).  Many preclinical animal 
studies have tested viral delivery of RNAi into nervous systems.  Xia et al. conducted 
intracerebellar administration of recombinant AAV vectors containing shRNA against 
spinocerebellar ataxia type 1 (SCA1) into SCA1 transgenic mice.  They found that the 
AAV-mediated RNAi was successfully achieved in vivo, resulting in the improvement of 
motor performance of the SCA1 mice (113).  Singer et al. used a lentiviral system to 
deliver BACE1 targeting siRNA via intracranial injection into the hippocampus of the 
APP transgenic mice.  They showed that lentiviral vector mediated-BACE1 RNAi 
significantly reduced the BACE1 expression and the Aβ production ameliorating 
behavioral abnormalities of the AD mice (114).  Recently, Foust et al. reported that 
AAV9-mediated RNAi against the SOD1 gene substantially reduced the mutant SOD1 
expression in the ALS mouse model throughout their lifespan and attenuated the 
progression of neurodegeneration, extending the survival period as well (115).  Even with 
multiple promising results from preclinical animal studies, there should be extreme 
caution when extrapolating preclinical results for clinical applications to humans because 
of the differences in brain anatomy and physiology between rodent animal models and 
humans.  In addition, it is difficult to estimate the exact dose and effective duration of the 





process and producing toxicity issues (88,116).  Generally, viral delivery in animal 
studies has been achieved by local administration such as intracerebral injection or 
intracerebroventricular injection.  However, it may not be readily feasible to apply those 
invasive procedures to human patients.  Moreover, it is possible that patients need to 
receive multiple injections of the therapeutic RNAi containing viral vectors for desired 
therapeutic outcome.  Apparently, each injection might involve a risk of hemorrhage, 
edema, bacterial infection, or immune responses (117).   
2.8.2.2 Nonviral delivery 
In contrast to viral delivery, nonviral RNAi delivery is more favorable for 
controlled dosing of therapeutic siRNA.  However, the duration of the RNAi effect is 
transient; it may not be a plausible choice for treatment of chronic pathology, which 
demands long-lasting RNAi effect.  As overviewed previously, naked siRNAs are highly 
susceptible to serum nuclease-mediated degradation and they cannot penetrate into the 
cell membrane without the assistance provided by delivery vehicles.  To address these 
issues, researchers have conceived a range of siRNA delivery strategies for in vivo 
application (Figure 2.6).  Particularly for brain-targeted siRNA delivery, chemically 
modified siRNAs, liposomes and exosomes, a cell-penetrating peptide-based system, 
antibody-fused system, and other types of cationic nanoparticles have been investigated. 
Chemically modified siRNAs such as cholesterol conjugated siRNAs, siRNAs 
containing partial phosphorothoiate linkages, 2’-Ο-methyl sugar modified siRNAs have 
shown a better pharmacological profile with improved stability against serum nucleases 
(118).  Nakajima et al. administered chemically modified Accell siRNA (Dharmacon) 





this study, they showed that a single icv injection (5 µg of Accell siRNA/rat) was 
sufficient to achieve significant target gene downregulation 4 days after the injection 
without any signs of neuroinflammation.  The target gene knockdown was observed in 
diverse brain regions including the cortex, striatum, hippocampus, midbrain and 
cerebellum.  Another study showed that the intravenous administration of cholesterol 
conjugated siRNAs incorporated into high-density lipoprotein (HDL) resulted in 
successful target gene downregulation in brain capillary endothelial cells (BCEC) in vivo 
(120).  In this work, they did not intend to deliver siRNA to the brain compartment, but to 
the brain endothelial cells; for this purpose, cholesterol is an optimal molecule, as it does 
not get into the brain (121) while lipoprotein mixture can be endocytosed via lipoprotein 
receptors on BCECs.  These studies indicate that chemically modified siRNA can be a 
promising mode of RNAi, particularly due to its enhanced stability compared to the 
naked siRNA.  However, chemically modified siRNAs may not exert satisfactory 
silencing effects depending on the modified position (122).  Moreover, it should be 
directly injected to the brain via local administration unless they are equipped with brain-
targeting moieties.  
Liposomal formulation of siRNA is another strategy for efficient siRNA delivery 
into the cells in vivo. Tao et al. encapsulated siRNAs into the core of polyethylene glycol 
(PEG)-coated liposomes that are decorated with the rabies virus glycoprotein (RVG) 
peptide as a brain-targeting moiety (123).  The RVG peptide is known to bind to the 
acetylcholine receptors (AchR), which are extensively expressed on brain cells as well as 
brain endothelial cells.  The intravenous injection of RVG-liposomes into mice 





mouse brain up to 24 hr after injection while displaying relatively lower distribution in 
other peripheral organs.  Although they did not mention the actual in vivo siRNA delivery, 
target gene silencing effect in mice, or any RVG-liposome associated toxicity, this study 
proposes that the targeted liposomal formulation has a promising potential for brain-
targeted siRNA delivery.  Another study showed that liposome-siRNA-nine arginine 
fused RVG peptide (RVG-9R) complex (LSPCs) can deliver siRNA to the brain cells in 
significant amounts, leading to the substantial knockdown of the target protein expression 
48 hr after the tail vein injection into the mice (124).  The ability of RVG-9R to deliver 
siRNA to the mouse brain in vivo has already been demonstrated by Kumar et al. (125).  
This group suggests that additional liposomal formulation to the RVG-9R enhances the 
siRNA protection against the serum proteins thereby improving the siRNA delivery to the 
brain compartment.  
Instead of using exogenous lipid components, the host-derived nanosized vesicles, 
namely exosomes, can be used to transport siRNA to the brain cells.  A research group 
used self-derived dendritic cells that were engineered to produce RVG peptide-fused 
exosomal proteins (126).  The exosomes obtained from these dendritic cells were 
electroporated with siRNAs and intravenously administered to the same mice.  In contrast 
to the naked siRNA, exosome-loaded siRNA were preferentially accumulated in brain 
tissues resulting in significant target gene knockdown 3 days after a single injection of 
150 μg of siRNA.  Exosome-mediated RNAi can be an advantageous approach 
particularly because the self-derived exosomes are unlikely to cause immunological 
toxicity issues.  However, the exosome production procedure, which includes the 





purification of the engineered exosomes may be time and labor intensive.  Also, the final 
yield of exosomes needs to be ensured to achieve effective treatment.   
Cell-penetrating peptide (CPP)-based systems are also useful vehicles for siRNA 
delivery.  Most CPPs contain positively charged residues such as arginines and lysines at 
such physiological pH that it facilitates the electrostatic interaction with the negatively 
charged plasma membrane possibly leading to the internalization of CPPs or CPP-
conjugated drugs into the cells (127).  Due to the powerful properties of CPPs, it has been 
vastly utilized to transport drugs such as plasmid DNA (pDNAs), siRNAs, peptides and 
proteins, small molecule drugs along with diverse nanoparticle drug delivery vehicles.  
Particularly, the positively charged cationic domain not only confers the ability to readily 
enter the cells across the cellular membranes, but also serves for siRNA condensation via 
electrostatic interaction.  Kumar et al. combined nine arginine repeats with RVG peptide 
(RVG-9R) for brain-targeted siRNA delivery in vivo (125).  They conducted multiple 
intravenous injections of the GFP targeting siRNAs complexed with RVG-9R peptides 
into the GFP expressing transgenic mice for 3 consecutive days, which resulted in 30-40% 
of GFP silencing effect in brain tissues 2 days after the last injection.  This result 
indicates that RVG-9R crosses the BBB and successfully delivers bioactive siRNA into 
brain tissues.  However, it is still unclear how the siRNAs are released from the RVG-9R 
system once they are internalized into the cells.  The incorporation of intracellular pH-
responsive amino acid sequences into this CPP system may improve the siRNA 
detachment from the delivery system.  In addition, exogenous peptide sequences should 
be carefully examined to rule out the possibility of host immune system stimulation.  





that bind to the receptors on the brain endothelium.  Xia et al. used biotinylated siRNAs 
that are bound to monoclonal transferrin receptor (TfR) antibody-conjugated streptavidin 
(128).  They showed that a single intravenous administration of luciferase targeting 5’-
biotinylated siRNA into tumor bearing rats effectively downregulated the luciferase 
activity (69%) in a luciferase expressing intracranial brain tumor 48 hr after the injection.  
It is a promising result supporting the use of targeting antibodies for brain-targeted 
siRNA delivery vehicles.  However, the TfRs are ubiquitously expressed on other 
peripheral organs aside from the brain endothelium (129). Although TfR has been one of 
the most popularly exploited brain-targeting receptors, it may also bind to other organs 
and produce nonspecific adverse effects.  They used the siRNA containing 2-nucleotide 
2’-deoxythymidine overhangs to avoid exonuclease attack in serum (130), but the 
structure of this system still exposes siRNA to the outer environment that the siRNA 
stability may be more affected compared to other encapsulating systems.  
Cationic polymer-based nanoparticles are another approach for effective siRNA 
delivery to the cells.  Recently, Kozielski et al. reported that linear poly (β-amino esters)s 
(PBAEs) containing disulfide bonds can be a promising siRNA delivery vehicle ensuring 
effective siRNA delivery as well as functional cytoplasmic release of siRNA (131).  
These bioreducible siRNA loaded nanoparticles produced a remarkable knockdown of 
the target gene expression (97%) in a human primary glioblastoma cell line (GBM 319) 
without displaying adverse effects, which demonstrates the utility of PBAEs as an 
effective and safe siRNA carrier.  Despite their exciting results, the lack of in vivo data 
give uncertainty about the actual brain-targeted RNAi effect in a living system.  To prove 





in an animal model.  Moreover, this approach does not have brain-targeting ability.  To 
achieve therapeutic RNAi effect in brain tissues, the carrier may need to incorporate a 
proper brain-targeting moiety or the local administration should be employed for in vivo 
application.       
2.8.3 Alternative RNAi delivery strategies 
Various RNAi delivery vehicles have notably improved the bioavailability and 
target gene silencing efficacy of RNAi drugs in multiple in vivo preclinical studies.  
However, the inherent limitations in RNAi should be addressed further, particularly for  
brain-targeted RNAi delivery.  Except for a few types of siRNA delivery vehicles that 
have brain-targeting moieties, other RNAi delivery systems with no neurotargeting 
modules are not suited for systemic administration, mainly because of the poor brain 
accumulation of the RNAi drugs.  These delivery systems may be redesigned to 
additionally accommodate a brain homing group of choice.  Studies have identified the 
peptide or ligands that bind to receptors expressed on the brain endothelium and neuronal 
cells.  These receptors include transferrin receptors (132), insulin receptors (133), low 
density lipoprotein receptors (134), acetylcholine receptors (135), leptin receptors (136), 
etc.  However, these receptors are not exclusively found in brain tissues.  To improve the 
brain-targeted RNAi delivery and reduce nonspecific adverse effects, further studies are 
required to discover brain-specific receptors and ligands that bind to those receptors with 
high affinity.   
For those not having the brain-targeting ability, a direct injection into the brain 
compartment would be desired to bypass the BBB and deliver RNAi to the brain.  Local 





ensure immediate RNAi delivery and robust therapeutic outcome with reduced dose 
requirement compared to systemic administration.  A recent study reported that siRNA-
encapsulated cationic lipid nanoparticles (LNP-siRNA) were able to induce significant 
target gene downregulation in both cases of intracerebral injection and 
intracerebroventricular injection (137).  In this study, more direct and efficient gene 
silencing effects were observed from the intracortical injection into the specific brain 
region while the intracerebroventricular injection resulted in a more widespread and 
diffuse effect.  However, these types of direct injections may not be feasible for practical 
clinical application.  Patients may need to receive multiple injections to reach sufficient 
RNAi effect and these injections may involve highly invasive and risky procedures.  In 
case the pathological condition requires long lasting suppression of the target gene, 
implantable pumps that continuously infuse RNAi drugs into the brain parenchyma or 
cerebrospinal fluid would be a conceivable option.  Preclinical studies have shown a 
robust gene silencing effect in rodent brain tissues with implantable osmotic pumps for 
sustained release of therapeutic siRNAs to the brain (138,139), suggesting the possible 
use of implantable pumps for clinical application.  Alternatively, researchers have 
investigated intranasal administration for brain-targeted siRNA delivery (140,141).  
Intranasal administration is an advantageous approach, particularly for CNS therapeutics 
as the drugs can be delivered to brain tissues while circumventing the BBB and the 
therapeutics are local acting, which eliminates concerns about potential adverse effects 
from systemic administration (142).  However, siRNA-loaded nanoparticles still need to 
survive in the mucous layer that covers the olfactory epithelium for effective siRNA 





In all cases of diverse RNAi delivery methods and alternative routes of 
administration, RNAi drugs should establish a reliable efficacy and safety profile to move 
forward to clinical application.  The important criteria for viable RNAi drugs include: 1) 
effective target gene knockdown, 2) predictable biodistribution of RNAi drugs, 3) safe 
clearance of delivery vehicles after RNAi performance, and 4) no apparent toxicity issues.  
Regarding the therapeutic effect, the level of pathology-associated biomarkers, such as 
CSF concentration of Aβ(1-42) and phosphorylated tau proteins for AD (144), should be 
closely monitored during therapy to adjust the dosage and treatment duration and to 
ultimately achieve desirable therapeutic outcomes.   
2.9 Concluding remarks 
 Current AD treatments lack disease-modifying effects.  Researchers have 
investigated drugs that directly combat the culprits accounting for AD pathogenesis.  
Despite numerous failures, many are under investigation in preclinical studies and 
clinical trials with a hope to prevent the onset or the progression of AD.  The RNAi 
approach is also a promising therapeutic option for NDDs as it modulates the genes 
associated with NDD pathological processes.  Researchers have attempted a wide variety 
of siRNA delivery modes to achieve the brain-targeted siRNA delivery and desired target 
gene knockdown effect while surmounting the BBB.  Many have shown impressive data 
in preclinical studies, but it appears that we need more thorough validation prior to 
clinical application for patients with NDDs.  Along with our current ability to harness 
diverse delivery strategies, efforts for further refinement of the siRNA carrier design 
should be continued to accomplish robust RNAi effects in the physiological environment.  





therapy would contribute immensely to the improvement of therapeutic outcomes.  
Because the neurodegeneration process is irreversible and it takes years before noticeable 
symptoms emerge, researchers generally agree that early treatments or preventive 
medicines would be beneficial to stop or delay disease progression.  Together with the 
development of novel and potent NDD drugs, precise and reliable diagnosis techniques 
and adequate preventive therapies would significantly lower incidence of NDDs and 
ameliorate the quality of life for patients with NDDs.   
 



















Asymptomatic subjects with PS1 
E280A mutation, age of 30 to 60 
years 
Crenezumab 
(a humanized monoclonal 
antibody against Aβ) 
Phase 2 
Scores of multiple cognitive tests, mean cerebral fibrillar 
Aβ accumulation, cerebral metabolic rate of glucose, 








Asymptomatic subjects at-risk 
for familial AD (mutations in 
APP, PS1, and PS2), within -15  




(a humanized monoclonal 
antibodies against Aβ) 
Phase 2 
Phase 3 
Amount of fibrillar amyloid deposition, concentration of 
CSF Aβ species, rate of brain atrophy, clinical dementia 
rating, minimental status exam 
NCT 
02008357 
Eli Lilly and 
Company 
Elderly subjects with  
evident brain amyloid pathology  
Solanezumab 
(a humanized monoclonal 
antibody against Aβ) 
Phase 3 
Free and cued selective reminding test, the logical memory 
IIa, digit symbol and minimental state exam, changes in 






Subjects with mild to moderate 
AD, age of 55 to 85 years 
MK-8931 
(a BACE1 inhibitor) 
Phase 2 
Phase 3 
Changes in ADAS-Cog score (cognitive function 
assessment) and ADCS-ADL score (functional 
performance assessment), changes in brain Aβ load, CSF 
total tau, total hippocampal volume 
NCT 
01807026 
Eli Lilly and 
Company 
Healthy subjects not taking any 
concomitant medications, age of 
18 years or older 
LY2886721 
(a BACE1 inhibitor) 
Phase 1 
Pharmacokinetic parameters (AUC and Cmax of plasma 
LY2886721, AUC and Cmax of CSF LY2886721), Aβ level 




Subjects with mild to moderate 
AD, age of 50 to 85 years 
Tideglusib 
(a small molecule non-ATP-
competitive GSK3 inhibitor) 
Phase 2 
Changes in ADAS-Cog score and ADCS-ADL score, tau 






Cognitively normal older adults, 
age of 65 to 85 years 
Escitalopram 
(s-enantiomer of citalopram, 
an antidepressant of the SSRI 
class) 
Phase 4 





Subjects with mild to moderate 
AD, age of 55 to 80 years 
CERE-110 
(adeno-associated virus 
delivery of NGF) 
Phase 2 
Changes in ADAS-Cog and ADCS-ADL, minimental state 
exam 
 
ADAS-Cog, Alzheimer's Disease Assessment Scale- Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Co-operative Study — Activities of 
Daily Living Inventory; ADCS–PACC, Alzheimer’s Disease Cooperative Study–Preclinical Alzheimer’s Cognitive Composite; APP, amyloid 
precursor protein; ATP, adenosine triphosphate; AUC, area under the curve; BACE1, β-secretase I; Cmax: maximum concentration; CSF, 
cerebrospinal fluid; GSK3, glycogen synthase kinase 3; MRI, magnetic resonance imaging; NGF, nerve growth factor; PET, positron emission 
tomography; PS, presenilin; SSRI, selective serotonin reuptake inhibitor.  Partly adapted from Becker et al. (145). 






Table 2.2. Potential RNAi targets for NDDs. 
 
NDD Type RNAi target Pathological function Ref. 
Alzheimer’s 
disease 
Swedish variant of APP (amyloid precursor 
protein) 
Abnormal production and accumulation of the 
toxic Aβ peptides 
(91) 
BACE1 (β-secretase) 
Increased β-secretase activity leads to the 
accumulation of toxic Aβ peptides 
(114) 
Missense mutations in presenilin 1 (PS1) and 
presenilin 2 (PS2) 
Affects the APP processing and leads to the 




Single point mutations in the α-synuclein gene, 
gene duplication and triplication 
Forms intracellular aggregates 





Mutant huntingtin protein (mHTT) Aberrant extension of polyglutamine repeats (148) 
Amyotrophic 
lateral sclerosis 































1 μL injected into three 
separate sites  
(1 × 1012 genome copies/mL) 
at 7 weeks of age 
From weeks 11 to 21, significant 












2 μL injection  
(1 to 5 × 1013 genome 
copies/mL) 
24.5% to 38% decreased expression of 
mHtt protein in the mHtt transgene and 
delayed onset of the rear paw clasping 











injection to the 
substantia nigra 
0.4 μl of purified virus 
suspended in PBS was 
injected 
30% reduction in tyrosine hydroxylase 
expression 2 weeks after the injection 
and a motor performance deficit and 
reduced response to a psychostimulant 










2 μL of the lentiviral 
preparations  
(1.5 × 107 transduction units) 
into the hippocampus 
> 2-fold decrease in BACE1 protein in 
hippocampus, reduced Aβ production 












2 μL injection  
(108 pg of p24 /mL) with 
polybrene (4 mg/mL) 
98% reduction in EGFP expression in 
adult C57BL/6 mice that were co-











Table 2.4. Examples of in vivo brain-targeted RNAi via nonviral delivery in rodent models. 
 
Types of RNAi carrier Target genes 
Routes of 
administration 
Dosage regimen Knockdown effect Ref. 









Single injection 5 µg of Accell 
siRNA/rat 
Knockdown of cyclophilin-B (38-61%) and GAPDH (23-34%) 
in cortex, caudate subregion of striatum, and CA1 subregion of 
hippocampus of adult rat brain at 4 days postinjection 
(119) 
Cholesterol conjugated 








Three injections of  1.0, 3.3, or 
10 mg/kg with 12 hr intervals 
50% reduction of OAT3 mRNA in 
brain capillary endothelial cells 6 hr after the last 
injection in female wild-type C57BL/6J mice 
(120) 
PEG-coated liposomes 





Single injection of 100 µL 
containing 0.1 mg total lipid 




arginine fused RVG peptide 





Single injection of 
4 nmoles of siRNA formulated 
with 4 nmoles of liposomes and 
40 nmoles of RVG-9R 








A single injection of exosomes 
loaded with 150 μg of siRNA 
Significant knockdown (~5%) in brain cortices of C57BL/6 
male mice at 3 days postinjection 
(126) 
RVG peptide (RVG-9R) GFP 
Intravenous 
injection 
Three injections with 24 h 
intervals (50 µg of 
siRNA/injection) 
30-40% of GFP silencing effect in brain tissues of GFP 
expressing transgenic mice 2 days after the last injection 
(125) 
Biotinylated siRNAs bound 





A single injection of 5’- 
biotinylated siRNA (80 µg/rat) 
conjugated to the TfRMAb/SA 
(736 µg/rat) 
Reduced luciferase activity (69%) in luciferase expressing 
intracranial brain tumor-bearing male fischer CD344 rats 48 h 













5 nL of 5 mg siRNA/mL for 
intracranial injection, 
2 µL of 5 mg siRNA/mL for 
intracerebroventricular injection 
PTEN reduced by 91% in brain cortex from intracranial 
injection. PTEN reduced by 55.8% in hippocampus 
and 51.2% in striatum from intracerebroventricular injection in 
Sprague–Dawley rats at 5 days postinjection 
(137) 
TAT-conjugated  
modified poly (ethylene 









(FAM-siRNA: 0.5 mg/mL) 
delivered in 5-10 µL drops, 
alternating every 2-3 min. A 
total volume of 80 µL was 
administered over a 30 min 
Significantly higher fluorescence intensity in brain tissues than 
intravenously injected group and naked siRNA delivered 







Figure 2.1. Transport systems at the blood-brain barrier.  Small ions and water penetrate 
into the brain via ion channels.  Small lipophilic molecules can cross the BBB through 
the cell membrane.  Hydrophilic molecules that are crucial for normal brain function are 
transported by carrier-mediated transport system.  Other molecules can be actively 
transported into the brain compartment via carrier-mediated transporters, receptor-














Figure 2.3. APP processing and tau phosphorylation. The Aβ fragment is generated by 
proteolytic cleavage from the amyloid precursor protein, APP.  β-secretase and γ-
secretase cleave, respectively, the extracellular domain and the transmembrane domain of 
the APP to produce the Aβ fragment.  The fibrillogenic Aβ species form oligomeric 
aggregates and further clump to Aβ plaques.  The microtubule (MT)-associated protein 
tau is hyperphosphorylated by multiple kinases under pathological condition.  
Hyperphosphorylated tau proteins dissociate from microtubules and form aggregates.  
Further accumulation of tau aggregates eventually form neurofibrillary tangles (NTFs).  






Figure 2.4. Dynamic biomarkers of the Alzheimer’s pathological cascade.  Aβ is 
identified by CSF Aβ42 or PET amyloid imaging.  Tau-mediated neuronal injury and 
dysfunction is identified by CSF tau or fluorodeoxyglucose-PET.  Brain structure is 





Figure 2.5. Diagram of the endogenous RNAi pathway.  The single stranded RNA 
processed from the RISC binds to its target mRNA species.  Depending on the level of 
sequence complementarity, different modes of the gene silencing mechanism are 
operated; nearly complete base-pairing leads to the target cleavage while incomplete 






Figure 2.6. Strategies for the siRNA delivery in vivo.  Diverse approaches have been 
undertaken for siRNA delivery in vivo.  The siRNA can be directly conjugated to ligands, 
polymers or aptamers for targeting purpose.  The negatively charged siRNAs can form 
complexes with positively charged peptide or protein linked to an antibody or a ligand.  
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A MYRISTOYLATED CELL-PENETRATING PEPTIDE BEARING  
A TRANSFERRIN RECEPTOR-TARGETING SEQUENCE  
FOR NEUROTARGETED SIRNA DELIVERY 1 
3.1 Abstract 
Many neurodegenerative disorders (NDDs) are characterized by aggregation of 
aberrant proteins and extensive oxidative stress in brain cells.  As a treatment option for 
NDDs, RNA interference (RNAi) is a promising approach to suppress the activation of 
abnormal genes and negative regulators of antioxidant genes.  Efficient neurotargeted 
siRNA delivery requires a delicate optimization of nucleic acid carriers, quite distinct 
from putative pDNA carriers in regard to stable condensation and serum protection of 
siRNA, blood-brain barrier (BBB) bypass, effective siRNA delivery to brain cells, and 
functional release of bioactive siRNA at therapeutic levels.  Here, we propose that a 
myristic acid conjugated, cell-penetrating peptide (transportan; TP), equipped with a 
transferrin receptor-targeting peptide (myr-TP-Tf) will lead to stable encapsulation of 
siRNA and targeted delivery of siRNA to brain cells overcoming the BBB.  Myr-TP-Tf 




Tf:siRNA complex formulated at 20:1 (peptide:siRNA) molar ratio provided prolonged 
siRNA stability against serum and ribonuclease treatment.  Fluorescence images clearly 
indicated that siRNA uptake was successfully achieved by myr-TP-Tf complex in both a 
murine brain endothelioma and a human glioma cell line.  The luciferase assay and the 
human placental alkaline phosphatase (hPAP) reporter assay results demonstrated the 
functional gene silencing effect of myr-TP-Tf:siRNA complex in a human glioma cell 
line, as well as in primary murine neurons/astrocytes, which are supportive of successful 
release of bioactive siRNA into the cytosol.  Finally, the transcytosis assay revealed that 
favorable siRNA transport via receptor-mediated transcytosis was mediated by myr-TP-
Tf complex.  In summary, these data suggest that myr-TP-Tf peptides possess promising 
properties as a vehicle for neurotargeted siRNA delivery.  We will further study this 
peptide in vitro and in vivo for transport mechanism kinetics and to validate its capability 
to deliver siRNA to the brain, respectively. 
3.2 Introduction 
Today, neurodegenerative disorders (NDDs) are a critical, rising major health 
concern across the globe, a burgeoning pandemic of dementia encompassing Alzheimer’s 
disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and 
Huntington’s disease (HD).  Based on the growing trend of the aging population, it is 
estimated that approximately 115 million people will suffer from NDDs by 2050 (1).  
The health care cost for the treatment of NDDs is estimated to reach $1.1 trillion by 2050 
in the US alone (2).  Despite increasing incidences and enormous economic, social, and 
emotional burdens of NDDs, relatively few NDD therapeutics are clinically viable.  This 




barrier (BBB), which has prompted many pharmaceutical companies to abandon their 
neuropharmaceutical programs (3,4).  Typically, the defensive brain vasculature allows 
passage of only small, hydrophobic compounds across the BBB because of the regulation 
provided by tight junction proteins found between endothelial cells.  Hence, there is an 
acute need for drug delivery vehicles and/or biotherapeutic formulations to cross the BBB 
with favorable PK/PD (5,6).  
Many NDDs are characterized by accumulation of abnormal proteins such as beta 
amyloid peptide (Aβ) and tau proteins found in AD (7), alpha-synuclein in PD (8), and 
polyglutamine repeats in HD (9).  Along with these protein aggregates, the elevated 
oxidative stress is also considered a key pathological factor for the onset and progression 
of NDDs (10).  As a therapeutic option for NDDs, an RNA interference (RNAi) approach 
has the potential to suppress the abnormally regulated genes or any negative regulators of 
endogenous antioxidant genes. For instance, the Nrf2 (NF-E2-related factor 2)-
Keap1(kelch-like ECH-associated protein) pathway is a promising target as Nrf2 
activates the expression of detoxifying and antioxidant genes, which relieves oxidative 
stress (10-13).  Because Nrf2 activity is normally restricted by Keap1, which sequesters 
Nrf2 in the cytoplasm and directs it to the proteasomal degradation pathway (14,15), it is 
expected that downregulation of the Keap1 protein using an RNAi approach will result in 
liberation and translocation of Nrf2 and subsequent expression of antioxidant genes, 
thereby providing cytoprotection to brain cells.  
However, drug delivery, let alone neurotargeted siRNA delivery, remains a 
daunting task.  First, the negatively charged backbone of siRNA presents a hurdle for 




due to its susceptibility to serum nucleases (16,17).  More crucially, the vascular 
endothelium of the BBB does not allow free passage from the systemic circulation to 
brain parenchyma.  Therefore, successful brain-targeted siRNA transport requires 
formulations that fully condense siRNA in vitro and remain stable in vivo, and delivery 
vehicles that deposit a bioactive, therapeutic level of siRNA without undue toxicity at the 
targeted site.  Diverse siRNA delivery platforms have been attempted including: 
chemically modified siRNA (18), polymeric nanoparticles (19,20),  liposomes or 
exosomes (21,22),  antibody-fusion molecules (23), and cholesterol-conjugated siRNA 
(24).  For clinical application, however, currently investigated siRNA vehicles still 
require optimization regarding physiological stability, BBB-targeting ability, and 
functional RNAi effect. 
To overcome the above listed obstacles, studies have indicated that cationic 
peptide repeats effectively encapsulate siRNA through electrostatic interactions (25-28) 
and also facilitate cellular uptake of nucleic acid (29,30).  Thus, it is conceivable that 
siRNA carriers comprised of a cationic domain fused with a BBB-targeting group should 
be capable of siRNA condensation and delivery across the BBB.  Kumar et al. presented 
transvascular delivery of siRNA to neurons using synthetic oligo-arginine peptides linked 
with a rabies virus glycoprotein (RVG)-derived domain that binds to acetylcholine 
receptors on neuronal cells (31).  This finding provided an encouraging basis for the 
development of neurotargeted, peptide-based siRNA carriers.  In a recent study, various 
cell-penetrating peptides were characterized and evaluated in regard to effective siRNA 
delivery to tumor cells; the myristoylated transportan peptide was identified as the most 




activator of transcription) cell penetrating peptide (32).  Myristolyation of the cell-
penetrating peptide is also a beneficial strategy for carrier design, as it is known to 
enhance the peptide affinity for the cellular membrane (33-35).  Another study showed 
that myristoylated poly-arginine peptides mediated efficient siRNA internalization to 
brain cells in vitro (36), but the physiological performance in vivo may not be ensured 
without an adequate neuro-targeted moiety.  
In the current work, we designed a BBB-targeting siRNA carrier exploiting the N-
terminally myristoylated transportan peptide as a cell-penetrating and siRNA 
condensation domain and a transferrin receptor-targeting 12 amino acid sequence 
(THRPPMWSPVWP)(37,38) as a BBB-targeting domain. We hypothesized that a 
myristic acid conjugated, cell-penetrating peptide (transportan) equipped with a 
transferrin receptor-targeting peptide (myr-TP-Tf) would enable the stable condensation 
of siRNA and facilitate targeted delivery of siRNA to brain cells through receptor-
mediated transcytosis, as illustrated in Figure 3.1A.  The data from in vitro studies 
confirmed that the myr-TP-Tf peptide formed stable peptide:siRNA complex and 
achieved superior siRNA uptake in brain endothelial cells and glioma cells when 
compared to putative Lipofectamine®:siRNA controls or nontargeted (scrambled) 
peptide:siRNA controls.  In addition, myr-TP-Tf:siRNA complex displayed the 
functional, reporter protein knockdown without affecting cell viability and favorable 




3.3 Materials and methods 
3.3.1 Peptide synthesis 
The myristic acid conjugated, cell-penetrating peptide (transportan) equipped with 
a transferrin receptor-targeting peptide (myr-TP-Tf) and its nontargeting scrambled 
control peptide (myr-TP-Scr) were prepared by solid-phase peptide synthesis at 
Selleckchem (Houston, TX). The peptide sequences for myr-TP-Tf and myr-TP-Scr are 
as follows: myristic acid-GWTLNSAGYLLGKINLKALAALAKKIL-GGGG-
THRPPMWSPVWP and myristic acid-GWTLNSAGYLLGKINLKALAALAKKIL-
GGGG-PWRPSHPVWMPT, respectively.  The purity (>95%) and the molecular weight 
(4.5 kDa) of the peptides were confirmed by high-performance liquid chromatography 
(HPLC) and mass spectrometry analyses upon receipt. 
3.3.2 Formulation of siRNA-carrier complex and gel retardation assay 
Myr-TP-Tf peptide was mixed with 20 pmol of siRNA at different molar ratios 
ranging from 1:1, to 10:1, 20:1, and 30:1 (peptide:siRNA) in distilled water. Samples 
were vortexed for 20 s and incubated for 20 min at room temperature.  Each sample was 
mixed with 6× DNA loading dye (Fermentas, Hanover, MD) and subject to 0.8% agarose 
gel electrophoresis for 20 min at 100V.  Bands were stained with SYBR® Green II RNA 
gel stain (Invitrogen, Carlsbad, CA) and visualized under UV light.  
3.3.3 Transmission electron microscopy 
The morphology of the myr-TP-Tf:siRNA complex was examined by 
transmission electron microscopy (TEM).  Briefly, 20 µL of the peptide:siRNA complex 




electron microscopy grids and air-dried for 1 hr.  The peptide:siRNA complex was 
negatively stained with 2% phosphotungstic acid for 30 s and the excess liquid was 
wicked away with a tip of filter paper.  The grids were then examined by a 120 kV 
Tecnai 12 TEM (FEI, Hillsboro, OR) at the electron microscopy lab in the University of 
Utah Health Sciences Center Core Research Facility. 
3.3.4 Particle size and zeta potential measurement 
The myr-TP-Tf:siRNA complex was prepared in either 10:1 or 20:1 molar ratio in 
distilled water (100 nM of siRNA).  The hydrodynamic diameter and the surface charge 
of the complex were determined by using a Zetasizer Nano ZS (Malvern Inc., 
Westborough, MA).  All measurements were collected in triplicate and expressed as 
mean ± standard errors.  Each measurement consisted of at least 11 runs.  
3.3.5 Examination of siRNA stability fetal bovine serum 
and ribonuclease A 
Naked siRNA and myr-TP-Tf:siRNA complex were incubated in 50% fetal 
bovine serum at 37°C.  Aliquots were collected at 0, 30 min, 4 hr, 8 hr, 24 hr of 
incubation and frozen for storage.  Each sample was then treated with proteinase K (1 
mg/mL) at 37°C for 10 min.  To evaluate the siRNA protection against RNase A, naked 
siRNA and myr-TP-Tf:siRNA complex were incubated in RNase A solution (0.04 
mg/mL) at 37°C for 0, 30 min, 1 h, 2 h, 4 h, and treated with 2 µL of 10 M NaOH 
solution to disrupt the complex structures.  All samples were mixed with 6× DNA 




were stained with SYBR® Green II RNA gel stain (Invitrogen) to examine the siRNA 
integrity under UV light. 
3.3.6 Cell culture: human glioma U87mg and murine brain endothelioma  
b.End3 cell lines 
  Human glioma U87mg cells that constitutively express luciferase were kindly 
donated by Prof. Randy Jensen (University of Utah; Dept. of Neurosurgery) and 
maintained in DMEM (Dulbecco's Modified Eagle's Medium, Invitrogen) supplemented 
with 10% fetal bovine serum, 100 U/mL of penicillin/streptomycin, and 0.5 mg/mL of 
Geneticin® selective antibiotic (G418 sulfate).  During the transfection studies, G418 was 
not contained in the culture medium.  Murine brain endothelioma b.End3 cells were 
purchased from ATCC (Manassas, VA) and maintained in DMEM supplemented with 10% 
fetal bovine serum and 100 U/mL of penicillin/streptomycin.  The cell cultures were 
maintained in a humidified atmosphere containing 5% CO2 at 37 °C. 
3.3.7 Cell culture: primary murine ARE:hPAP(+) neurons/astrocytes 
ARE:hPAP (antioxidant response element:human placental alkaline phosphatase) 
(+) transgenic mice were kindly gifted by Prof. Jeffrey Johnson (University of 
Wisconsin-Madison) and maintained in accordance with University of Utah Institutional 
Animal Care and Use Committee (IACUC) guidelines.  The mice were mated and the 
mother mice were sacrificed at day 15 of pregnancy to isolate the E15 brain cortices from 
embryonic mice.  The tissues were washed with HBSS (Invitrogen) and digested with 
0.05% trypsin for 20 min at 37°C.  The cell suspensions were filtered through 70 µm cell 




plates in EMEM supplemented with 10% FBS, 10% horse serum, 2 mM of L-glutamine, 
and 100 U/mL of penicillin/streptomycin following the protocol established by the 
Johnson lab (39).  On day 2, the medium was replaced with neurobasal medium 
(Invitrogen) containing B27 supplements, 2 mM of L-glutamine, and 100 U/mL of 
penicillin/streptomycin.  The primary neurons/astrocytes were cultured at 37°C in a 
humidified trigas chamber (5% CO2 / 5% O2 / 90% N2). 
3.3.8 Cell transfection 
  U87mg-Luc cells were plated on 96-well plates with 104 cells/well and grown to 
70-80% confluency.  The cells were transfected with peptide:luciferase siRNA complex 
(4 pmol of siRNA/well) in DMEM without serum and antibiotics for 3 hr  and then 
incubated in complete culture medium for an additional 45 hr.  Lipofectamine® 
RNAiMAX Reagent (Invitrogen) was used as the control transfection reagent following 
the manufacturer's protocol. 
3.3.9 Immunocytochemistry for transferrin receptors 
  U87mg cells and b.End3 cells were grown on 6-well plates up to 70% confluency.  
The cells were twice washed with ice-cold phosphate buffered saline (PBS) and fixed 
with 4% paraformaldehyde for 15 min at room temperature.  Following three additional 
rinses of PBS, the cells were incubated with a polyclonal, rabbit antibody to the 
transferrin receptor (Abcam Inc., Cambridge, MA) in PBS at 4°C overnight.  After 
washing the samples with ice-cold PBS 3 times, 5 min each, the cells were incubated 
with Alexa Fluor® 488 Goat Anti-Rabbit IgG (Invitrogen) for 1 hr and examined using an 




3.3.10 Fluorescence imaging of siRNA uptake 
 To examine the siRNA uptake by U87mg cells and b.End3 cells, siGLO RNA-
induced silencing complex (RISC)-free control siRNA labeled with Dy547 fluorescent 
dye (Thermo Scientific, Rockford, IL) was used to formulate peptide:siRNA complex. 
The cells were grown on 6-well plates to 70% confluency and each well subsequently 
treated with 100 pmol of siRNA in either a naked or a peptide:siRNA complex form in 
DMEM for 3 hr and were then washed with PBS 3 times.  The fluorescence images were 
acquired by using an Olympus IX71F fluorescence microscope and the red fluorescence 
color was added to the acquired images by Image J software (NIH Image, Bethesda, MD). 
3.3.11 Cellular luciferase assay expression for examination of  
functional gene silencing effect 
Upon 48 hr of incubation after transfecting luciferase siRNA, the U87mg-Luc 
cells were washed with PBS and lysed in a passive lysis buffer (Promega, Madison, WI) 
for 15 min.  Twenty µL of the lysates were transferred to white 96-well plates and 100 
µL of luciferase assay reagent (Promega) was added per well.  After 2 min of dark 
incubation, the luminescence intensity from each well was measured using a PlateLumino 
Luminometer (Stratec Biomedical Systems, Birkenfeld, Germany).  The total protein 
amount was quantified by a bicinchoninic acid (BCA) assay to correct the luminescence 
intensity per mg of protein. 
3.3.12 Human placental alkaline phosphatase (hPAP) assay 
The hPAP assay was performed following the protocol established by Prof. 




neurons/astrocytes were lysed in TMNC lysis buffer (0.05M Tris, 0.005M MgCl2, 0.1M 
NaCl, 1% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate [CHAPS]) and 
incubated at 65°C for 30 min in 0.2M diethanolamine buffer.  The CSPD® 
(chemiluminescent substrates for alkaline phosphatase) and Emerald™ (luminescence 
enhancer) reagents from Applied Biosystems (Bedford, MA) were used as substrates to 
quantify the hPAP activity and the luminescence intensity was measured using a 
luminometer.  A BCA assay followed to normalize the hPAP activity to total protein. 
3.3.13 Cell viability assay 
Cell viability was determined by using a tetrazolium salt 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) 
substrate – as per the cell proliferation kit (Promega) and following the manufacturer's 
instruction.  
3.3.14 Transcytosis assessment 
The b.End3 cells were seeded at a density of 6×104/cm2 onto 12 mm transwell 
inserts (polycarbonate membrane, 0.4 µm pore size, Corning, NY) and the cells at day 8 
were used for experiments.  The inserts were filled with 300 µL of DMEM and the 
bottom compartments with 500 µL of DMEM.  Fifty pmol of peptide:Dy547-labeled 
siRNA complex was applied onto the b.End3-coated, transwell inserts and incubated in a 
37°C CO2 incubator.  To evaluate the siRNA transport, 200 µL of the medium was 
collected from the abluminal compartment 6 hr postincubation.  The fluorescence 
intensity from the aliquots was measured by using a microplate reader (Bio-Rad, 




siRNA was calculated from a standard curve generated from the fluorescence intensity of 
the known amount of Dy547-labeled siRNA.  Transendothelial electrical resistance 
(TEER) was measured before and after the siRNA treatment to ensure the b.End3 cell 
monolayer integrity.  The paracellular barrier integrity was additionally monitored by 
measuring the permeability coefficient of sodium fluorescein (376.3 Da).  Ten μM of 
sodium fluorescein in Krebs-Ringer buffer was loaded to the insert well and the 
abluminal medium aliquots were collected every 15 min over an hour to determine the 
diffused concentration.  
3.3.15 Statistical analysis 
The data are expressed as mean ± standard errors and were statistically analyzed 
by conducting a one-way ANOVA, followed by Tukey-Kramer HSD post-hoc analysis.  
A Student's t-test was performed for the siRNA transport study.  Statistical significance is 
indicated by asterisks (*p < 0.05; **p < 0.01; ***p < 0.001).  JMP® v10.0 (SAS Institute 
Inc., Cary, NC) was used for performing the statistical analyses and the graphs were 
generated by SigmaPlot 10.0 (Systat, San Jose, CA).  
3.4 Results 
3.4.1 Characterization of myr-TP-Tf peptide 
The myr-TP-Tf peptide was successfully synthesized with high purity and precise 
molecular weight (data not shown).  We first investigated the optimal molar ratio of myr-
TP-Tf to siRNA at which the complex would achieve stable electrostatic condensation.  
The gel retardation assay revealed that the myr-TP-Tf peptide condensed siRNA 




surface charge were measured for the complex formulated at 10:1 and 20:1 molar ratios 
(Figure 3.1C).  The 10:1 complex (85.5 ± 2.1 nm) displayed a relatively smaller size than 
the 20:1 complex (100.4 ± 4.8 nm), which may be due to an increased association number 
(NA) or number of peptides per complex.  Experiments are ongoing to further elucidate 
this trend.  The zeta potential of the 10:1 complex (7.0 ± 0.2 mV) was less than the myr-
TP-Tf itself, indicating that the cationic charge of myr-TP-Tf was shielded by the 
electrostatic interaction with the negatively charged siRNA backbone.  The 20:1 complex 
displayed a higher positive charge range (23.4 ± 3.7 mV) compared to the 10:1 complex, 
which further substantiates our hypothesis of an increased NA with complex formation. 
Molar ratios of 30:1 or higher were not included in this study as the excessive cationic 
charge induced potent cytotoxicity.  The general morphology of the peptide:siRNA (20:1) 
was examined by transmission electron microscopy (TEM).  The representative TEM 
images show that the complex possesses spherical structures, which was in accordance 
with expectations (Figure 3.1D).  The size of the complex was smaller (~30 nm) in the 
TEM images than the dynamic laser scattering measurements due to shrinkage under the 
anhydrous, vacuum environment. 
3.4.2 Enhanced siRNA stability 
The siRNA instability is a major concern for therapeutic RNAi application in vivo.  
We investigated the siRNA integrity in 50% fetal bovine serum (FBS) and RNase A 
solution to evaluate the siRNA protection ability of the peptide:siRNA complex.  It was 
observed that the siRNA in the complex form displayed prolonged stability, showing at 
least partial stability for up to 8 hr in 50% FBS, whereas the naked form of siRNA was 




of the complex was more dramatic in the RNase A treatment assay.  Over the 4 hr 
incubation time, the siRNA band intensity of the complex stayed nearly intact while the 
naked siRNA immediately began to degrade (Figure 3.2B).  The literature shows that 
even chemical modification of siRNA does not necessarily improve the gene silencing 
effect in vivo, despite reported enhanced serum stability (16).  From a clinical perspective, 
it would be imperative to achieve the therapeutic concentration at the target organ within 
a reasonable timeframe in regard to the half-life of the complex.  
3.4.3 Favorable siRNA uptake 
It is well-known that brain endothelial cells, neurons, and astrocytes express high 
levels of TfR proteins for transferrin-mediated iron supply, which is an essential cellular 
process for normal brain functions (40).  Prior to applying the myr-TP-Tf peptide, we 
completed immunostaining to verify the abundant expression of TfR on murine brain 
endothelial b.End3 and human glioma U87mg cells used in this study.  Representative 
images support the choice of TfR as a targeting receptor for both cell types (Figure 3.3A 
and C).  However, nonspecific uptake by other organs of the complex is expected upon in 
vivo administration because TfR proteins are ubiquitously expressed to varying extents.  
It should be noted that brain-targeting may not be exclusively achieved, except 
preferentially with the high levels of TfR existing on the brain endothelial cells (41).  
Next, siRNA uptake in b.End3 cells and U87mg cells was examined to evaluate siRNA 
delivery capability of myr-TP-Tf peptides.  To visualize siRNA internalization, Dy547 
fluorescent dye-labeled siRNA was used in the peptide:siRNA complex formulation.  As 
shown in Figure 3.3B and D, b.End3 cells and U87mg cells displayed intense red 




the complex successfully transported siRNA (Figure 3.3B and D) across the cell 
membrane barrier.  To evaluate the targeting effect of the myr-TP-Tf peptide, b.End3 and 
U87mg cells were treated with either naked Dy547 siRNA or nontargeted, myr-TP-
Scr:Dy547 siRNA complex.  As anticipated, the naked Dy547 siRNA-treated group did 
not show detectable red fluorescence (Figure 3.4A and D).  It was observed that the 
nontargeted control (scrambled) peptide complex was able to deliver siRNA to the cells 
(Figure 3.4B and E).  This observation was not surprising because the control peptide 
also contains the cationic cell-penetrating peptide sequence and therefore has the same 
ability to condense siRNA.  Compared to the targeting complex, however, the extent of 
internalized siRNA was much less prominent, demonstrating that the enhanced cellular 
uptake of siRNA is possible when combined with a receptor-mediated pathway (Figure 
3.4C and F). 
3.4.4 Transfection of a human glioma cell line 
           Next, we investigated if the internalized siRNA functionally downregulates the 
target protein in brain cells.  To this end, we used human glioma U87mg-Luc cells which 
constitutively express luciferase.  The U87mg-Luc cells were treated with either naked 
siRNA targeting luciferase mRNA or peptide:luciferase siRNA complex for 3 hr and the 
luciferase activity was measured 45 hr posttransfection.  As shown in Figure 3.5A, the 
luciferase-specific siRNA was successfully delivered to the U87mg cells by myr-TP-Tf 
peptide complex (20:1) and effectively silenced the luciferase mRNA, which is 
implicated in the significantly reduced luminescence intensity.  The nontargeting peptide 
complex (20:1) also resulted in a significant gene silencing effect to a certain degree.  




levels produced by the targeting peptide, which complied with the different levels of 
cellular uptake of siRNA (Figure 3.4).  The complex prepared at a 10:1 molar ratio did 
not exert any significant RNAi effect.  We hypothesize that the higher cationic surface 
charge and the multivalent presentation of targeting peptides account for the greater 
mRNA silencing effect of the 20:1 complex, but we did not attempt higher ratios as we 
had established that higher molar ratios induce potent cytotoxicity.  Throughout the 
transfection study, no significant cytotoxicity was observed from peptide:siRNA complex 
treatments (Figure 3.5B). 
3.4.5 Transfection of primary murine neurons/astrocytes 
Primary cells are often considered generally difficult to transfect.  In order to 
further validate the carrier transfection ability, primary murine neurons/astrocytes were 
extracted from brain cortices of E15 ARE:hPAP(+) transgenic mice, in which the hPAP 
reporter gene is inserted downstream of the ARE.  As remarked upon in the Introduction, 
the Keap1-Nrf2 pathway is a promising target for the treatment of NDDs.  It is expected 
that downregulation of Keap1 mRNA, using an RNAi approach, will result in liberation 
and translocation of Nrf2 to the nuclear ARE with subsequent activation of antioxidant 
genes, thereby providing cytoprotection to brain cells.  ARE:hPAP(+) transgenic mice 
serve as a useful tool to examine the activation of ARE by analyzing the reporter hPAP 
activity.  Here, primary murine neurons/astrocytes were transfected with myr-TP-
TfR:siRNA complex against Keap1 and the hPAP activity measured 48 hr 
posttransfection.  As shown in Figure 3.6A, the myr-TP-Tf:Keap1 siRNA complex 
significantly induced hPAP activity (Figure 3.6A) as compared to the control groups.  




to a lesser degree.  As with the immortalized cell lines, the cell viability assay result 
indicated no significant cytotoxicity of the primary murine neurons/astrocytes (Figure 
3.6B).   
3.4.6 siRNA transport assay 
The actual transport of the siRNA across brain endothelial cells was examined in 
vitro using a transwell system in which b.End3 cells were grown as a confluent 
monolayer on inserts.  We treated the inserts with 50 pmol of peptide:Dy547-labeled 
siRNA complex for 6 hr and assessed the transport of Dy547 siRNA by measuring the 
fluorescence intensity of the medium collected from the bottom compartments.  The myr-
TP-Tf:siRNA complex treated group clearly showed an enhanced transport profile 
compared to the scrambled myr-TP-Scr:siRNA (Figure 3.7A).  However, the transported 
siRNA quantity was less than the original amount, indicating that a significant portion of 
siRNA remained in the b.End3 cells monolayer over the 6 hr.  A naked siRNA-treated 
group was not included as the naked form of siRNA was not visibly uptaken by b.End3 
cells.  To examine if the b.End3 cell monolayer remained intact during the transcytosis 
experiment, the TEER values before and after the siRNA treatments were compared and 
no notable changes were detected (Figure 3.7B).  The permeability coefficient of the 
water soluble sodium fluorescein compound was additionally examined to evaluate the 
monolayer integrity.  Even though it was higher [(6.8 ± 0.9)·10-6 cm/s] than the reported 
value from other in vitro BBB models established with primary rat brain endothelial cells 
[(3.5 ± 0.1)·10-6 cm/s] (42), the order of magnitude of 10-6 cm/s is extremely small and 




siRNA quantity over 6 hr was found less than the loaded amount, it remains encouraging 
that the myr-TP-Tf complex showed a promising siRNA transport property.  
3.5 Discussion 
The physicochemical characteristics of the myr-TP-Tf:siRNA complex were, in 
principle, well-suited for cell-targeted in vivo administered RNAi.  First, the myr-TP-Tf 
peptide successfully electrostatically condensed siRNAs with apparently optimal 
condensation in a reasonable range of peptide:siRNA molar ratios below the cytotoxic 
line of 30:1 molar ratio.  Second, the negative staining images of the peptide:siRNA 
complex under TEM revealed these complexes formed spherical structures, whereupon 
supramolecular self-assembly promoted core siRNA encapsulation in a core-shell 
architecture.  The moderately positive surface charge of the complex appeared to enhance 
complex interactions with brain cells.  It should be noted that the excessive cationic 
charge of nanoparticles normally involves detrimental effects to cells (44), but these 
peptide:siRNA complexes did not arouse any notable cell viability changes to both the 
glioma cells and the primary murine brain cells within their measured and transfected 
surface charge range.  Fourth, the particle size of the complex was found to be fairly 
small considering that the siRNA molecule itself is quite bulky (14 kD).  However, the 
particle size values measured in distilled water may not reflect the actual size in the 
culture medium or in the bloodstream.  Indeed, when formulated in PBS (pH 7.4), the 
particle size was quite increased (230 ± 27.6 nm) while the surface charge was relatively 
maintained (28.6 ± 0.9 mV).  It is likely that the ionic strength in buffer affects the 
tightness of the peptide-siRNA interaction, leading to particle expansion (45).  Even with 




formation.  The imaging and the transfection results support that these complexes remain 
structurally viable for targeted cellular uptake and functional siRNA release in the brain 
cells.  
In addition, the peptide:siRNA complex was advantageous in regard to the siRNA 
stability in serum.  The improved siRNA stability in the complex also indicated that the 
siRNAs were protectively loaded within the complex structure.  However, the in vitro 
serum stability testing may not present an accurate level of stability in vivo.  This 
potential instability is a factor of the bloodstream itself, which may contain multiple 
nucleases in various ranges of concentration, resulting in dissimilar patterns of siRNA 
degradation kinetics (46).  Furthermore, it is plausible for this complex to be entrapped 
by phagocytic cells and rapidly cleared from the bloodstream.  Despite these multiple 
hurdles, an effective concentration of peptide:siRNA complex should reach the brain, 
preserving bioactive siRNA integrity within the brain interstitial tissue while awaiting 
endo-/transcytosis.  In depth studies elucidating the physiological stability needs and 
mechanisms of transport across the BBB are ongoing.  
The transferrin receptor-targeting capacity of the complex may raise questions 
because the nontargeting carrier with a scrambled sequence also showed the ability to 
deliver siRNA to the brain cells and exert some level of target gene silencing.  For our 
purposes, we hypothesize that not only the targeting moiety, but also the cationic surface 
charge on the complex, plays a significant role for the cellular uptake of the complex.  At 
a lower molar ratio (10:1), even for the TP-targeted carrier, no significant RNAi effect 
was observed, which may be the outcome of an insufficient cationic charge to interact 




receptors.  Nevertheless, the targeted complex formulated at a seemingly optimal (20:1) 
molar ratio showed preferential siRNA uptake and more significant target gene 
knockdown compared to a nontargeted complex at the same molar ratio.  These data 
suggest that the receptor targeting ability provides an added effect for enhanced siRNA 
delivery.  The siRNA transport results from the transwell system also substantiate the 
benefit of the TfR-targeting peptide sequence in the siRNA carrier.  To achieve the 
highly selective targeting and thereby avoid the adverse effects from the nonspecific 
binding, further research efforts are required to find the optimal receptor candidates and 
identify their ligand binding modes.  
In the siRNA transport assay, the targeting complex also showed more favorable 
siRNA transport to the abluminal compartment compared to the nontargeting complex.  
However, this result may not be directly translatable to the in vivo condition; it should be 
noted that the in vitro BBB model used in our study is limitedly simulating the 
physiological BBB.  Although the b.End3 cells can grow as a monolayer on the transwell 
insert membrane and express various tight junction proteins, the tightness of the 
monolayer, usually represented as TEER, never attains the values obtained from the in 
vivo BBB (47).  Being aware of the limitation, we conducted the experiments when the 
b.End3 cells formed a morphologically mature monolayer and the TEER values reached a 
fairly stable level.  To exclude the possibility of any free Dy547 dye existence, HPLC-
purified siRNAs were used and the siRNA integrity was further examined on a couple of 
polyacrylamide gels before any assay.  Though the b.End3 cells grown in a transwell 
system may not be the most desirable surrogate for the physiological BBB, it served as a 




further complete examination for the siRNA transport should be followed by testing the  
complex in animal models.  
As our studies were executed only in vitro, the in vivo performance of the 
complex is therefore not yet guaranteed, even with its promising properties.  One 
reasonable question is whether this single delivery system will or will not achieve the two, 
seminal intracellular trafficking processes: (i) receptor-mediated transcytosis across the 
BBB and (ii) subsequent cytosolic and/or transcytotic release of therapeutic levels of 
bioactive siRNA in the brain parenchyma.  Transport mechanism studies are beyond the 
scope of this manuscript; however, the data are encouraging and similar peptide-based 
delivery systems have shown levels of brain-targeted siRNA delivery and RNAi in the 
mouse brain (31,36).  These authors did not provide a detailed explanation of proposed 
transport mechanisms; however, again, these studies remain encouraging for peptide-
mediated siRNA delivery across the BBB.  Our goal is to achieve neurotargeted siRNA 
delivery, following systemic administration of the complex.  However, we recognize the 
established difficulties of peptide-mediated, systemically administered, targeted drug 
delivery, let alone the complicated issues surrounding the applicability and relevance of 
RNAi therapy when compared to small molecules therapies.  We remain optimistic, as 
RNAi therapy remains a potent mode of treatment, while continuing to provide exciting 
challenges for therapeutic efficacy.  Systemic administration may be overcome by 
alternative routes, such as local, intrathecal, or nasal delivery to avoid prolonged serum 
exposure, RES clearance, and inefficient neurotargeting.  Nasal delivery, with its readily 
accessible pathways to the brain parenchyma is a viable option (48).  It would avoid the 




tissue-targeting capability to deliver bioactive and therapeutic levels of RNAi without 
compromising cell viability remain the key components in the continued advancement of 
the RNAi field. 
To conclude, the myr-TP-Tf peptide shows stable siRNA condensation and 
protection capability against serum and RNase A.  Moreover, the novel peptide construct 
successfully delivered siRNA in amounts that significantly reduced reporter luciferase 
levels beyond that of the established, industrial siRNA-delivery vehicle of 
Lipofectamine® in immortalized and primary cell lines.  When combined, the data present 
an encouraging basis for continued exploration of the peptide in vitro and in vivo.  In 
future work, we plan to use a fluorescently labeled peptide to better understand the exact 
transport mechanism(s) in vitro and in vivo.  It will also elucidate the biodistribution 
pattern and neurotargeting ability of the peptide in a living system.  The successful 
completion of preclinical studies will ultimately provide a promising strategy for 
therapeutic siRNA delivery to brain tissues, which may be useful for treating or relieving 






Figure 3.1. Design and characterization of myristoylated transportan peptide equipped 
with transferrin receptor targeting short peptide (myr-TP-Tf).  (A) Illustration of myr-TP-
Tf peptide and its postulated peptide:siRNA complex structure and expected brain-
targeted siRNA delivery mechanism; (B) Gel retardation assay. Samples prepared in 
distilled water were loaded in a 0.8% agarose gel for electrophoresis at 100 V for 20 min 
in 1× TAE buffer (Tris-Acetate-EDTA) and (C) zeta potential and particle size 
measurements (n=3/group). Data reported as mean ± standard error; and (D) transmission 




Figure 3.2. Comparison of siRNA stability – naked siRNA vs. siRNA-peptide complex 
forms.  (A) siRNA stability against 50% fetal bovine serum, 0.8% agarose gel 
electrophoresis at 100V for 20 min in 1× TAE buffer and (B) siRNA stability against 






Figure 3.3. Verification of transferrin receptor expression and siRNA uptake in U87mg 
and b.End3 cells.  Immunostaining of TfR on U87mg cells (A) and on b.End3 cells (C) 







Figure 3.4. Enhanced siRNA uptake mediated by myr-TP-Tf.  Naked Dy547-labeled 
siRNA-treated U87mg (A) and b.End3 cells (D); myr-TP-Scr:Dy547 siRNA complex-
treated U87mg (B) and b.End3 cells (E); and myr-TP-Tf:Dy547 siRNA complex-treated 








Figure 3.5. Transfection of myr-TP-Tf: Luciferase-siRNA to U87mg-Luc glioma cells.  
(A) Luciferase assay (n=5-7/group) and (B) cell viability assay (n=5/group) at 48 hr post-
transfection. Data reported as mean ± standard error; one-way ANOVA with Tukey-






Figure 3.6. Transfection of myr-TP-Tf:Keap1 siRNA complex to primary murine 
neurons/astrocytes.  (A) Human placental alkaline phosphatase (hPAP) assay (n=6/group) 
and (B) cell viability assay (n=5/group) at 48 hr posttransfection.  Data reported as mean 
± standard error; one-way ANOVA with Tukey-Kramer post-hoc test was performed (*p 







Figure 3.7. Assessment of siRNA transport across the b.End3 monolayer in a transwell 
system 6 hr after serum-free treatment.  (A) Comparison of siRNA transport by myr-TP-
Scr peptide:Dy547 siRNA complex vs. myr-TP-Tf:Dy547 siRNA complex (n=6/group). 
Student's t-test was performed (*p < 0.05) and also (B) TEER measurements before and 











3.6 Supplementary section 
To examine the size distribution, the peptides and the siRNA-peptide complexes 
(100 nM of siRNA) were prepared in distilled water, separately.  Samples were vortexed 
for 20 s and incubated for 20 min at room temperature.  The size was measured with 
Zetasizer Nano ZS (Malvern Inc., Westborough, MA).  Both myr-TP-Tf and myr-TP-Scr 
were found to be quite large (309.5 nm for myr-TP-Tf and 259.6 nm for myr-TP-Scr), 
which indicated that the peptides themselves may form larger structures or aggregates 
rather than being suspended as monomers (Figure 3.S1).  The siRNA-peptide complexes 
displayed smaller size than the peptide sample (92.1 nm for siRNA/Myr-TP-Tf complex 
and 153.6 nm for siRNA/Myr-TP-Scr complex) with relatively narrow size distributions.  
It appears that the electrostatic interaction between the negatively charged siRNAs and 
the positively charged peptides contributes to the tight complex formation.  The size 
difference between the siRNA/Myr-TP-Tf complex and the siRNA/Myr-TP-Scr complex 
was unexpected because the myr-TP-Tf and the myr-TP-Scr are basically the same, but 
only different in the arrangements of 12 amino acids in the targeting domain.  It is 
thought that the distinct arrangement of the amino acids at the C-terminus may affect the 
complex size, possibly due to the different intermolecular interaction with the peptides 
and the aqueous medium.  The dispersity (PDI) of the peptides and the complexes were 
not in the monodisperse range (PDI < 0.1), indicating that the actual hydrodynamic size 
of the peptides and the complexes can be varied. 
To measure the zeta potential, the siRNA, peptides and the siRNA-peptide 
complexes (1:20) were prepared in distilled water, separately.  Samples were vortexed for 




with Zetasizer Nano ZS (Malvern Inc., Westborough, MA).  The siRNA displayed a 
negative surface charge (-18.0 mV) because of its anionic phosphate backbone.  Both 
myr-TP-Tf and myr-TP-Scr peptides showed positive surface charges (32.5 mV for the 
myr-TP-Tf and 28.0 mV for the myr-TP-Scr), which stem from four lysine residues in the 
transportan CPP domain and an arginine residue in the targeting domain (Figure 3.S2).  
The negative charge of the siRNA was shielded by the cationic peptides upon the siRNA-
peptide complex formation (29.1 mV for siRNA/Myr-TP-Tf complex and 28.9 mV for 
siRNA/Myr-TP-Scr complex), which was consistent with the gel retardation assay result 
(Figure 3.1B). 
Similar systems in the literature were looked at in order to understand the 
hydrodynamic size of the peptide.  Ren et al. used a myristoylated cell-penetrating 
peptide fused with a tumor-targeting sequence as a siRNA delivery system, which 
displayed the particle size of 343 nm and the zeta potential of 31 mV when it formed 
siRNA-peptide complex.  However, they did not show the particle size data of the peptide 
itself (49).  Another group used a myristoylated polyarginine peptide to deliver siRNA to 
the cells (50) and Kumar et al. exploited nine arginie repeats linked to the rabies virus 
glycoprotein as a neurotargeted siRNA delivery system (51).  However, both studies did 
not include any physicochemical characterization data although they showed positive 
biological effects.   
Instead, a study about surfactant-like peptides that contain hydrophobic tails and 
one or two hydrophilic amino acids was checked (52).  In this study, a short peptide 
composed of ten glycines and two aspartic acids (G10D2) was expected to have a length of 




acids with a myristic acid at the N-terminal residue, it is expected that the myr-TP-Tf 
peptide can be larger than this G10D2 peptide.  However, the hydrodynamic diameter of 
the myr-TP-Tf peptide sample (310 nm) was obviously too large to be considered as 
individual peptides.  The molecular modeling and TEM images of the surfactant-like 
short peptides showed that they can form bilayer structures such as nanotubes with ~50 
nm of diameter and varying ranges of length, and nanovesicles that are ~100 nm in 
diameter.  This led us to think that our peptide system, even without siRNA, may also 
possibly form such structures that display relatively large size and longer length than the 
peptide monomer. 
Many studies have used peptide amphiphiles that were designed for the anticancer 
drug delivery.  For example, Javali et al. prepared C16 (palmitic acid)-RGD (arginine-
glycine-aspartic acid) and C18 (stearic acid)-RGD for active targeting of tumor 
endothelium (53).   We examined this study as our peptide system can also be classified 
into fatty acid-conjugated peptides.  According to their data, these C16-RGD and C18-
RGD formed self-assembled peptide amphiphile nanostructures and displayed a particle 
size of 266 nm and 450 nm, respectively.  These relatively large hydrodynamic sizes 
were similar to what we observed from our peptide system.  Although they described 
these as peptide amphiphile micelles and also showed critical micelle concentrations, the 
particle sizes were too large to be considered as micelles.  We think that these fatty acid-
conjugated peptide amphiphiles may possibly form large bilayer structures such as 
nanotubes and nanovesicles just as the surfactant-like peptides also do.  
In a recent study, the Tirrell group investigated the in vivo biodistribution and the 





alanine, a fibrin-binding peptide) (54).  This amphiphilic peptide formed spherical 
micelles that showed ~8 nm of hydrodynamic diameter in the DLS measurement.  Our 
peptide system is quite different from this peptide amphiphile in that it has a single fatty 
acid chain per peptide and a longer amino acid sequence.  If it can form micelle-like 
structures, however, it should still show small hydrodynamic sizes like this amphiphilic 
peptide.  The relatively large particle size of our peptide system (260-310 nm) indicated 
that myr-TP-Tf peptides exist as large structures instead of micelles in the aqueous 
environment. 
Another group used C16-ARLPRTMVHPKPAQP (Pal-L1), which can bind to 
hemagglutinin (HA), the surface protein of influenza virus (55).  This palmic acid-
conjugated peptide showed surfactant-like behaviors  and formed micelles with a size of 
~7 nm in diameter.  Along with this small sized micelles, the DLS measurement showed 
an additional broad peak in 50-200 nm range.  They explained that this Pal-L1 peptide 
may aggregate to form bigger micelles, rods or cylindrical form.  Considering its similar 
composition with our peptide system, we think that myr-TP-Tf may also have the 
potential to form micelle structures.   Judging from the size measurements (Figure 3.S1), 
however, it appears that the myr-TP-Tf peptides are more likely to form larger structures 
















Figure 3.S1. Particle size measurements of the peptides and the siRNA-peptide 
complexes.  (A) Myr-TP-Tf; (B) siRNA/Myr-TP-Tf complex (1:20); (C) Myr-TP-Scr; 



















Figure 3.S2. Zeta potential measurements of the siRNA, peptides, and the siRNA-peptide 
complexes.  (A) siRNA; (B) Myr-TP-Tf; (C) siRNA/Myr-TP-Tf complex (1:20); (D) 
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CYTOPROTECTION AGAINST BETA-AMYLOID (Aβ) PEPTIDE- 
MEDIATED OXIDATIVE DAMAGE AND AUTOPHAGY  
BY KEAP1 RNAI IN HUMAN GLIOMA U87MG CELLS 1 
4.1 Abstract 
Extensive oxidative stress has been considered one of the primary pathological 
factors responsible for the onset and/or progression of many neurodegenerative disorders 
(NDDs).  We speculated that the oxidative damage to brain cells can be managed by 
promoting the endogenous cellular antioxidant defense system through the RNA 
interference (RNAi) approach against the Keap1 (kelch-like ECH-associated protein) 
gene.  Keap1 acts as a negative regulator of Nrf2 (NF-E2-related factor 2) that represses 
the activation of the antioxidant responsive element (ARE) and thus endogenous 
antioxidant transcription.  Here, we investigated whether Keap1 knockdown enhances the 
cellular antioxidant capacity and ultimately provides neuroprotection against oxidative 
stress from hydrogen peroxide and beta-amyloid (Aβ) peptide in human glioma U87mg 
cells.  We found that the Keap1 siRNA pretreated group displayed higher expression of 




control group.  Moreover, the Keap1 RNAi exerted a cytoprotective effect against 
exclusive H2O2 treatment.  In Aβ peptide treatment experiments, the Keap1 siRNA 
pretreated groups maintained acceptable cell viability, relatively intact cellular 
morphology, and controlled oxidative damage levels while the control groups were 
affected by Aβ peptide-mediated neurotoxicity.  Autophagosome staining and 
immunoblotting for the LC3-II (microtubule-associated protein light chain 3) protein, an 
autophagy marker, indicated that Keap1 RNAi may attenuate the oxidative stress-
mediated autophagy as well.  These findings suggest that Keap1 RNAi can serve as a 
therapeutic strategy for relieving oxidative stress-associated symptoms in many NDDs.  
4.2 Introduction 
Neurodegenerative disorder (NDD) incidences have been growing steadily on a 
global scale, making Alzheimer’s disease (AD) the most common form of dementia; it is 
ranked sixth among the leading causes of death in the US as of 2013 (1).  Memory 
robbing AD is typified by progressive loss of neuronal functions and brain shrinkage, 
with pathogenesis initiated from the accumulation of amyloid plaques, according to the 
amyloid hypothesis (2).  Thus, therapeutic development has focused on clearing the 
plaques by using amyloid plaque-specific antibodies such as solanezumab and 
bapineuzumab.  However, recent clinical trials of these drugs have failed to show 
determinative effects on cognitive improvement (3).  Currently, crenezumab, another 
amyloid plaque targeting antibody, is being tested as a preventive medicine for a 
population with no AD signs, but that are at high risk to develop early onset AD due to 
the presenilin-1 mutation (4).  Instead of targeting the amyloid plaques, beta-secretase 1 




interfering with the enzyme that cleaves the amyloid precursor protein (APP) to generate 
beta-amyloid (Aβ) (5).  A clinical trial with a BACE inhibitor is also in progress with 
promising news of Aβ level reduction in cerebrospinal fluid (6).  Along with amyloid 
plaques, hyperphosphorylated tau is considered a prime pathogenic contributor for AD 
(7).  Inhibitors for protein kinases such as glycogen synthase kinase-3 have been 
investigated as a therapeutic intervention against the hyperphosphorylated tau-mediated 
pathology, and some are under clinical evaluation (8,9).  Despite broad research efforts, 
there remains a critical need for cures or treatments to attenuate AD progression.  
Other therapeutic strategies have targeted the extensive oxidative stress 
commonly observed in many NDDs, including AD.  It has been suggested that oxidative 
stress is highly associated with neurodegeneration as either the cause or the consequence 
of its pathology (10).  In AD, Aβ peptide-mediated oxidative stress has been considered a 
major contributing factor to neuronal damage (11).  Therefore, researchers have 
attempted the administration of various antioxidants to deactivate the toxic reactive 
oxygen species (ROS).  For example, α-tocopherol (vitamin E) showed a therapeutic 
effect in lowering amyloid plaque accumulation in a transgenic AD mouse model (12).  
The recent clinical trial also reported encouraging data that vitamin E slows the cognitive 
decline in AD patients (13).  However, it does not appear to prevent disease progression 
and the high dosage of vitamin E may increase all-cause mortality (14).  
As an alternative approach to exogenous antioxidants, the Nrf2 (NF-E2-related 
factor 2)-Keap1 (kelch-like ECH-associated protein) pathway has been highlighted for its 
cytoprotective potential in neurodegenerative conditions (15).  Nrf2 is a transcription 




(antioxidant responsive element), leading to the expression of an array of various 
antioxidants and detoxification proteins (16).  However, Keap1 normally suppresses Nrf2 
activity by cytoplasmic sequestration and ubiquitin-mediated degradation (17).  Hence, 
the downregulation of Keap1 through the RNAi approach will rescue Nrf2 activation, 
which will ultimately provide cellular antioxidant defense against oxidative assault.  
Indeed, studies have indicated that the knockdown of Keap1 or the overexpression of 
Nrf2, protected cells from oxidative damage (18,19).  In addition, Keap1 RNAi was 
suggested as a chemoprevention strategy for cancer in which oxidative stress plays a key 
role for the initiation and promotion of the disease (20).  Oxidative stress often induces 
autophagic signaling pathways, whose prolonged activation can lead to cell death as 
opposed to its beneficial roles for cell survival (21).   It was also reported that the Aβ 
peptide induces autophagic cell death in U87 cells (22).  This finding raised speculation 
that Keap1 RNAi would relieve oxidative stress through activation of the antioxidant 
defense system and therefore reduce autophagy-mediated cell death in brain cells. 
Brain-targeted siRNA delivery, however, has been a formidable task largely due 
to the instability of naked siRNA in serum and the tight junctions in the brain vasculature 
which do not allow bulky and charged molecules, such as siRNA, to move across the 
BBB (22,23).  Previously, we have designed a neurotargeting peptide-based siRNA 
carrier (myr-TP-Tf) that can protectively load siRNA and deliver bioactive siRNAs to 
brain cells.  This leads to target gene silencing with a potential to cross a brain 
endothelial cell line monolayer in vitro, although the in vivo performance is yet to be 
proven (24).  In the current study, we attempted Keap1 siRNA delivery with this carrier 




mediated oxidative stress in U87mg cells.  As delineated in Figure 4.1, our hypothesis is 
that Keap1 siRNA delivered as a siRNA-peptide carrier complex will downregulate the 
Keap1 protein, allowing the nuclear translocation of Nrf2 and the subsequent activation 
of the ARE.  The ensuing upregulation of antioxidant and detoxifying enzymes will 
protect cells from Aβ peptide and H2O2 -mediated oxidative stress.  Here, the results 
showed that Keap1 RNAi enhanced the antioxidant capacity and provided cellular 
defense against the Aβ peptide and H2O2 as manifested by higher viability, relatively 
managed oxidative damage levels, and the basal autophagy level compared to the control 
groups.  Taken together, the data suggest that Keap1 RNAi possesses the therapeutic 
potential for relieving the oxidative stress-associated damage in NDDs, which encourages 
further exploration in in vivo studies.   
4.3 Materials and methods 
4.3.1 Preparation of Keap1 siRNA and a peptide-based siRNA carrier 
Human Keap1 siRNA was synthesized and purified at the DNA/Peptide Lab in 
the University of Utah HSC Core Research Facility.  The sequence for each strand is as 
following; (sense) 5'-GGCCUUUGGCAUCAUGAACTT-3', (antisense) 5'-
GUUCAUGAUGCCAAAGGCCTG-3' (20,25).  The myristic acid conjugated, cell-
penetrating peptide (transportan) equipped with a transferrin receptor-targeting peptide 
(myr-TP-Tf) was prepared by solid-phase peptide synthesis at Selleckchem (Houston, 
TX).  The peptide sequence for myr-TP-Tf is as follows: myristic acid-
GWTLNSAGYLLGKINLKALAALAKKIL-GGGG-THRPPMWSPVWP.  The purity 




4.3.2 Cell culture: a human glioma U87mg cell line 
Human glioma U87mg cells were maintained in DMEM (Dulbecco's Modified 
Eagle Medium, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum 
and 100 U/mL of penicillin/streptomycin.  The cells were cultured in a humidified 
incubator containing 5% CO2 at 37 °C.  
4.3.3 Formulation and transfection of Keap1 siRNA-peptide complex 
 Each strand of Keap1 siRNA was dissolved in sterile RNase-free water and 
annealed together by incubating both strands in an annealing buffer (10 mM Tris, 20 mM 
NaCl, pH 8.0) at 90 °C for 1 min and then cooling to room temperature.  The siRNA 
solution was mixed with myr-TP-Tf peptide in distilled water at a 20:1 (peptide to siRNA) 
molar ratio which was determined as an optimal siRNA condensation ratio in our 
previous study (24).  This mixture was vigorously vortexed for 20 s and incubated at 
room temperature for 20 min to form a siRNA-peptide complex.  The U87mg cells were 
seeded either in 96-well plates or in 6-well plates at a density of 104 cells/cm2 and grown 
until they reached 70-80% confluency.  The cells were transfected with Keap1 siRNA-
peptide complex in DMEM without serum and antibiotics for 3 hr and further incubated 
in a complete culture medium. 
4.3.4 cDNA synthesis and quantitative real time PCR (qRT-PCR) 
Total RNA of U87mg cells was extracted using Trizol reagent (Invitrogen) 
according to the manufacturer’s instructions.  RNA samples with purity of 1.9 or higher 
and 260/280 absorbance ratio were used to synthesize cDNA.  Briefly, 1 μg of RNA was 




Biolabs, Beverly, MA), heated for 3 min at 70 °C, and then cooled in ice for 2 min.  
Subsequently, MMuLV RTase and RNase inhibitor (NEB) were added to make the final 
volume 20 μL.  The cDNA synthesis reaction was conducted at 42 °C for an hour and 
then an enzyme deactivation step (90 °C for 10 min) was followed in a thermal cycler, 
after which cDNA samples were stored at -20 °C until use.  Dilute cDNA and each gene-
specific primer set were added to Express SYBR® GreenER™ qPCR Supermix 
(Invitrogen) and qRT-PCR was performed on a StepOnePlus™ real-time PCR system 
(Applied Biosystems, Carlsbad, CA).  The reaction was conducted as follows: 50 °C for 2 
min and 95 °C for 10 min (denaturation), 40 cycles of 95 °C for 15 s (amplification), and 
60 °C for 1 min (elongation).  The GAPDH (glyceraldehyde 3-phosphate dehydrogenase) 
mRNA transcript was included in the analysis as an internal control to determine the 
relative quantification of individual gene expression levels.  The primer sequences are 
listed in Table 4.1.  
4.3.5 Immunoblotting 
The cells were washed with ice-cold phosphate buffered saline (PBS) and 
harvested using a cell lysis buffer (62.5 mM Tris-HCl (pH 6.8), 2% w/v SDS, 10% 
glycerol, 1% protease inhibitor).  The cell lysates were sonicated for 10 s and centrifuged 
at 13,000 × g for 15 min to remove the cell debris.  The supernatants were transferred to 
fresh tubes and each protein sample was quantified by a bicinchoninic acid (BCA) 
protein assay kit (Pierce, Rockford, IL) as per the manufacturer’s instruction.  Twenty µg 
of protein were loaded on each well of NuPAGE® Novex® 4-12% Bis-Tris gels 
(Invitrogen) for SDS-PAGE (120 V for 1.5 hr) in NuPAGE® MES SDS running buffer 




transfer buffer (Invitrogen) at 30 V for an hour.  The membranes were blocked with 
TBST (Tris-buffered saline with 0.1% Tween-20) buffer containing 5% (w/v) nonfat dry 
milk for an hour and then washed with TBST buffer 3 times for 5 min each.  The 
membranes were incubated with rabbit polyclonal anti-Keap1 antibody (Abcam Inc., 
Cambridge, MA, #ab139729), rabbit polyclonal anti-Nrf2 antibody (Santa Cruz 
Biotechnology, Inc., Dallas, TX, #sc-722), rabbit polyclonal anti-LC3B antibody (Sigma-
Aldrich, St. Louis, MO, #L7543), and rabbit polyclonal anti-β actin antibody (Abcam, 
#ab8227) separately in TBST buffer containing 5% bovine serum albumin (BSA) at 4°C 
overnight.  After rinsing 3 times for 5 min each, the membranes were incubated with goat 
polyclonal antibody to rabbit IgG conjugated with horseradish peroxidase (HRP) (Abcam, 
#ab6721) for an hour and then washed 3 times.  The protein blots were visualized with 
WesternBright Quantum HRP substrate (Advansta, Menlo Park, CA) and the 
chemiluminescent images were acquired by using FluorChem FC2 imaging system 
(Alpha Innotech, San Leandro, CA). 
4.3.6 Total antioxidant capacity (TAC) assay 
Endogenous antioxidant activation was examined by measuring the cellular total 
antioxidant capacity using a TAC assay kit from Cell Biolabs, Inc. (San Diego, CA).  
This assay is based on the activities of antioxidant enzymes that reduce copper (II) to 
copper (I) through a single electron transfer mechanism (SET).  The resulting copper (I) 
ions subsequently react with a coupling chromogenic reagent that has maximum 
absorbance at 490 nm.  Briefly, the cells were harvested by trypsinization and washed 
twice with cold PBS.  The cell suspension was sonicated for cell lysis and then 




mixed with the assay buffer containing copper ion reagent and incubated for 5 min, after 
which the absorbance at 490 nm was measured using a microplate reader.  The 
absorbance values were compared with a standard curve prepared with a set of uric acids 
with known concentrations and the total reductive capacity was normalized to the protein 
amount determined from a BCA assay.  
4.3.7 Hydrogen peroxide (H2O2) treatment 
Hydrogen peroxide solution (30% w/w in H2O, Sigma-Aldrich) was diluted in 
sterile distilled water to prepare the stock solutions with concentrations from 10 mM to 
30 mM.  These stock solutions were then diluted in the complete culture medium to make 
cell treatments with concentrations ranging from 0.4 mM to 1.2 mM.  The treatment 
volume was controlled not to exceed 5% of the total media volume and the nontreated 
control groups were given the equal volume of plain PBS.  
4.3.8 Beta-amyloid (Aβ) peptide treatment 
Aβ peptide (1-42) fragment was purchased from AnaSpec (San Jose, CA).  The 
purity and the molecular weight of the peptide were confirmed upon receipt.  The 
lyophilized peptide powder was dissolved in sterile distilled water and incubated at 37°C 
for 4 days to generate oligomeric forms.  The peptide concentration was determined by 
using a NanoDropTM 2000 spectrophotometer (Thermo Scientific, Wilmington, DE) that 
calculates the concentration from the absorbance at 280 nm and the parameters including 
the extinction coefficient (ε=1,280) and the molecular weight (4.51 kDa).  Four hundred 
μM of Aβ peptide stock solution prepared in distilled water was diluted in the complete 




4.3.9 Cell viability assay 
Cell viability was determined by the cellular dehydrogenase activities that reduce 
the WST-8 (water soluble tetrazolium salt) to form colorimetric formazan dyes.  The 
yellow colored formazan products are quantified from the absorbance at 450 nm.  This 
assay was performed by using a CCK-8 assay kit (Dojindo, Rockville, MD) as per the 
manufacturer’s instruction.  
4.3.10 Malondialdehyde (MDA) assay 
Oxidative damage to lipids was evaluated by measuring the MDA level using a 
lipid peroxidation assay kit (Abcam).  Cells were collected by trypsinization and 
sonicated in MDA lysis buffer, after which the cell lysates were centrifuged at 13,000 × g 
for 10 min at 4°C.  The supernatants were mixed with tribarbituric acid (TBA) solution 
and incubated at 95 °C for an hour to allow for the MDA-TBA adduct formation, which 
can be quantified by the absorbance at 532 nm.  Samples were then cooled down in ice 
and placed in a 96-well plate for analysis in a microplate reader.  The absorbance values 
were compared with a standard curve generated with MDA standard solutions.  The 
MDA level was standardized to the protein amount determined from a BCA assay.    
4.3.11 Protein carbonyl assay 
Oxidative damage to proteins was examined by measuring the protein carbonyl 
content using a protein carbonyl colorimetric assay kit (Cayman Chemical Company, 
Ann Arbor, MI) as per the manufacturer’s instructions.  Briefly, the cells were lysed with 
sonication and then centrifuged at 10,000 × g for 10 min at 4°C.  The supernatants were 




respectively.  The 2,4-dinitrophenylhydrazine (DNPH) solution was added to the sample 
tubes and the 2.5 M hydrochloric acid solution was added to the control tubes.  Both were 
incubated at room temperature in the dark for an hour to allow the reaction between 2,4-
dinitrophenylhydrazine (DNPH) and protein carbonyls to form a Schiff base which can 
be analyzed colorimetrically by absorbance at 360-385 nm.  After several steps of rinsing 
with trichloroacetic acid (TCA) solutions (20% and 10%), ethanol/ethyl acetate solution, 
the precipitated pellet was finally resuspended in guanidine hydrochloride solution and 
the protein-hydrozone products were quantified spectrophotometrically in a microplate 
reader.  The resulting values were normalized to protein concentration calculated from a 
BCA assay. 
4.3.12 Autophagy assay 
Autophagy was assessed by staining cells with a fluorescent marker for 
lysosomal/autophagic vacuoles using a Cyto-ID® Autophagy Detection Kit from Enzo 
Life Sciences Inc. (Farmingdale, NY).  Briefly, the cells were washed with the assay 
buffer and incubated with the Cyto-ID® green and Hoechst 33342 dyes diluted in DMEM 
containing no phenol red for 30 min.  Following several rinses with the assay buffer, the 
relative autophagy level was determined by the fluorescence intensity measured with a 
wavelength set of Ex/Em (480 nm / 530 nm).  The Hoechst 33342, used for the nuclei 
counter stain, was read with a wavelength set at 340/480 nm in a microplate reader.  
Fluorescence images were also acquired to visually examine the extent of autophagosome 
formation using an Olympus IX71F fluorescence microscope (Scientific Instrument 




4.3.13 Statistical analysis 
The data were expressed as mean ± standard errors of the mean.  The statistical 
analysis was conducted with one-way ANOVA followed by Tukey-Kramer HSD post-
hoc analysis of the cell viability, oxidative damage and autophagy assays, and with a 
Student's t-test for qRT-PCR results.  Statistical significance was noted by asterisks (*p < 
0.05; **p < 0.01; ***p < 0.001).  The graphs were drawn by using SigmaPlot 10.0 
(Systat, San Jose, CA) and the statistical analysis was performed with JMP® v10.0 (SAS 
Institute Inc., Cary, NC). 
4.4 Results 
4.4.1 Functional downregulation of Keap1 gene and subsequent activation  
of antioxidant genes via Keap1 siRNA-peptide complex 
We examined whether the Keap1 siRNA-peptide complex treatment affects cell 
viability in U87mg cells.  The cells plated in 96-well plates were treated with either the 
siRNA-peptide complex (a mixture of 4 pmoles of siRNA and 80 pmoles of siRNA 
carrier peptide/well), or the myr-TP-Tf siRNA carrier itself (80 pmoles of siRNA carrier 
peptide/well) for 3 hr in serum-free DMEM and then subjected to the CCK-8 assay.  The 
result revealed that neither the siRNA-peptide complex nor the carriers caused any 
noticeable cytotoxicity issues compared to the control group (Figure 4.2A).  The Keap1 
siRNA-peptide complex were also able to deliver functional siRNA to the cytosol, 
leading to the effective downregulation of Keap1 mRNA transcripts (72.2% reduction) at 
48 hr posttransfection as shown in the qRT-PCR result (Figure 4.2B).  The Keap1 RNAi 
ultimately downregulated the Keap1 protein expression level as well (> 90% reduction), 




Keap1 gene expression level was not significantly different for the prolonged transfection 
group (72 hr) at the mRNA level, so we chose the 48 hr posttransfection as an optimal 
Keap1 gene downregulation time-point for the rest of our experiments.  The Nrf2 proteins 
are identified as two bands at 98 kDa and 118 kDa.  Along with the Keap1 
downregulation, the Nrf2 protein level was increased compared to the control group 
(Figure 4.2E and F).  The qRT-PCR results showed that Keap1 gene silencing did not 
affect the Nrf2 mRNA expression pattern (Figure 4.3A).  However, it did subsequently 
facilitate the activation of various endogenous antioxidants and detoxifying enzymes 
under the ARE, such as NQO1 (NAD(P)H dehydrogenase, quinone 1) (3.1-fold, Figure 
4.3B), SOD1 (superoxide dismutase 1) (1.8-fold, Figure 4.3C), and GCLM (glutamate-
cysteine ligase, modifier subunit) (1.8-fold, Figure 4.3D).  This result indicates that the 
Keap1 RNAi does not alter the basal Nrf2 mRNA expression, but may post-
transcriptionally increase the Nrf2 protein level leading to subsequent ARE activation in 
U87mg cells. 
4.4.2 Enhanced antioxidant capacity and cytoprotective effect  
against H2O2-induced oxidative assault 
We investigated if Keap1 RNAi-mediated antioxidant upregulation enhances the 
cellular antioxidant capacity compared to the control group.  To test this, the total 
antioxidant capacity (TAC) was evaluated by measuring the cellular reductive activity 
that converts the copper ion (I) to copper ion (II) by a single electron transfer mechanism.  
As anticipated, it was found that the TAC was significantly increased in the Keap1 RNAi 
group at 48 hr posttransfection (1.7-fold) while making little difference at 24 hr 




was achieved at 48 hr posttransfection, the higher TAC level at 48 hr than at 24 hr 
posttransfection is possibly explained by the time-point at which the antioxidant genes 
are effectively activated.  The improved antioxidant capacity was further assessed by 
monitoring the cell viability changes in response to the H2O2 treatment for 18 hr.  
Although both the control group and the Keap1 siRNA-peptide complex pretreated group 
showed dose-dependent cell death in the range of 0.4 mM to 1.2 mM of H2O2 treatment, 
the Keap1 RNAi groups generally showed better tolerance to the oxidative stress by 
displaying a bit higher viability than control groups at each concentration, except at 1.2 
mM, the highest concentration (Figure 4.4B).  In addition, the cells in the Keap1 RNAi 
group maintained relatively normal morphologies, whereas the control group had more 
dead cells losing their normal morphology at 0.8 mM of H2O2 treatment (Figure 4.4C).  
4.4.3 Alleviation of Aβ peptide-induced cytotoxicity 
The oligomeric forms of the Aβ (1-42) peptide are known to induce oxidative 
damage, which plays a key role in the neurodegeneration process in patients with AD 
(26).  We examined whether the Keap1 siRNA-peptide complex pretreatment can provide 
cellular protection against the Aβ peptide in U87mg cells.  The Keap1 siRNA-peptide 
complex pretreated groups were treated with Aβ peptide at 5 μM and 20 μM for 18 hr 
along with the control groups and the CCK-8 assay followed.  As opposed to the control 
groups, which showed a dose-dependent decrease in cell viability to the Aβ treatment 
(~80% viability at 5 μM Aβ and ~57% viability at 20 μM Aβ), the Keap1 RNAi group 
displayed fairly intact cell viability at both 5 μM and 20 μM of Aβ concentration (Figure 
4.5A), supporting our hypothesis that the Keap1 RNAi-mediated antioxidant activation 




control groups were more vulnerable to the Aβ treatment, as revealed from their unusual 
cell aggregate formation and somewhat abnormal morphology (Figure 4.5B, upper panel).  
On the other hand, the Keap1 siRNA-peptide complex pretreated group displayed 
relatively normal cell shapes with fewer cell clumps (Figure 4.5B, lower panel). 
4.4.4 Endogenous antioxidant defense against oxidative damage  
to cellular components 
To ascertain whether the Keap1 RNAi has a neuroprotective effect against 
oxidative stress, the extent of the oxidative damage to biomolecules such as lipids and 
proteins was assessed.  First, the control group and the Keap1 siRNA-peptide complex 
pretreated group were treated with 20 μM of Aβ for 18 hr and then cells were assayed.  
The lipid damage and the protein damage were examined by quantifying the 
malondialdehyde (MDA) level and the protein carbonyl content, respectively.  As shown 
in Figure 4.6A, the nontreated group had ~30% higher MDA levels after oxidative assault 
compared to the control group, whereas the Keap1 RNAi group did not show a 
significant difference in MDA levels with the nontreated group.  The protein carbonyl 
content exhibited even more of a prominent difference between these two groups; the 
control group had ~ 4-fold increased protein carbonyl content in response to the Aβ 
treatment while only ~1.5-fold increased protein carbonyl level was observed in the 
Keap1 RNAi group (Figure 4.6B).  These findings corroborated our speculation that the 
activation of endogenous antioxidant genes elicited a neuroprotective effect against Aβ 




4.4.5 Controlled autophagy level in U87mg cells 
It has been reported that oxidative stress causes autophagy in human glioma cell 
lines (27).  To examine the Keap1 RNAi effect on the autophagy level, we stained the 
cells with an autophagosome vacuoles-specific fluorescent dye.  The fluorescence 
intensity indicated that the control group had relatively more autophagic activity under 
oxidative stress while the Keap1 RNAi group displayed similar levels of intensity with 
the nontreated group (Figure 4.7A).  The autophagosomal staining was also visually 
examined under a fluorescence microscope.  As shown in Figure 4.7B, the control groups 
had more punctate autophagic vacuoles in response to the oxidative stress compared to 
the Keap1 RNAi group, as in accordance with the fluorescence intensity data.  In the non-
treated groups, the green fluorescence was dispersed through the cytosol or was rather 
weak, while its intensity was increased and focused upon oxidative assault.  The punctate 
green fluorescence was also observed in Keap1 RNAi groups under oxidative stress, but 
to a relatively lesser extent compared to the nontreated control.  It is well known that, 
along with autophagy activation, the LC3-I protein is converted into the LC3-II form 
which is specifically associated with the autophagosomal membrane (28).  Therefore, the 
amount of LC3-II has served as a good indicator of the autophagic activity.  The 
immunoblotting showed that the control groups had increased LC3-II form in response to 
the oxidative stress compared to the Keap1 siRNA-peptide complex pretreated group, 
which relatively maintained its basal level of LC3-II protein (Figure 4.7C).  Contrary to 
our expectation, LC3-I was not decreased along with the LC3-II conversion and showed 
rather increased band intensity.  A report explains that the LC3-II is usually detected with 




than the LC3-I/II ratio is a more accurate indication of the autophagy (22,29).  
Considering that the loading was controlled, it seems the increase in the absolute amount 
of LC3-II indicates autophagy activation upon oxidative stress.  These results supported 
our postulation that the enhanced cellular antioxidant capacity balances the ROS level so 
that it can protect the cells from autophagy-mediated cell death.  
4.5 Discussion 
Extensive oxidative stress is highly involved in the pathology of many NDDs, 
including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease 
(HD), and amyotrophic lateral sclerosis (ALS) (30).  In order to prevent and relieve the 
detrimental effects of oxidative damage, it seems promising to enhance the intrinsic 
cellular antioxidant defense system.  In this study, we proposed the Keap1 RNAi 
approach to suppress the Keap1-directed negative regulation on Nrf2 and to eventually 
activate the Nrf2-ARE pathway for the expression of diverse antioxidants and 
detoxifying proteins.  The results showed that Keap1 downregulation provides 
cytoprotective effects against Aβ and H2O2-mediated oxidative stress in U87mg cells.  
This demonstrates the therapeutic potential of Keap1 RNAi in brain cells under a 
pathological oxidative stress environment.  
In a recent study, the Keap1 knockdown was attempted in a human colon cancer 
cell line where it showed relatively less accumulation of 4-HNE (4-hydroxynonenal), a 
lipid peroxidation indicator, upon oxidative assault compared to the control groups (19).  
Likewise, we were able to observe that Keap1 downregulation groups were more 
resistant to oxidative stress in U87mg cells displaying lower levels of MDA and protein 




generally higher in the Keap1 RNAi groups than in the control groups.  However, the 
Keap1 RNAi groups were still subject to H2O2 toxicity, showing a dose-dependent 
decrease in cell viability and morphological changes.  In addition, the Aβ treatment 
resulted in increased protein carbonyl content in the Keap1 RNAi group as well, although 
the extent of the increase was much higher in the control groups (Figure 4.6B).  It is 
likely that the oxidative stress beyond the endogenous antioxidant capacity would not be 
ameliorated properly, leading to oxidative damage and neuronal demise.  To maximize 
cytoprotection, in the RNAi therapy aspect, we may adjust the parameters such as siRNA 
concentration, transfection duration, and even the siRNA sequences for the potent 
downregulation of the Keap1 gene.  
Although the Keap1 knockdown holds therapeutic potential for oxidative stress-
associated pathological conditions, the complete knockout of the Keap1 gene may not be 
beneficial as learned from a study in which homozygous Keap1 mutant mice did not 
survive more than 3 weeks after birth even with the constitutive expression of antioxidant 
proteins and drug metabolizing enzymes (31).  This indicates that a certain level of 
Keap1 activity is required for survival.  The siRNA amount used in our in vitro 
experiments was sufficient to significantly downregulate the Keap1 protein while having 
no harmful effect on cell viability.  When the Keap1 RNAi therapy is applied to a living 
system, it will require a thorough consideration of the dose and the administration 
intervals of Keap1 siRNA to accomplish the anticipated therapeutic effect with no 
toxicity issues.  Another consideration is that the Keap1 RNAi may not be effective if the 
Nrf2-ARE pathway is affected by the pathological condition.  A study reported that Nrf2 




suggesting that the machinery for the nuclear localization of Nrf2 may be impaired in AD 
(32).  In this case, Keap1 knockdown may not be able to change the antioxidant 
expression status.  This suggests that Keap1 RNAi therapy should be applied in the early 
stage of NDD progression because the treatment may not exert the adequate therapeutic 
effect due to the dysregulation of the Nrf2-ARE pathway and the excessive ROS 
generation in advanced NDD.  
As Keap1 RNAi is expected to work better as a preventive medicine rather than a 
treatment for the later stages of NDDs, an earlier diagnosis should be accompanied for 
desired therapeutic outcomes.  Many NDD drugs have failed partly because the treatment 
usually started after the neurodegeneration had already progressed too far to benefit from 
the therapeutics (33); this also shows the need for early diagnostic tools.  In a recent 
study, the researchers validated a blood test in which the levels of ten lipids can be used 
to predict AD onset within 2 to 3 years with high accuracy (34).  This early diagnostic is 
advantageous over current diagnosis techniques, such as lumbar puncture and PET 
scanning, which are invasive or expensive, and often unreliable.  To achieve better 
clinical benefits from the Keap1 RNAi and other NDD therapeutics in general, it would 
also be very important to develop early diagnostic tools with high sensitivity and 
specificity. 
Accumulation of the autophagic vacuoles has been commonly found in the 
postmortem brain tissues from AD patients and also in AD animal models, indicating that 
the autophagic pathway is highly associated with AD pathology (35,36).  Although 
autophagy is a normal process that breaks down and recycles the unnecessary or damaged 




pathological conditions and cell death.  For example, studies have shown that the 
modulation of the autophagy process contributes to the accumulation of aberrant proteins 
and neurodegeneration (36,38).  Extensive oxidative stress can also lead to prolonged 
autophagy, resulting in cell death (21).  In this study, we have found that the Aβ and 
H2O2 treated cells displayed higher autophagic activity than the Keap1 RNAi groups, 
which also supports the view that the oxidative stress activates the autophagic pathway.  
Though it is not confirmed if the activated autophagy could serve as a survival process or 
a cell death mechanism, the attenuation of the oxidative stress via Keap1 RNAi seems 
beneficial for maintaining basal autophagy levels and cell survival.   
While the Keap1 RNAi approach is to alleviate oxidative stress, it is still unclear 
if oxidative stress is the primary cause or the consequence of the neurodegenerative 
process.  It was reported that metal-catalyzed oxidation contributes to the formation of 
Aβ aggregates in AD pathology (39).  On the other hand, aberrant protein aggregates can 
be a major player that results in oxidative stress and neurodegeneration as evidenced by a 
study that showed Aβ produces H2O2 in brain cell lines and primary rat neuronal cultures 
(40).  Although the underlying pathology for neurodegeneration has not been fully 
understood, it appears that oxidative stress, abnormal protein aggregates, and other 
neurodegenerative phenomena are closely linked, not necessarily as a sequential flow but 
presumably as a cycle of events (41).  Thus, in a therapeutic point of view, it is also 
conceivable to apply a combinatorial approach such as Keap1 RNAi with an amyloid 
plaque-targeting therapeutic.  The expectation of which is that it would manage the 
oxidative stress and clear the pathological plaques simultaneously, which might be more 




In conclusion, we propose Keap1 RNAi as an NDD treatment for cytoprotection 
of brain cells against oxidative stress and autophagy-mediated cell death, possibly 
through the augmentation of the endogenous antioxidant capacity.  In order to attain 
clinically meaningful therapeutic results, there should be more comprehensive 
considerations which include an appropriate regimen of Keap1 siRNA, a timely treatment 
with the aid of early diagnostic tools, and combined approaches with an anti-amyloid 
therapy to maximize the therapeutic benefit.  Although it is still preliminary, the results 
here encourage us to further evaluate the therapeutic potential of Keap1 RNAi in a living 




Table 4.1. Gene-specific primer sequences for qRT-PCR.  
 
Gene Forward primer Reverse primer 
hGAPDH 5'CCACTCCTCCACCTTTGAC3' 5'ACCCTGTTGCTGTAGCCA3' 
hKeap1 5'CAGATTGGCTGTGTGGAGTT3' 5'GCTGTTCGCAGTCGTACTTG3' 
hNrf2 5'ATAGCTGAGCCCAGTATC3' 5'CATGCACGTGAGTGCTCT3' 
hSOD1 5'GATTCCATGTTCATGAGTTT3' 5'AGGATAACAGATGAGTTAAG3' 
hNQO1 5'CAGTGGTTTGGAGTCCCTGCC3' 5'TCCCCGTGGATCCCTTGCAG3' 
hGCLM 5'TGAAGGGACACCAGGACAGCC3' 5'GCAGTGTGAACCCAGGACAGC3' 







Figure 4.1. Illustration of the siRNA-peptide complex and Keap1 RNAi-mediated 







Figure 4.2. The cell viability and the gene regulation of Keap1 and Nrf2 after the 
treatment of Keap1 siRNA-peptide complex to U87mg cells.  U87mg cells were 
transfected with Keap1 siRNA-peptide complex for 3 hr in a serum-free condition and 
then further incubated in a complete medium until specific times for assays.  (A) Cell 
viability (n=5/group); (B) qRT-PCR for Keap1 mRNA transcript (n=3/group); (C) 
immunoblotting for Keap1 protein; (D) Keap1 protein band intensity; (E) 







Figure 4.3. Gene regulation of Nrf2 and antioxidant genes under the antioxidant 
responsive element (ARE) after the treatment of Keap1 siRNA-peptide complex (48 h) in 
U87mg cells (n=3/group).  (A) NRF2 mRNA; (B) NQO1 mRNA; (C) SOD1 mRNA; and 









Figure 4.4. Keap1 siRNA-peptide complex treatment enhanced total antioxidant capacity 
and provided partial protection against hydrogen peroxide-mediated cell death in U87mg 









Figure 4.5. Aβ-induced cell stress and cytoprotection with pretreatment of Keap1 siRNA-
peptide complex in U87mg cells.  The cells were incubated with either 5 μM or 20 μM of 
Aβ peptide for 18 hr.  (A) Cell viability (n=4/group); and (B) cell morphology 







Figure 4.6. Protective effect of Keap1 RNAi against oxidative damage from Aβ peptide.  
U87mg cells were grown in 6-well plates and transfected with Keap1 siRNA-peptide 
complex for 3 hr and further incubated for 48 hr.  The cells were then incubated with Aβ 
peptide for 18 hr until reaching specific time-points for oxidative damage assays.  (A) 
Lipid damage (MDA assay, n=3/group); and (B) protein damage (protein carbonyl 







Figure 4.7. Protective effect of Keap1 RNAi against Aβ peptide-induced autophagy.  
U87mg cells were grown in 6-well plates and transfected with Keap1 siRNA-peptide 
complex for 3 hr and further incubated for 48 hr.  The cells were then incubated with 
either Aβ (1-42) peptide or H2O2 for 18 hr until used for the autophagy assay and 
immunoblotting for LC3 protein.  (A) The fluorescence intensity measured after the 
autophagic vacuole specific green fluorescent dye staining (n=4/group); (B) fluorescence 
microscopy images of cells stained with the autophagic vacuole specific green 
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IN VIVO EVALUATION OF A MYRISTOYLATED CELL-PENETRATING  
PEPTIDE FOR BRAIN-TARGETED SIRNA DELIVERY 
5.1 Abstract 
RNAi technology holds a therapeutic promise for many neurological diseases.  
However, brain-targeted siRNA delivery is challenged by restrictive brain vasculature.  
To obtain access to the brain compartment, we have designed a myristoylated cell-
penetrating peptide equipped with a transferrin-receptor targeting short peptide (myr-TP-
Tf) as a brain-targeted siRNA delivery system.  Our previous work demonstrated that this 
siRNA-peptide complex system was able to achieve successful neuronal cell uptake and 
functional target gene silencing effect in vitro.  Herein, we move forward to an in vivo 
study to examine whether this siRNA-peptide complex shows the brain targeting ability 
and the target gene downregulation effect in a living system.  To compare the effects 
from local vs. systemic administration, the siRNA-peptide complex was given to adult 
mice via two different routes of administration: intracranial vs. retrobulbar injections.  As 
expected for the direct administration, the intracranial injection groups displayed strong 
and persistent siRNA accumulation signals in the brain area and significant target gene 
silencing effect even at a relatively lower dose.  Although the extent of the brain 
accumulation and the gene downregulation effect were lower than those of the 




brain-targeted siRNA delivery, which produced a significant reporter protein (hPAP; 
human placental alkaline phosphatase) activity compared to other control groups.  The 
results in this study, albeit limited, suggest that the siRNA/myr-TP-Tf complex system 
has a promising potential as an RNAi therapy tool for various neurological diseases. 
5.2 Introduction 
A recent study reported that the clinical trials for Alzheimer’s disease (AD) 
treatments attempted over the last decade  (2002-2012) recorded 99.6% failure rate with 
only five approved drugs, which merely provide temporary symptomatic relief (1).  In 
light of the health and economic effects of AD, more research endeavors are required to 
develop AD drugs with substantial therapeutic effects.  The investigational drugs studied 
until now include symptomatic agents, disease-modifying small molecules, and disease-
modifying immunotherapies (2).  While the amyloid deposits and the tau protein have 
been frequently focused as key pathological causes for neurodegeneration, no agent has 
been yet validated for these targets in clinical trials.  To improve the success rate of AD 
drug trials, diverse modes of therapeutics with varying mechanisms of action need to be 
explored.  
As one of the promising approaches for neurodegenerative disorders (NDDs), 
RNAi therapy has also a great therapeutic potential (3,4).  The powerful gene silencing 
mechanism of RNAi can be employed to effectively downregulate the genes associated 
with the NDD pathogenesis.  For instance, the β-secretase 1 (BACE 1), which contributes 
to the generation of the neurotoxic form of Aβ fragment, can be targeted to suppress the 
amyloid accumulation in an AD brain (5,6).  The hyperphosphorylated tau protein, 




tau protein kinases such as glycogen synthase kinase 3 (GSK3) and cyclin-dependent 
kinase 5 (CDK5) (7-9).  To protect neuronal cells against extensive oxidative stress, a 
common hallmark found in many NDDs, the RNAi approach could be utilized for the 
activation of the endogenous antioxidant system.  In the Keap1 (kelch-like ECH-
associated protein)-Nrf2 (NF-E2-related factor 2) pathway, the Nrf2, which is responsible 
for the activation of ARE (antioxidant responsive system), is repressed by the Keap1 
protein.  By downregulating the Keap1 gene, the Nrf2 can translocate to the nucleus 
where it binds to the ARE and subsequently activates the expression of various 
antioxidants and detoxifying enzymes (10).   
However, the brain entry of large and charged molecules such as siRNA is 
impeded by the blood-brain barrier (BBB) (11,12).  Moreover, siRNAs are susceptible to 
the serum nuclease-mediated degradation and clearance in the blood stream, raising a 
challenge for its use in vivo application (13-15).  Previously, we have sought to overcome 
this obstacle by using a myristoylated cell-penetrating peptide equipped with a 
transferrin-receptor targeting sequence (myr-TP-Tf) for brain-targeted siRNA delivery.  
The siRNA-peptide complex demonstrated its promising properties in vitro by showing 
successful cellular uptake into the brain endothelial cells (b.End3) and primary murine 
neurons/astrocytes, functional target gene downregulation, and favorable siRNA transport 
across the b.End3 cell monolayer (16).  In this study, the siRNA-peptide complex was 
further evaluated concerning brain targeting ability and the target gene silencing effect in 
a living system.   
To assess the Keap1 gene RNAi effect, ARE-hPAP transgenic mice that contain 




were used as an animal model.  The siRNA-peptide complex was injected into these mice 
via two different routes to compare the performance from the local vs. systemic 
administrations.  Although the tail vein injection is the most commonly adopted route for 
the systemic administration, the hPAP transgenic mice (C57/BL) were not favorable for 
this method because their dark and thick tail skins made it difficult to locate the veins.  
As an alternative, retrobulbar injection was attempted as a systemic administration 
method.  It involves little distress to animals when properly executed under anesthesia.  
In addition, there are multiple veins located at the retrobulbar sinus (superficial temporal 
vein, supraorbital vein, ocular angle vein, dorsal nasal vein, inferior palpebral vein, and 
facial vein), which makes retrobulbar injection useful as an alternative route of systemic 
administration (17,18).  As illustrated in Figure 5.1, the siRNA-peptide complex was 
prepared by mixing the siRNA and the peptide-based carrier at an optimal molar ratio 
(1:20 of siRNA to peptide), which was determined in the previous study.  The siRNA-
peptide complex suspension was given to the mice via either intracranial or retrobulbar 
injections per the dosage regimen described in the scheme.  Here, the brain targeting 
ability of the siRNA-peptide complex was examined in live animals and the target gene 
knockdown capacity was assessed from brain tissues isolated after the injections.  
5.3 Materials and methods 
5.3.1 Formulation of the siRNA-peptide complex 
The myristic acid conjugated cell-penetrating peptide (transportan) equipped with 
a transferrin receptor-targeting peptide (myr-TP-Tf) and the nontargeting scrambled 
peptide (myr-TP-Scr) were prepared by solid-phase peptide synthesis technique at 




are as follows: myristic acid-GWTLNSAGYLLGKINLKALAALAKKIL-GGGG-
THRPPMWSPVWP (myr-TP-Tf) and myristic acid-GWTLNSAGYLLGKINLKALAA-
LAKKIL-GGGG-PWRPSHPVWMPT (myr-TP-Scr).  The purity (>95%) and the 
molecular weight (4.5 kDa) of each peptide were validated in high-performance liquid 
chromatography (HPLC) and mass spectrometry analysis.  The mouse Keap1 siRNA was 
prepared at the DNA/Peptide Lab in the University of Utah HSC Core Research Facility.  
The sequence for each strand is as follows: (sense) 5'- GCUAUGACCCGGACAGUGA-
UU-3', (antisense), 5'- UCACUGUCCGGGUCAUAGCUU-3'.  For the imaging study, 
the 5' end of the sense strand was labeled with Cy5.5 fluorescent dye.  To prepare the 
siRNA-peptide complex, the siRNA solution was mixed with the peptide carrier in 
distilled water at a 20:1 (peptide to siRNA) molar ratio following our previous work (16).  
This mixture was vigorously vortexed for 20 s and incubated at room temperature for 20 
min.  All siRNA-peptide complex suspensions were freshly prepared before the injection.  
5.3.2 Animals: human placental alkaline phosphatase (hPAP)  
transgenic mice/C57BL 
Human placental alkaline phosphatase (ARE-hPAP) (+) transgenic mice were 
obtained from the Dr. Jeffrey Johnson lab (University of Wisconsin) and maintained in an 
animal facility according to the protocol approved by IACUC at University of Utah.  
Mice were genotyped with tail biopsy before weaning to verify the presence of the hPAP 
reporter gene and allowed to grow until they were 7 to 8 months old.  The hPAP(+) mice 
were allocated for the gene downregulation study and the  hPAP (-) mice were used for 
the imaging study.  Both genders were included in this work.  The average body weight 




them showed any significant body weight change or detectable health issues during the 
study.   
5.3.3 Retrobulbar and intracranial injection of the siRNA-carrier complex 
The retrobulbar injection groups received three consecutive injections (50 μg of 
siRNA suspended in 100 μL of phosphate buffered saline loaded in 30-gauge insulin 
syringes) through the retrobulbar sinus with 24 hr intervals and were euthanized a day 
after the last injection for brain isolation.  The retrobulbar injection technique was 
performed following the tips described in the literature (17).  The intracranial injection 
groups also received three consecutive injections (5 μg of siRNA suspended in 5 μL of 
phosphate buffered saline per injection) into the brain cortices.  The intracranial injection 
groups were prepared as following.  The mouse head was shaved to remove the hair and 
disinfected with povidone-iodine solution.  A ~2 to 3 mm incision was made along the 
midline of the scalp and a ~1 mm hole was made on the skull at a point 2 mm lateral and 1 
mm anterior to the bregma by carefully drilling with a 26-gauge needle.  The sterilized 
guide screw was rotated into the hole with a specially devised screwdriver and the 
incision was closed using tissue adhesives.  The mice were placed back to the cages for 3 
days to allow the incisions to be healed.  The siRNA suspension was loaded into a 
modified 10 μL syringe (Hamilton Co. Reno, NV) attached to a 26-gauge needle and 
injected into the brain cortices by placing the needle through the guide screw, which 
controls the injection site and depth (~3 mm).  The siRNA suspension was delivered over 
a minute and the needle was retained for additional 30 sec to ensure injection.  During the 
injections and the screw insertion procedure, mice were anesthetized by placing the head 




liter/min).  In the imaging study, the mice received a single injection for each route and 
were used immediately for taking images.  Postprocedural monitoring was accompanied 
to examine any significant body weight changes or adverse signs during the study.  
5.3.4 In vivo fluorescence imaging 
For the imaging study, Cy5.5-labeled siRNA were used to formulate the siRNA-
peptide complex.  The PBS control, naked Cy5.5-siRNA-injected, Cy5.5 siRNA/myr-TP-
Tf complex-injected, and Cy5.5 siRNA/myr-TP-Scr complex-injected mice were lined up 
under anesthesia and the near-infrared fluorescence (NIR) images were acquired using an 
IVIS 200 imaging system (Caliper Life Sciences, Hopkins, MA) at 1 hr, 2 hr, 24 hr, and 
48 hr postinjection with a wavelength setting as excitation/emission of 675/694 nm.  Both 
belly-side up and belly-side down positions were taken at each time-point to examine the 
fluorescence distribution. 
5.3.5 Human placental alkaline phosphatase (hPAP) assay 
The hPAP assay was performed according to the protocol established by the Dr. 
Jeffrey Johnson lab (19).  Briefly, flash-frozen mouse brain tissues were homogenized in 
Tris/MgCl2/NaCl/CHAPS (TMNC) lysis buffer (0.05 M Tris, 0.005 M MgCl2, 0.1 M 
NaCl, 4% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate [CHAPS]) and 
incubated at 65°C for 30 min in 200 mM diethanolamine buffer.  The CSPD and Emerald 
reagents from Applied Biosystems (Bedford, MA) were used as substrates to evaluate the 
hPAP activity.  Samples were placed in a white 96-well plate and the luminescence 
intensity was measured in a luminometer.  Bicinchoninic acid (BCA) protein assay 




activity was normalized to the protein quantity. 
5.3.6 cDNA synthesis and quantitative real time PCR (qRT-PCR) 
Total RNA of brain tissues was extracted using Trizol reagent (Invitrogen) 
according to the manufacturer’s instructions.  RNA samples with purity of 1.9 or higher 
and 260/280 absorbance ratio were used to prepare cDNA.  Briefly, 1 μg of RNA was 
mixed with random primers, dNTPs in the reverse transcription buffer (New England 
Biolabs, Beverly, MA), heated for 3 min at 70 °C, and then cooled in ice for 2 min.  
Subsequently, MMuLV RTase and RNase inhibitor (NEB) were added to the reaction 
mixtures.  The cDNA synthesis was conducted at 42 °C for an hour and then an enzyme 
deactivation step (90 °C for 10 min) followed.  Diluted cDNA and each gene-specific 
primer set were mixed with EXPRESS SYBR® GreenER™ qPCR Supermix (Invitrogen) 
and qRT-PCR was performed on a StepOnePlus™ real-time PCR system (Applied 
Biosystems, Carlsbad, CA).  The reaction was conducted as follows: 50 °C for 2 min and 
95 °C for 10 min (denaturation), 40 cycles of 95 °C for 15 s (amplification), and 60 °C 
for 1 min (elongation).  The GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was 
included as an internal control for the relative quantification of each gene expression 
level.  The sequences of the primer sets used in this study are listed in Table 5.1.  
5.3.7 Immunoblotting 
The flash-frozen mouse brain tissues were homogenized in a lysis buffer (62.5 
mM Tris-HCl (pH 6.8), 2% w/v SDS, 10% glycerol, 1% protease inhibitor).  The tissue 
lysates were sonicated for 10 s and centrifuged at 13,000 × g for 15 min to remove the 




quantified by performing a BCA assay.  Twenty µg of proteins were loaded on each well 
of NuPAGE® Novex® 4-12% Bis-Tris gels (Invitrogen) for SDS-PAGE (120 V for 1.5 
hr) in NuPAGE® MES SDS running buffer (Invitrogen).  The proteins were then 
transferred to PVDF membranes in NuPAGE® transfer buffer (Invitrogen) at 30 V for an 
hour.  The membranes were blocked with TBST (tris-buffered saline with 0.1% Tween-
20) buffer containing 5% (w/v) nonfat dry milk for an hour and then washed with TBST 
buffer 3 times for 5 min each.  The membranes were incubated with rabbit polyclonal 
anti-Keap1 antibody (Abcam Inc., Cambridge, MA, #ab139729), and rabbit polyclonal 
anti-β actin antibody (Abcam, #ab8227) separately in TBST buffer containing 5% bovine 
serum albumin (BSA) at 4°C overnight.  After rinsing 3 times for 5 min each, the 
membranes were incubated with goat polyclonal antibody to rabbit IgG conjugated with 
horseradish peroxidase (HRP) (Abcam, #ab6721) for an hour and then washed 3 times.  
The protein blots were visualized by using WesternBright Quantum HRP substrate 
(Advansta, Menlo Park, CA) and the chemiluminescent images were taken in a 
FluorChem FC2 imaging system (Alpha Innotech, San Leandro, CA). 
5.3.8 U87mg cell transfection 
Human glioma U87mg cells were plated in 6-well plates at a density of 104 
cells/cm2 and grown until they reached 70-80% confluency.  Cells were maintained in 
DMEM (Dulbecco’s Modified Eagle Medium, Invitrogen, Carlsbad, CA) supplemented 
with 10% fetal bovine serum and 100 U/mL of penicillin/streptomycin and cultured in a 
humidified incubator containing 5% CO2 at 37°C.  The cells were transfected with Keap1 
siRNA-peptide complex in DMEM either with or without serum for 3 hr and further 




prepared at the University of Utah HSC Core Research Facility.  The siRNA sequences 
are as following; (sense) 5'-GGCCUUUGGCAUCAUGAACTT-3', (antisense) 5'-
GUUCAUGAUGCCAAAGGCCTG-3'.  
5.3.9 Hemolysis assay 
The hemolysis assay was performed following the protocol described by Yu et al. 
(20).  Briefly, the whole blood drawn from two mice was stored in heparinized tubes.  A 
measure of 2.5 mL of mouse whole blood was combined with 10 mL of Dulbecco's 
phosphate-buffered saline (DPBS) and the red blood cells (RBCs) were isolated by 
centrifugation at 10,000 × g for 5 min.  The RBCs were washed with DPBS 5 times and 
then diluted in 40 mL of DPBS.  Two hundred μL of the diluted RBCs were added to 400 
μL of siRNA-peptide complex-containing DPBS suspensions.  The siRNA-peptide 
complex was prepared at various molar ratios with 100 pmoles of siRNA.  The mixture of 
RBC and siRNA-peptide complex was incubated for 4 hr at room temperature.  Finally, 
the sample containing tubes were vortexed and centrifuged at 10,000 × g for 5 min.  The 
supernatants were transferred to a 96-well plate and the absorbance for hemoglobin and 
the reference absorbance were measured at 577 nm and 655 nm of wavelength, 
respectively.  The percentage of hemolysis was calculated as follows: Hemolysis % = 
[(sample absorbance - negative control) / (positive control - negative control)] x 100%.   
5.3.10 Statistical analysis 
The data were expressed as mean ± standard errors.  The statistical analysis was 
conducted with one-way ANOVA followed by Tukey-Kramer HSD post-hoc analysis.  




The graphs were generated using SigmaPlot 10.0 (Systat, San Jose, CA) and the 
statistical analysis was performed with JMP® v10.0 (SAS Institute Inc., Cary, NC). 
5.4 Results 
5.4.1 Brain targeting ability of the siRNA-carrier complex 
To evaluate the brain-targeting ability of the siRNA/myr-TP-Tf complex and 
compare the direct vs. local injection effect, the siRNA-peptide complex was prepared 
with Cy5.5-labeled siRNA and administered into mice via either intracranial or 
retrobulbar routes.  PBS-injected mice were used as a negative control and naked Cy5.5-
siRNA-injected mice were included to distinguish the siRNA carrier effect.  The 
siRNA/myr-TP-Scr complex-injected mice were used to compare the brain targeting 
effect.  Following the injection, the fluorescence from Cy5.5-siRNA was imaged at 1 hr, 
2 hr, 24 hr, and 48 hr postinjection.  In accordance with our expectation, the mice given a 
direct injection of Cy5.5-siRNA displayed intense and focused fluorescence on the brain 
areas up to 48 hr postinjection regardless of the presence of the peptide carrier and 
targeting moiety (Figure 5.2, A-D).  There was almost no difference in fluorescence 
intensity in the brain areas among Cy5.5-siRNA injected groups, but the naked Cy5.5-
siRNA injected one slightly lost the intensity at 48 hr postinjection implying that the 
peptide-based siRNA carriers help sustain the siRNA accumulation in the brain.  Overall, 
the images from intracranial injection groups showed that direct injection ensures siRNA-
peptide complex delivery to the brain. 
On the contrary, the mice given a retrobulbar injection of Cy5.5-siRNA displayed 
little or lower fluorescence intensity on the brain areas compared to the intracranial 




with Cy5.5-siRNA/myr-TP-Tf complex showed better fluorescence distribution on the 
brain area at every time-point compared to other groups.  While naked Cy5.5-siRNA- and 
the Cy5.5-siRNA/myr-TP-Scr complex-injected mice had the fluorescence signal only in 
the area close to the injection sites at 1 hr and 4 hr postinjection and almost no signal 
after that, the Cy5.5-siRNA/myr-TP-Tf complex-injected mice had measurable 
fluorescence on the brain area, which was observed up to 48 hr postinjection with a 
declined intensity.  It appeared that the naked Cy5.5-siRNA and the Cy5.5-siRNA/myr-
TP-Scr complex do not readily reach brain tissues when systemically administered, 
whereas the Cy5.5-siRNA/myr-TP-Tf complex was able to get into the brain to some 
extent as manifested by detectable fluorescence signal on the brain area.  Compared to 
the intracranial injection group, however, the retrobulbar injection of Cy5.5-siRNA/myr-
TP-Tf complex achieved a limited distribution of the fluorescence, being mostly focused 
on the olfactory bulb and the frontal lobe area.  This result led us to presume that the 
proximity to the injection site also influences the distribution of the siRNA-peptide 
complex.  There were some autofluorescence exhibited by feet and tails of the mice and 
this should be distinguished from the Cy5.5-associated fluorescence.  The belly-side up 
positions of the mice was also monitored at each time-point to examine the fluorescence 
distribution over the whole body (Figure 5.3).  Although there were some changes in the 
fluorescence distribution along the time course, it was too ambiguous to determine 
whether the fluorescence originated from the Cy5.5 or not because of the 
autofluorescence exerted from the mouse body (e.g., dark agouti colored coat, feet, tails, 




5.4.2 Functional target gene silencing 
To evaluate the target gene silencing effect, the hPAP transgenic mice were 
injected with Keap1 siRNA-peptide complex 3 times in 24 hr intervals either via 
intracranial or retrobulbar routes.  A day after the last injection, mice were euthanized for 
brain isolation.  The brain tissues at the injection sites (for intracranial injection groups) 
and the frontal lobe areas (for retrobulbar injection groups) were collected and used for 
the hPAP assay to examine the Keap1 gene downregulation effect.  As a negative control 
for the hPAP activity, brain tissues from the hPAP (-) mice were included in the hPAP 
assay.  In the intracranial injection groups, all of the Keap1 siRNA-injected groups 
showed significantly increased hPAP activities compared to the PBS-injected control 
group (Figure 5.4A); this indicates that the Keap1 gene was successfully silenced 
following the Keap1 siRNA administration.  It was consistent with the imaging result 
where the direct intracranial injection groups exhibited a strong and persistent 
fluorescence signal of Cy5.5-siRNA in the brain areas (Figure 5.2).  Among the 
intracranial injection groups, the Keap1 siRNA/myr-TP-Tf complex-injected group 
showed the most dramatic increase in hPAP activity on average by 24.6-fold compared to 
the PBS control, while the naked Keap1 siRNA-injected group and the Keap1 
siRNA/myr-TP-Scr complex-injected group elicited 2.5-fold and 9.9-fold increases, 
respectively.  This result clearly demonstrates that the myr-TP-Tf peptide ensures 
enhanced siRNA delivery and functional target gene silencing compared to the 
nontargeting myr-TP-Scr peptide, as well as the naked form of siRNA.  The nontargeting 
myr-TP-Scr peptide also showed approximately 3-fold higher hPAP activity than the 




a beneficial role in siRNA delivery.  Collectively, the Keap1 siRNA/myr-TP-Tf complex-
injected group showed the highest increase in hPAP activity, which suggests that not only 
the cell-penetrating peptide, but also the brain-targeting moiety contributes to the 
favorable cellular uptake of siRNA-peptide complex and the effective RNAi. 
In the retrobulbar injection groups, the increase in hPAP activity was also 
observed from the Keap1 siRNA-injected groups (Figure 5.4B).  However, the extent of 
the hPAP activation was quite less than those found in the intracranial injection groups: 
the naked Keap1 siRNA-injected group (1.8-fold), the Keap1 siRNA/myr-TP-Tf 
complex-injected group (3.3-fold), and the Keap1 siRNA/myr-TP-Scr complex-injected 
group (1.6-fold).  Although the intracranial injection groups showed more dramatic 
increases in hPAP reporter activity, the myr-TP-Tf peptide complex still proved to have 
better brain targeting ability compared to the naked siRNA or the nontargeting myr-TP-
Scr peptide complex, displaying the highest hPAP activity increase among other groups 
of the retrobulbar injection.  This result indicates that the systemic administration of the 
siRNA/myr-TP-Tf complex can be a valid approach for brain-targeted RNAi therapy.  To 
improve RNAi effect, however, it seems that a follow-up study is required to optimize the 
dose, number of injections, injection intervals, etc.    
The protein and mRNA levels of Keap1 were further examined by performing 
Western blot and qRT-PCR experiments.  In the intracranial injection groups, the Keap1 
siRNA/myr-TP-Tf complex-injected group showed reduced Keap1 protein expression, 
which was consistent with the hPAP activity result.  This indicates the successful 
knockdown of the Keap1 gene (Figure 5.5A).  However, the Keap1 protein levels were 




groups (Figure 5.5B).  Moreover, the qRT-PCR did not yield the matched results with the 
hPAP activity (Figure 5.6A and B).  There was no significant difference in Keap1 mRNA 
levels among groups in both the intracranial and the retrobulbar injection groups.  We 
presume that this was because the brain tissues collected for these assays were located 
apart from where the siRNA-peptide complex could reach and that the data were not 
congruent with the hPAP assay result.  To elucidate the RNAi effect thoroughly, an 
additional number of mice should be included and the brain tissues need to be collected 
region by region for a more detailed gene expression analysis.  
5.4.3 Other considerations for in vivo application 
To examine any adverse effects associated with the siRNA-peptide complex, we 
conducted postprocedural monitoring during the injection period by measuring the body 
weight and examining the activity or behavioral changes of the mice.  The body weight of 
the mice was measured every other day and no significant changes were observed (Figure 
5.7).  In addition, there were no noticeable alterations in appearance or behaviors among 
different groups during the injection course, indicating that the siRNA-peptide complex 
administration does not affect the general health of the animals. 
Prior to in vivo administration, an in vitro experiment was performed to determine 
whether the siRNA-peptide complex can transfect the neuronal cells in the presence of  
serum, a physiologically relevant environment.  The Keap1 siRNA/myr-TP-Tf complex 
were transfected into U87mg cells for 3 hr either with or without serum and the cells 
were collected at 48 hr posttransfection for the mRNA and protein level analysis.  The 
Keap1 mRNA expression level was reduced to 28.2% in the serum-free condition, and to 




with the cellular uptake of the siRNA-peptide complex (Figure 5.8A).  Even so, the 
Keap1 silencing effect was still significant for the serum-containing condition compared 
to the nontreated control group, validating the utility of the siRNA-peptide complex for in 
vivo application (Figure 5.8A and D).  The Keap1 silencing did not affect the Nrf2 
mRNA expression level, consistent with our previous result (Figure 5.8B).  The 
expression of Nqo1 (NAD(P)H dehydrogenase, quinone 1), one of the ARE downstream 
genes, was found to be increased by 454.7% for the serum-free condition and by 167.1% 
for the serum-present condition.  Although the difference between the control and the 
serum-present condition was not statistically significant, the increasing expression pattern 
still indicated that the Keap1 RNAi was followed by ARE activation under the serum-
containing condition as well (Figure 5.8C).   
To investigate the potential adverse interaction between the siRNA-peptide 
complex and RBCs (red blood cells) in the bloodstream, a hemolysis assay was 
conducted.  The siRNA-peptide complex was prepared at varied molar ratios and 
combined with the diluted mouse RBCs.  Along with the increasing molar ratio of siRNA 
to peptide carrier, higher hemolytic activity was observed (Figure 5.9).  This was 
expected to a certain degree because the cationic surface charge of the siRNA-peptide 
complex would possibly perturb the membranes of RBCs, causing them to leak out 
hemoglobin (21).  The siRNA-peptide complex prepared at 1:20 (siRNA to peptide) 
molar ratio, which was relevant to the dose used in this study, resulted in approximately 
10% of hemolysis (implying a slightly toxic property).  Among ~10% of hemolytic 
activity, in the strict sense, the water content from the siRNA and the peptide suspension 




DNA delivery system, a hemolytic activity less than 15% is regarded as nontoxic and 
considered suitable for intravenous administration (22).  This supports the siRNA-peptide 
complex as a viable mode for in vivo RNAi application.     
5.5 Discussion 
Collectively, the data presented in the current study showed that the direct 
injection of the siRNA-peptide complex to the brain cortex ensures surpassing 
performance with regard to brain-targeted siRNA delivery and the target gene 
downregulation effect.  Despite the relatively lower RNAi effect, the retrobulbar injection 
of the siRNA/myr-TP-Tf complex still proved its brain targeting ability and functional 
target gene silencing capability compared to the naked siRNA and the nontargeting 
complex.  The absence of evident toxicity issues and acceptably minor hemolytic activity 
at current doses also substantiate the in vivo utility of the siRNA-peptide complex.  
Overall, the results described herein suggest that the myr-TP-Tf peptide can serve as a 
useful tool to achieve brain-targeted siRNA delivery both via local and systemic 
administration.  
It is understandable that the direct injection of the siRNA-peptide complex to the 
brain cortex produced a greater gene silencing effect than the systemic administration; 
apparently because the intracranial route allows direct access of the agent to the focused 
brain parenchyma with higher concentration while obviating the need for passing through 
the BBB.  Furthermore, the direct injection provides a pharmacokinetic benefit owing to 
the advantageous brain distribution of the therapeutics compared to the systemic 
administration (23).  The direct injection effect may be even more enhanced by applying 




pump infuses the agent through intracranially placed catheters (24,25).  Notwithstanding 
advantages of direct injection, its actual application may involve complex and invasive 
procedures, which can be a limiting factor if multiple injections over an extended period 
are required to elicit a desired therapeutic effect.  Practically, the systemic administration 
is a preferred method as it is minimally invasive, less costly, and relatively favorable for 
patient convenience.  As learned from the imaging study, however, the brain targeting 
ability of the siRNA/myr-TP-Tf complex was shown to be weaker in retrobulbar injection 
groups (Figure 5.2) while the intracranial injection group displayed an intense 
fluorescence signal in the brain area even up to 96 hr postinjection (data not shown).  In 
line with the imaging result, the target gene downregulation effect represented by the 
hPAP activity was also a lot stronger in the intracranial injection groups than in the 
retrobulbar injection groups (Figure 5.4).  Even though the current formulation proved its 
brain targeting and gene silencing ability in retrobulbar injection groups, the results 
obtained in this study informs us that further optimization of the siRNA-peptide complex 
is needed to be fully functional for the systemic administration approach.  
As a refinement plan, the transferrin receptor (TfR)-binding short peptide 
sequence of the myr-TP-Tf can be replaced with other types of brain-specific moieties for 
improved siRNA accumulation in the brain.  Although the siRNA/myr-TP-Tf complex 
showed its ability to reach brain tissues compared to the naked siRNA and the 
nontargeting complex, the TfR may not be an ideal targeting receptor because of its 
ubiquitous expression on other peripheral organs (26).  Depending on the siRNA species 
loaded on the complex, nonspecific uptake of the siRNA-peptide complex by other 




effort to accomplish brain-targeted drug delivery, researchers have attempted diverse 
brain-targeting moieties for the receptors, including LDLR-related protein (LRP1) (27), 
insulin receptor (28), diphtheria toxin receptor (29), acetylcholine receptor (30), leptin 
receptor (31), etc.  However, these receptors are not exclusively found on the brain 
endothelium either.  To optimize the brain targeting ability of the siRNA-peptide 
complex, further research endeavors are encouraged for the identification of novel brain-
specific receptors and receptor targeting moieties that can bind to those receptors with 
high affinity.   
Another consideration for enhancing the efficacy of the systemic administration is 
to optimize the dosage regimen.  In the current study, only a single dosage protocol (three 
injections of 50 µg of siRNA in 24 hr intervals for the retrobulbar injection group) was 
tested due to the limited number of animals per group, which is a major limiting factor.  
In addition, the brain tissues collected from the same mouse were divided for multiple 
assays including the hPAP assay, Western blotting, and qRT-PCR.  This made it difficult 
to examine the gene knockdown effect precisely, particularly because of the differential 
RNAi effect over the brain tissues.  By increasing the number of animals per group, a 
range of multiple doses from high to low needs to be further tested along with the 
adjustment of the number of injections and the injection intervals in order to find an 
optimal dosage protocol that maximizes the gene silencing effect of the siRNA-peptide 
complex.  In addition, a more thorough gene expression analysis should be followed with 
brain tissues at specific regions collected from separate mice for each assay.  Concerning 
the dosage adjustment, however, it should be noted that the cationic charged carrier may 




the systemic administration.  As tested in the hemolysis assay, the myr-TP-Tf peptide 
showed a slight hemolytic activity (~10%) though it was still considered within a safe 
range (Figure 5.9).  To prevent excess hemolysis at high doses of the siRNA-peptide 
complex, the PEGylation strategy can be used for the siRNA carrier design.  Indeed, 
studies have shown that the PEGylated drug delivery systems exhibited significantly 
reduced hemolytic activities compared to the nonmodified ones (35-37), possibly because 
the PEG coating provides the steric hindrance that lowers the interaction between the 
drug-loaded systems and the RBCs in the bloodstream (38,39).  In addition, the 
PEGylation approach can also protect the siRNA-peptide complex from the 
reticuloendothelial system (RES)-mediated clearance (40).  
To step forward to the clinical setting, not only the RNAi therapeutic effect, but 
also the biodistribution pattern and pharmacokinetic properties of the siRNA-peptide 
complex should be further elucidated.  Although the fluorescently-labeled siRNA was 
used in the imaging study, it did not clearly visualize the biodistribution of the siRNA-
peptide complex, largely because of the autofluorescence from the hPAP transgenic mice 
(Figure 5.3).  To investigate the potential nonspecific absorption of the siRNA-peptide 
complex to other peripheral organs, we need to increase the number of animals and 
perform ex vivo organ imaging over multiple time-points, which eliminates the confusion 
from the whole body autofluorescence.  As the peptide carriers were not labeled 
fluorescently, it may not be conclusive as to whether the fluorescence indicates the 
siRNA in the peptide complex form or just free siRNA.  We have attempted to use a 5-
FAM-labeled peptide carrier, but it failed to maintain the identical siRNA condensation 




carrier individually, the peptide carriers may need to be labeled with alternative dyes or 
radioactive isotopes that do not interfere with the normal electrostatic interaction between 
the peptide and the siRNA. 
RNAi therapy has received a spotlight for its powerful gene modulation ability in 
pathological conditions.  Regarding various neurodegenerative disorders, researchers 
have suggested multiple RNAi targets that include variants of APP, BACE1, presenilin 1 
and 2 for AD, α-synuclein for PD, ataxin-1 for spinocerebellar ataxia, etc.  Although 
RNAi approaches targeting those genes have shown promising therapeutic results in 
many preclinical validation studies with rodent models, there is no successful RNAi drug 
available for treating neurodegenerative disorders, yet.  This is because the siRNAs are 
vulnerable to the serum nucleases in the bloodstream and are unable to cross the BBB, 
which all result in poor accumulation in the target site.  Considering the clinical benefits 
from the highly specific and effective gene silencing mechanism of the RNAi, it is 
imperative to develop RNAi carrying vehicles that can protectively load siRNAs and 
functionally deliver them to the brain parenchyma.  Our current work is in line with this 
effort and further research should also continue.  
To conclude, the in vivo data here validated the myristoylated cell-penetrating 
peptide equipped with a brain-targeting moiety as a functional brain-targeted siRNA 
delivery vehicle.  As a next step in the preclinical stage, we can administer therapeutic 
siRNAs/peptide complex to AD or other types of NDD animal models and evaluate the 
therapeutic outcome with regard to target gene knockdown, as well as the symptomatic 
and behavioral improvement.  We expect that further optimization of the carrier design 




Table 5.1. qRT-PCR primer sequences  
 
Gene Forward primer Reverse primer 
mGAPDH 5'AACTTTGGCATTGTGGAAGG3' 5'TGTGAGGGAGATGCTCAGTG3' 
mKeap1 5'AAGGACCTTGTGGAAGACCA3' 5'CCCTGTCCACTGGAATTGAT3' 
hGAPDH 5'CCACTCCTCCACCTTTGAC3' 5'ACCCTGTTGCTGTAGCCA3' 
hKeap1 5'CAGATTGGCTGTGTGGAGTT3' 5'GCTGTTCGCAGTCGTACTTG3' 
hNrf2 5'ATAGCTGAGCCCAGTATC3' 5'CATGCACGTGAGTGCTCT3' 
hNQO1 5'CAGTGGTTTGGAGTCCCTGCC3' 5'TCCCCGTGGATCCCTTGCAG3' 






Figure 5.1. Illustration of the siRNA-peptide complex preparation and the dosage 
regimen for the retrobulbar and intracranial injections for adult mice.  All siRNA-peptide 
complex suspensions were freshly prepared in sterile phosphate buffered saline and 
incubated at room temperature for 20 min before injection.  In the imaging study, animals 
were given a single injection of fluorescently labeled siRNA-peptide complex and 







Figure 5.2. Fluorescence imaging of mice injected with Cy5.5-labeled siRNA (belly 
down).  The fluorescence signal was taken at 1 hr, 4 hr, 24 hr and 48 hr postinjection. 
Mice were lined up (from left to right) as PBS control, naked Cy5.5-siRNA, Cy5.5-
siRNA/myr-TP-Tf complex, and Cy5.5-siRNA/myr-TP-Scr complex-injected ones.  The 
intracranial injection groups are shown in left panel (A, B, C, and D) and the retrobulbar 







Figure 5.3. Fluorescence imaging of mice injected with Cy5.5-labeled siRNA (belly up).  
The fluorescence signal was taken at 1h, 4h, 24h and 48h post-injection. Mice were lined 
up (from left to right) as PBS control, naked Cy5.5-siRNA, Cy5.5-siRNA/myr-TP-Tf 
complex, and Cy5.5-siRNA/myr-TP-Scr complex-injected ones.  The intracranial 
injection groups are shown in left panel (A, B, C, and D) and the retrobulbar injection 








Figure 5.4. hPAP activity.  Relative hPAP activity in brain tissues of the Keap1 siRNA-
injected mice were examined via luminescence measurements.  (A) hPAP activity in 
intracranial injection groups; and (B) hPAP activity in retrobulbar injection groups.  Data 
are expressed as mean ± standard error.  One-way ANOVA was conducted with Tukey-






Figure 5.5. Western blot analysis of Keap1 protein expression level.  (A) Keap1 protein 
level in intracranial injection groups; and (B) Keap1 protein level in retrobulbar injection 








Figure 5.6. qRT-PCR analysis of Keap1 mRNA expression level (n=3/group).  (A) Keap1 
mRNA level in intracranial injection groups; and (B) Keap1 mRNA level in retrobulbar 









Figure 5.7. Body weight monitoring during the course of injections (n=3/group). (A) 
Body weight changes in intracranial injection groups; and (B) body weight changes in 







Figure 5.8. Transfection of Keap1 siRNA/myr-TP-Tf complex to U87mg cells in the 
presence and absence of serum (n=3/group).  Cells were transfected with Keap1 
siRNA/myr-TP-Tf complex for 3 hr with or without serum and further incubated for 48 
hr in a complete medium to examine the serum effect in transfection and gene 
downregulation.  (A) Keap1 mRNA level; (B) Nrf2 mRNA level; (C) Nqo1 mRNA level; 







Figure 5.9. Hemolysis assay on siRNA-peptide complex prepared at various siRNA to 
peptide molar ratios (n=2/group). (A) Visual representation of the hemolytic activity; and 
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CONCLUSIONS AND FUTURE WORK 
6.1 Conclusions 
The RNAi approach can serve as a promising mode of treatment for 
neurodegenerative disorders.  In order to achieve the brain-targeted delivery of 
therapeutic siRNAs, we have designed a myristoylated cell-penetrating peptide equipped 
with a transferrin-receptor targeting peptide sequence (myr-TP-Tf).  In the in vitro 
characterization study, we have found that the myr-TP-Tf peptides optimally 
encapsulated siRNAs at a 20: 1 molar ratio (peptide to siRNA) where the siRNAs 
exhibited prolonged stability against the serum and RNase A.  The siRNA-peptide 
complex displayed spherical structures with fairly small size (~100 nm in diameter) and a 
moderately positive surface potential value (~23 mV); this was generally in accordance 
with our expectation for the siRNA carrier physicochemical characteristics.  In addition, 
the peptide-siRNA complex successfully delivered bioactive siRNA in both the 
immortalized brain cell line and primary brain cells and significantly downregulated the 
target gene expression.  The siRNA transport across the brain endothelial cell monolayer 
in the transwell system indicated the capability of myr-TP-Tf to deliver the siRNA across 
the BBB model in vitro.  Overall, the myr-TP-Tf peptide demonstrated its potential as a 
siRNA carrier for brain-targeted delivery. 




in order to provide cytoprotection to the brain cells against oxidative stress and 
neurodegenerative conditions.  Using the myr-TP-Tf carrier, we examined the 
neuroprotective effect of Keap1 RNAi in a human glioma cell line under Aβ peptide and 
H2O2-mediated oxidative stress.  Our findings showed that the Keap1 RNAi enhanced the 
endogenous antioxidant capacity, possibly through the Nrf2-mediated activation of a 
variety of antioxidant and detoxifying proteins.  Furthermore, the Keap1 RNAi groups 
exhibited higher cell viability and less oxidative damages under oxidative assault, 
compared to the control groups.  The basal autophagy level was also relatively 
maintained in the Keap1 RNAi group while the control group had an elevated level of 
autophagic activity.  Therefore, it is concluded that the Keap1 RNAi has a promising 
therapeutic potential for brain cells under the pathological oxidative stress condition such 
as in many NDDs.  
  Finally, we have conducted in vivo validation of the siRNA-peptide complex to 
examine its brain targeting ability and its functional target gene silencing effect in a 
living system.  The fluorescently labeled siRNA revealed that the systemic administration 
of the myr-TP-Tf complex into adult mice was able to deliver siRNAs to the brain 
parenchyma compared to the naked siRNA or nontargeting complex, thereby 
demonstrating its brain targeting ability.  Successful siRNA delivery was also manifested 
by the activation of a reporter protein from the harvested brain tissues.  However, the 
brain accumulation extent and the target gene downregulation effect were more 
pronounced in direct local administration groups than the systemic administration groups.  
Hence, we conclude that the myr-TP-Tf peptide possesses promising properties as a 




optimized in order to fine-tune the targeting ability and ultimately maximize the 
therapeutic effects.  
6.2 Experimental design for a complete in vivo study 
Based on the preliminary in vivo results in Chapter 5, the experimental design 
herein is suggested for the further study to fully evaluate the brain targeting ability and 
the target gene silencing capacity of the siRNA-peptide complex in the living system.  
The RNAi effect from local administration vs. systemic administration was briefly 
compared in the preliminary study.  In accordance with our expectation, the intracranial 
injection  resulted in more prevalent brain accumulation of the siRNA as well as  a 
greater target gene silencing effect compared to retrobulbar injection (Figure 5.2).  
However, the small number of animals per group was a major limiting factor in the 
previous study.  In addition, the  retrobulbar route may not be a feasible option for the 
clinical application even if it is widely used as an alternative route to tail vein injection in 
many preclinical studies.  Moreover, there can be a benefit for the retrobulbar route in 
reaching the brain due to the close distance between the retrobulbar sinus and the brain 
area.  In furture studies, more animals will be included to enhance the statistical power 
and the RNAi effect from two modes of systemic administration (retrobulbar injection vs. 
tail vein injection) will be compared.  
To examine brain-targeting ability, siRNA labeled with near-infrared fluorescent 
dye such as Cy5.5 will be used to formulate the siRNA-peptide complex and the mice 
will be imaged in the in vivo fluorescence imaging system at various time-points (e.g.,1 
hr, 3 hr, 8 hr, and 24 hr)  after the injection.  The experimental groups include PBS 




siRNA/Myr-TP-Scr complex group.  To assess the distribution of the siRNA, the flipped 
position of the mice will be additionally taken at each time-point.  The hPAP transgenic 
mice in the previous study displayed autofluorescence from various parts of the body 
which caused confusion with the siRNA fluorescence signals (Figure 5.3).  In further 
study, mice with white coats such as Balb/c mice will be used instead to exclude the 
autofluorescence issue.  In addition, ex vivo imaging at each time-point will be conducted 
for more precise analyses of the fluorscence distribution over the brain as well as other 
peripheral organs.  In this same study, mice will be sacrified at each time-point and the 
primary organs (brain, heart, lung, liver, stomach, spleen, kindey, small intestines, large 
intestines, reproductive organs; testis for males and ovaries for females) will be isolated 
for immediate imaging.  Both genders will be included to examine any gender-related 
response difference.  
To evaluate the gene silencing effect, Keap1 siRNA will be administered to 
hPAP(+) transgenic mice and the hPAP activity will be examined from isolated brain 
tissues.  In the previous study, only a single dosage regimen (3 injections of 50 μg 
siRNA/injection in 24 hr intervals) was tested; the effect in the retrobulbar injection 
groups was much lower than the one in the intracranial injection groups (Figure 5.4).  In 
the further study, we suggest three different doses (50 μg siRNA, 100 μg siRNA, 150 μg 
siRNA) that follow the same injection repeats (3 injections) at the same interval (24 hr) to 
examine the dose-dependent gene silencing effect and any dose-associated toxicity issues.  
Previously, the Keap1 expression level was not correlated with the hPAP activity result 
for the retrobulbar injection groups (Figure 5.5 and 5.6).  We thought that this was 




lack of animals.  To examine the target gene downregulation effect more precisely, we 
suggest using separate animals for each assay (hPAP assay, qRT-PCR, Western blot).  
These assays can also be conducted with the other organs, which may show significant 
fluorescence signals in the imaging study, to examine the nonspecific RNAi effect.  
During the course of study, the general health of the animals should be monitored 
everyday to check if there is any toxicity issues.  The body weight will be measured and 
recorded everyday and any abnormalities in behaviors or activity will also be examined.  
The required sample size per group was calculated using G*Power software 3.1 
(IDRE Research Technology Group, Los Angeles, CA).  The desired level of significance 
was set at 0.05 (α) and the power (1-β) was set at 0.9.  When the medium effect size (0.5 
by convention) was used, the required sample size was 86 subjects per group, which was 
too large for conducting actual experiments.  Therefore, the parameters needed to be 
adjusted in a range of reasonable values.  When we set 200 RLU/mg protein of hPAP 
activity as a minimally meaningful difference that we would like to detect, and used the 
standard deviations from the previous hPAP activity data (Figure 5.4B), the effect size 
became 1.33 and the calculated sample size was 13 per group.  For 300 RLU/mg protein 
of hPAP activity as a minimally meaningful difference to be detected, the effect size was 
2 and the required sample size was 7 per group.  Here, the hPAP activity was converted 
to effect size in G*Power by putting the arbitrarily chosen mean difference (200 RLU/mg 
protein was attempted first as it was the mean difference between the PBS control group 
and the Keap1 siRNA-treated group) and the averaged standard deviation value (~150 
mg/RLU) of the previous hPAP activity data.  When the power is reduced from 0.9 to 0.8, 




for an effect size of 1.33, and 6 per group for an effect size of 2.  Considering that similar 
studies in the literature used 3-4 mice per group (30,31), we estimate that 6-13 mice per 
group would be fair enough for obtaining statistical significance if there is difference.  
The sample size for the imaging study was not calculated, but 4-5 animals seems 
appropriate for the visual examination of the fluorescence signals.  Based on the 
experimental design described above and the calculated sample size, the experimental 
groups and the number of animals needed were determined as shown in Table 6.1.  The 
required amounts and the estimated cost of the siRNA, peptides, and mice are listed in 
Table 6.2.   
The number of mice in Table 6.1 may not be practical to perform the experiments 
considering time, cost, and labor.  The required number can be reduced if 4 mice/group is 
used instead of 5 in the imaging study.  Also, the mice for PBS group can be reduced as 
they serve as a negative control.  In addition, only one gender can be included for the 
study.  In the gene silencing study, the number of animals can be reduced if the same 
mouse is used for the three different assays (hPAP assay, qRT-PCR, Western blot), 
although it may compromise the precise gene silencing analyses.  Alternatively, we may 
compare just two different doses instead of three.  Again, only one gender can be 
included for this study to reduce the use of animals.  
6.3 Future work 
6.3.1 Optimization of the siRNA carriers 
To improve the brain targeting ability of the siRNA-carrier complex, we can 
attempt and evaluate alternative brain-targeting moieties besides the TfR-binding 




are known to bind to the receptors expressed on the brain endothelial cells.  For example, 
the ligands for low-density lipoprotein receptor (LDLR), LDLR-related protein (LRP1), 
insulin receptor, and diphtheria toxin receptor can be incorporated in drug delivery 
vehicles to achieve brain-targeted drug delivery through the receptor-mediated 
transcytosis mechanism (1).  The potential limitation in this approach is that the modified 
ligand binding may lead to disruptions in the normal biological functions of the natural 
ligands.  In addition, the efficiency of the ligand conjugation is often unsatisfactory, 
depending on the complexity of the conjugation chemistry. 
As another option, various brain-targeting short peptide sequences can be 
integrated into the carrier peptide.  The short peptide sequences are compatible with our 
peptide-based siRNA carrier design and also favorable for scalable production using the 
solid phase peptide synthesis technique.  The following are the examples of the brain-
targeting peptide sequences that were investigated in the literature: the LRP1-binding 
sequence (TFFYGGSRGKRNNFKTEEY) (2), the acetylcholine receptor targeting 
sequence derived from the rabies virus glycoprotein (RVG) 
(YTIWMPENPRPGTNSRGKRASNG ) (3), and the leptin-receptor binding peptide 
which is the sequence 12-32 (g21) of leptin (TLIKTIVTRINDISHTQSVSA) (4). 
Other than using these known sequences, we can employ the phage display 
technology to screen the short peptide sequences that bind to the receptors on the brain 
endothelium.  The TfR-binding sequence in the current construct was originally found by 
using this technique (5).  By introducing the phages that display the candidate short 
peptide sequences into mice or rats and performing in vivo brain perfusion, the peptide 




constructs with new targeting sequences are prepared, physicochemical characterization 
and in vitro transfection studies should be conducted to assess the capability in regard to 
the siRNA encapsulation, serum stability, and functional silencing of the target gene.  In 
addition, any cytotoxic effects from the new constructs should also be examined.  The 
peptide sequence that proves to have the most promising properties in all aspects will be 
chosen as an optimized peptide-based siRNA carrier. 
6.3.2 Efficacy assessment of the siRNA-peptide complex treatment  
in NDD animal models 
RNAi therapy using the siRNA-carrier complex should eventually be applied in 
NDD animal models in order to comprehensively evaluate the therapeutic efficacy and 
the safety profile of the treatment.  In AD treatment, as briefly introduced in Chapter 2, 
the examples of the therapeutic siRNAs that can be loaded on the carrier complex are as 
follows: the Keap1 siRNA for rescuing the Nrf2 activity to enhance the cellular 
antioxidant capacity; the APP (amyloid precursor protein) siRNA to reduce the 
production of the Aβ peptide by directly suppressing the APP expression from upstream; 
the BACE (beta secretase 1) siRNA to downregulate the enzyme that is responsible for 
generating the Aβ peptide via the APP cleavage; and the CDK5 (cyclin-dependent kinase 
5) siRNA to reduce the tau phosphorylation activity.  We can even attempt a 
combinatorial approach with mixtures of more than one therapeutic siRNA to examine 
any additive or synergistic effects concerning the therapeutic benefits.  
The therapeutic or disease modifying effects of the treatment can be evaluated 
from various angles.  On the pathophysiological level, the followings are positive 




decreased formation of amyloid plaques and neurofibrillary tangles in brain tissues, 
reduced inflammatory markers in body fluids, and declined levels of oxidative damage 
markers such as lipid peroxidation products and protein carbonyls (6).   In regard to the 
memory dysfunction, cognitive enhancement can be assessed by evaluating learning and 
memory skills based on performance in various behavioral tests such as spatial navigation 
tests, passive/active avoidance learning tests, cued/contextual learning tests, and 
schedule-induced learning tests.  Concerning the BPSD (behavioral and psychological 
signs and symptoms of dementia)-related symptoms, the noncognitive symptoms can be 
examined with the following tests: aggressive behavior tests, activity disturbances tests, 
depression-related symptoms tests, anxiety/fear tests (6).  
The safety of the siRNA-carrier complex in in vivo application will also be 
assessed.  Importantly, the treatment should not result in increased mortality and 
morbidity.  The following five aspects of the animal’s condition are commonly monitored 
to evaluate general adverse effects from treatment: the body weight, physical appearance, 
measurable clinical signs, unprovoked behavior and response to external stimuli (7).  The 
behavioral abnormalities as a part of NDD symptoms in NDD animal models should be 
carefully differentiated from the treatment-caused alterations.  Another consideration is 
the immunogenicity issue involved in the siRNA as well as the peptide carriers.  It was 
reported that siRNAs could induce interferons and immunostimulatory cytokines 
depending on their nucleotide sequences (8).  Therefore, we need to analyze the animal 
serum before and after the treatment to examine whether the treatment leads to antibody 
production against the carrier peptide and whether the levels of diverse cytokines and 




absence of adverse signs will be encouraging evidence for the use of our siRNA carrier 




Table 6.1. The experimental groups and the number of animals needed.  
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PBS - 7 mice 7 mice - - 
Keap1 siRNA 50 µg 7/dose * 3 
doses * 3 
assays = 63  
7/dose * 3 
doses * 3 







50 µg 7/dose * 3 
doses * 3 
assays = 63 
7/dose * 3 
doses * 3 







50 µg 7/dose * 3 
doses * 3 
assays = 63 
7/dose * 3 
doses * 3 






PBS - 7 mice 7 mice - - 
Keap1 siRNA 50 µg 7/dose * 3 
doses * 3 
assays = 63 
7/dose * 3 
doses * 3 







50 µg 7/dose * 3 
doses * 3 
assays = 63 
7/dose * 3 
doses * 3 







50 µg 7/dose * 3 
doses * 3 
assays = 63 
7/dose * 3 
doses * 3 








Table 6.2.  Required amounts and the estimated cost of the siRNA, peptides, and mice. 
  
Materials Amount/injection Required amount Estimated cost 
Cy5.5 siRNA  
(Imaging 
study) 
50 µg of siRNA  
(=4 nmoles) 
4 nmoles/injection * single 
injection * 5 mice/time-point * 4 
time-points* 3 groups * 2 routes of 
administration * 2 genders  
→Total 960 nmoles. 
Core facility charges $7.00/base for 1 
µmole scale, $20.00 for set up fee, 
$75.00 for HPLC purification and 
$150.00 for Cy5.5 conjugation. 200 
nmol RNAi syntheses generally give 
40 -70 nmoles of desalted material (20-
35% yield).  If 5 µmoles are requested, 
$7.00* 21 nt*2 strands *5 + $75.00 + 






50 µg of siRNA 
(=4 nmoles) 
 
100 µg of siRNA  
(=8 nmoles) 
 
150 µg of siRNA  
(=12 nmoles) 
4 nmoles/injection * 3 injections * 
7 mice/assay * 3 assays * 3 groups 
* 2 routes of administration * 2 
genders = 3,024 nmoles for 50 µg 
of siRNA dose. 6,048 nmoles for 
100 µg of siRNA dose and 9,072 
nmoles for 150 µg of siRNA dose.  
→Total 18.144 µmoles. 
If 50 µmoles are requested, $7.00* 21 





study + Gene 
silencing 
study) 
50 µg of siRNA 
(80 nmoles of 
peptides)  
 
100 µg of siRNA  
(160 nmoles of 
peptides) 
 
150 µg of siRNA  
(240 nmoles of 
peptides) 
80 nmoles/injection * single 
injection * 5 mice/time-point * 4 
time-points* 2 routes of 
administration * 2 genders =6,400 
nmoles of peptide (Imaging study)  
 
80 nmoles/injection * 3 injections 
* 7 mice/assay * 3 assays * 2 
routes of administration * 2 
genders = 20,160 nmoles for 50 µg 
of siRNA dose. 40,320 nmoles for 
100 µg of siRNA dose, and 60,480 
nmoles for 150 µg of siRNA dose 
are needed (Gene silencing study) 
→Total 127.36 µmoles. 
127.36 µmoles corresponds to 570 mg 
of peptide. 
 
Selleckchem provides significant 
discount for the large scale synthesis. 
 
$109.80/amino acid for 1,000 mg * 43 
amino acid= 





study + Gene 
silencing 
study) 
50 µg of siRNA 
(80 nmoles of 
peptides)  
 
100 µg of siRNA  
(160 nmoles of 
peptides) 
 
150 µg of siRNA  
(240 nmoles of 
peptides) 
80 nmoles/injection * single 
injection * 5 mice/time-point * 4 
time-points* 2 routes of 
administration * 2 genders =6,400 
nmoles of peptide (Imaging study)  
 
80 nmoles/injection * 3 injections 
* 7 mice/assay * 3 assays * 2 
routes of administration * 2 
genders = 20,160 nmoles for 50 µg 
of siRNA dose. 40,320 nmoles for 
100 µg of siRNA dose, and 60,480 
nmoles for 150 µg of siRNA dose 
are needed (Gene silencing study) 
→Total 127.36 µmoles. 
127.36 µmoles corresponds to 570 mg 
of peptide. 
 
Selleckchem provides significant 
discount for the large scale synthesis.  
 
$109.80/amino acid for 1,000 mg * 43 
amino acid= 
$4,721.40 (+ myristic acid conjugation 
fee-not sure) 
 
Animal Type Required number of animals Estimated cost 
Mice Balb/c mice 160-320 mice  
(Adjustable depending on the 
experimental design) 
Balb/c mice from the Jackson 
laboratory are priced as following; 
15 week-old mouse: $36.75/animal 
$36.75 * 320 mice =$11,760.00 
$36.75 * 160 mice =$5,880.00 
hPAP (+) mice 392-784 mice 
(Adjustable depending on the 
experimental design) 
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